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Abstract
Multidrug resistance (MDR) mediated by a drug efflux mechanism is one of the
major drug resistance problems not only in bacteria but also in other microorganisms.
NorA MDR efflux protein is a well characterized and major efflux pump in the
pathogenic Gram-positive bacterium, Staphylococcus aureus.

It contributes to the

resistance to berberine and ciprofloxacin antibiotics by extrusion of these drugs from the
cells of S. aureus. In order to overcome this type of drug resistance by dual action
agents incorporating efflux pump inhibitor properties and antibacterial activity, a variety
of new, aryl group-substituted 2-aryl-5-nitro-1H-indole efflux pump inhibitors were
synthesized. In the synthesis of these 2-aryl-5-nitro-1H-indoles, a new procedure for the
N-acylation of indoles was developed based on DCC/DMAP coupling with carboxylic
acids. This method was particularly effective with 5-nitro-1H-indole. The activity of
these indole derivatives as inhibitors of the NorA MDR pump in S. aureus was
assessed. It was found that some of the 2-aryl-5-nitro-1H-indole derivatives potentiated
the activity of the antibacterial agents berberine and ciprofloxacin against the resistant
strain, K2361, of S. aureus.

The new 2-aryl-5-nitro-1H-indole inhibitors were

particularly effective in potentiating the antibacterial activity of berberine.

The

compound [4-benzyloxy-2-(5-nitro-1H-2-yl)-phenyl]-methanol (43) was the most potent
NorA pump inhibitor found in this work.
A number of dual action antibacterial agents were designed and synthesized.
These included dual action prodrugs, in which the MDR pump inhibitor and berberine
were attached in the same molecule with enzymatically cleavable linkages (ester or
amide groups), and dual action drugs with a non-cleavable linkage (methylene group).
In the synthesis of the dual action agents, a direct new approach to 13-substituted
berberine derivatives was found.

This approach involved alkylation of 8x

allyldihydroberberine followed by the elimination of propene.

The antimicrobial

activity of these indole-berberine compounds was assessed against a variety of
pathogenic microorganisms. One of the dual action drugs, 9,10-dimethoxy-13-[2-(5nitro-1H-indol-2-yl)benzyl]-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium
bromide (64), was a potent antimicrobial agent at a clinically viable concentration
against various bacteria in vitro, including Staphylococcus aureus K2361, Enterococcus
faecalis V583, and Salmonella enterica Serovar Typhimurium SL1344R2. This
compound also had good activity against the protozoan, Plasmodium falciparum K1 (in
vitro).
In the case of the dual action prodrugs, the amide prodrugs were more active than
the ester prodrugs against the Gram-positive bacterium S. aureus and vice versa against
the Gram-negative bacterium S. enterica Serovar Typhimurium. However, minimum
inhibitory concentrations for all the dual action drugs and dual action prodrugs were
near or at clinically useful concentrations (ca. 1µg/mL or less) as antibacterial agents
against S. enterica Serovar Typhimurium SL1344R2, and they showed 400- to 1600fold higher activity than the parent antibacterial agent berberine. The design principle
of having in the one molecule an MDR inhibitor moiety and an antibacterial moiety was
established as a viable one, which potentially could be extended to other types of
antimicrobial agents.
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Abstract
Multidrug resistance (MDR) mediated by a drug efflux mechanism is one of the
major drug resistance problems not only in bacteria but also in other microorganisms.
NorA MDR efflux protein is a well characterized and major efflux pump in the
pathogenic Gram-positive bacterium, Staphylococcus aureus.

It contributes to the

resistance to berberine and ciprofloxacin antibiotics by extrusion of these drugs from the
cells of S. aureus. In order to overcome this type of drug resistance by dual action
agents incorporating efflux pump inhibitor properties and antibacterial activity, a variety
of new, aryl group-substituted 2-aryl-5-nitro-1H-indole efflux pump inhibitors were
synthesized. In the synthesis of these 2-aryl-5-nitro-1H-indoles, a new procedure for the
N-acylation of indoles was developed based on DCC/DMAP coupling with carboxylic
acids. This method was particularly effective with 5-nitro-1H-indole. The activity of
these indole derivatives as inhibitors of the NorA MDR pump in S. aureus was
assessed. It was found that some of the 2-aryl-5-nitro-1H-indole derivatives potentiated
the activity of the antibacterial agents berberine and ciprofloxacin against the resistant
strain, K2361, of S. aureus.

The new 2-aryl-5-nitro-1H-indole inhibitors were

particularly effective in potentiating the antibacterial activity of berberine.

The

compound [4-benzyloxy-2-(5-nitro-1H-2-yl)-phenyl]-methanol (43) was the most potent
NorA pump inhibitor found in this work.
A number of dual action antibacterial agents were designed and synthesized.
These included dual action prodrugs, in which the MDR pump inhibitor and berberine
were attached in the same molecule with enzymatically cleavable linkages (ester or
amide groups), and dual action drugs with a non-cleavable linkage (methylene group).
In the synthesis of the dual action agents, a direct new approach to 13-substituted
berberine derivatives was found.

This approach involved alkylation of 8x

allyldihydroberberine followed by the elimination of propene.

The antimicrobial

activity of these indole-berberine compounds was assessed against a variety of
pathogenic microorganisms. One of the dual action drugs, 9,10-dimethoxy-13-[2-(5nitro-1H-indol-2-yl)benzyl]-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium
bromide (64), was a potent antimicrobial agent at a clinically viable concentration
against various bacteria in vitro, including Staphylococcus aureus K2361, Enterococcus
faecalis V583, and Salmonella enterica Serovar Typhimurium SL1344R2. This
compound also had good activity against the protozoan, Plasmodium falciparum K1 (in
vitro).
In the case of the dual action prodrugs, the amide prodrugs were more active than
the ester prodrugs against the Gram-positive bacterium S. aureus and vice versa against
the Gram-negative bacterium S. enterica Serovar Typhimurium. However, minimum
inhibitory concentrations for all the dual action drugs and dual action prodrugs were
near or at clinically useful concentrations (ca. 1µg/mL or less) as antibacterial agents
against S. enterica Serovar Typhimurium SL1344R2, and they showed 400- to 1600fold higher activity than the parent antibacterial agent berberine. The design principle
of having in the one molecule an MDR inhibitor moiety and an antibacterial moiety was
established as a viable one, which potentially could be extended to other types of
antimicrobial agents.
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1

Chapter1: Introduction

1.1 Isoquinoline alkaloids as natural antimicrobial agents
Antimicrobials can be both natural products and synthetic chemicals, which are
designed to inhibit or destroy pathogenic microorganisms, such as bacteria, fungi,
protozoa, and viruses. Amongst the natural products, alkaloids play an important role as
medicinal agents and as poisons, and they have been found in such varied sources as
plants, animals, insects, marine invertebrates and microorganisms. A general definition
of an alkaloid has been given by Pelletier1 as “An alkaloid is a cyclic compound
containing nitrogen in a negative oxidation state which is of limited distribution in
living organisms.” Alkaloids can be classified into several categories based on the
chemical structure of their nucleus. Isoquinoline alkaloids are thus based on the
isoquinoline nucleus. A few isoquinoline alkaloids, such as berberine and sanguinarine,
are currently used clinically as antimicrobial agents,2 but many others show
antimicrobial activity. Berberine and sanguinarine occur in several genera of families
including the Berberidaceae, Papaveraceae, and Rutaceae, and possess a variety of
pharmacological properties including antimicrobial, antileukemic, antiulcerous, gastric
antisecretory, and enzyme inhibitory activities.2,3
O
O

O
O

N

Berberine (1)

N

CH3

OCH3

O

OCH3

O

Sanguinarine

Berberine is a member of the protoberberine class of isoquinoline alkaloids, but
sanguinarine is a member of the benzophenanthridine class of these alkaloids. The
mechanism of antimicrobial activity of berberine and sanguinarine is related to their
effect on DNA intercalation and inhibition reverse transcription and DNA synthesis in
1

microorganism cells.4 The therapeutic uses of berberine are in the treatment of infected
eyes and eye irritations (MurineTM) while sanguinarine is used as an antiplaque in
toothpaste and mouthwash.5 Sanguinarine has been classified by the FDA as being
unsafe for use in food and drugs.6

1.1.1 Antimicrobial

activity

and

structure-activity

relationships

(SARs) of berberine and related alkaloids
Berberine was first isolated from the plant Xanthoxylon cava in 1926. Berberine
extracts from plants have been used in the treatment of cholera and other bacterial
diarrhoeas in Native American, Chinese, and Japanese traditional folk medicine for
centuries. It has been reported that berberine and related alkaloids exhibit antibacterial
activity against Gram-positive bacteria (e.g. Staphylococcus aureus, Staphylococcus
epidermidis, Enterococcus faecalis, Bacillus subtilis) and Gram-negative bacteria (e.g.
Escherichia coli, Klebsiella pneumoniae), antifungal activity against Candida albicans
and Aspergdlus fumigatus, antiplasmodal activity against Plasmodium falciparum, and
several other pharmacological activities. The extensive antimicrobial screening data
(Amin et al.7) of berberine sulfate are shown in Table 1-1. Moreover, it has recently
been reported that berberine possesses anti-tumour activity.8 It is likely that berberine
and its analogues show these activities because of the presence of the iminium ion
moiety in the aromatic structure which could react with nucleophilic amino acid
residues in enzymes and receptors of microorganisms. There have been some previous
studies on the relationships between the structure and biological activity of these
compounds in order to determine the structural regions important for antimicrobial
activity. These studies may be summarized as follows:
2

Table 1-1 A ntib acterial activity o f berberinium su lfate7

Organism

M inimum growth inhibitory concentration
(xM*

(ag/mL
Bacillus pum ilus

25

57.7

Bacillus cerus

50

115.5

Bacillus sublilis

25

57.7

C orynebacterium diphtheriae

6.2

14.3

Escherichia coli

50 - greater than 100 115.5 - greater than 230.9

K lebsiella pneum oniae

25

57.7

Pseudom onas pyocyanea

>100

>230.9

Pseudom onas fluorescens

>100

>230.9

Salm onella paratyphi

>100

>230.9

Salm onella schottm uelleri

>100

>230.9

Salm onella typhimurium

>100

>230.9

Salm onella typhi

>100

>230.9

Shigella boydii

12.5

28.9

Staphylococcus aureus

6.2 - 50.0

14.3 - 115.5

Staphylococcus albus

50

115.5

Streptococcus pyogenes

12.5

28.9

Vibrio cholerae Inaba 569B

25

57.7

Vibrio cholerae E l Tor O gaw a

50

115.5

X anthom onas citri

3.1

7.2

Xanthom onas campestris

6.2

14.3

Xanthom onas malvacearum

12.5

28.9

Erwinia carotovora

100

230.9

P seudom onas m angiferae

>100

>230.9

Pseudom onas solanacearum

>100

>230.9

C andida utilis

12.5

28.9

C andida albicans

12.5

28.9

C andida tropicalis

3.1

7.2

Sporotrichum schenkii

6.2

14.3

*The m inim um inhibitory concentrations w ere converted from |xg/mL into (iM, using a
calculated m olecular w eight o f berberinium sulfate o f 433 daltons.

Influence o f the oxygen substituents in ring A

According to Iwasa et al,9 the antimalarial activity of protoberberine alkaloids was
influenced by the type of oxygen substituent on ring A (Figure 1-la).

Compounds

having a methylenedioxy group on ring A (where Ri + R2 = CH 2) showed a higher
activity against P. falciparum than compounds having a methoxy group at the same

positions, (R1 = R2 = OCH3). In addition, replacement of a methoxy group at C-2 or C3 by a hydroxy group resulted in an increase in activity.
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Figure 1-1 General structures and numbering of protoberberine alkaloid derivatives for SARs

Influence of substituents on ring C
There have been several investigations by Iwasa et al9-12 on the effect of
substituents at C-8, C-13, and of the quaternary ammonium ion of this ring on
antibacterial and antimalarial activities. For example, the introduction of an alkyl group
at C-8 (R3 = CH3, C2H5, n-C3H7, and n-C4H9) (Figure 1-1a) increased the antibacterial
activity against S. aureus and B. subtilis as the alkyl side chain length increased.
Adding a bromine atom at C-12 on ring D of these compounds also increased
antibacterial activity (Figure 1-1a). Substitution of various alkyl groups at C-13 (R4,
Figure 1-1a) was evaluated and optimized. The alkyl side chain length was increased
from methyl to n-hexyl group, with the 13-hexylberberine derivatives found to exhibit
the highest antibacterial activity. The R4 substituent at C-13 also was changed to OH,
OMe, OEt, OCOOEt, and OCON(Me)2. Their antimalarial activities were lower than
berberine itself against P. falciparum. Reduction of protoberberinium salts (Figure 11a) to tetrahydroberberine derivatives (Figure 1-1b) significantly reduced the
antibacterial activity against S. aureus and B. subtilis. Making the N-metho salts (R7 =
Me in Figure 1-1b), and also adding a methyl group at C-13 caused an increase in
activity. Moreover, changing of the B/C junction of the N-metho salt derivatives in the
4

tetrahydroberberine series from trans to cis caused a decrease in the activity. The SARs
for antibacterial and antimalarial activities were not compared by Iwasa.

Influence of type and position of oxygen on ring D
The type of oxygen group at C-9 strongly affected the antimicrobial activity in the
berberine series. It has been reported13 that berberine and berberrubine, the latter
differing in structure from berberine only at C-9, where R5 = H (Figure 1-1a), both
mediate DNA cleavage but in the DNA cleavage assay berberrubine was more active
than berberine. Alkylation of the hydroxy group of berberrubine at C-9 with an alkyl
halide, where the alkyl groups were hexyl, heptyl, octyl, nonyl, decyl, and undecyl
groups, gave alkyl ether products with higher antibacterial activities against Grampositive bacteria than those for berberrubine. The activities increased as the alkyl chain
length increased up to dodecyl, but alkyl chains longer than the dodecyl had decreased
activity. In the same way, acylation of the hydroxy group of berberrubine at C-9 was
also investigated.

The acyl groups were varied from octanoyl, decanoyl, lauroyl,

myristoyl, to palmitoyl groups. The antibacterial activities increased as the length of the
chain increased, but then decreased with longer chains than the lauroyl group.14,15

1.1.2 Cytotoxicity of berberine and related alkaloids
Berberine is known to possess cytotoxic activity. The IC50 values are 7.32 µM
against KB cells (human carcinoma of the nasopharynx),16 0.03 µM against Hela
(human uterus carcinoma), less than 0.03 µM against SVKO3 (human ovary carcinoma),
Fadu (human pharynx carcinoma), Hep-2 (human larynx carcinoma) and moderate
toxicity against primary cultures from mouse embryos and human fibroblasts. The
cytotoxic activity comparison of berberine with related alkaloids was evaluated using
5

human cancer cell lines. Berberine showed higher cytotoxicity than lincangenine, 8hydroxydihydroberberine and 8-hydroxylincangenine, and thaicanine which has a transquinolizidine conformation.17
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In addition, Iwasa et al18 investigated the cytotoxicity of several protoberberine
alkaloids against human cancer cell lines (lung, colon, CNS, stomach, ovarian, breast,
renal, melanoma), and they showed that the cytotoxic activity paralleled the
antimicrobial activity. Compounds bearing a methylenedioxy group at C-2 and C-3
were more cytotoxic than those with a methoxy group at the same positions.
Compounds having alkyl side chains at C-13 also showed cytotoxicity, with an increase
in cytotoxicity occurring with an increasing chain length.

1.1.3 Structural features for antimicrobial and cytotoxic activities
In summary, it has been established that the following features are important for
antimicrobial and cytotoxic activities in the berberine series:
1. a quaternary nitrogen atom
2. aromaticity of ring C
3. the type of O-alkyl substituent on rings A and D
4. the size of the substituent at C-13.

6

1.2 Antibacterial drug resistance problem
A number of antibiotics were developed in the 20th century to combat bacterial
infections. Penicillin, one of the earliest antibiotics, is produced by the fungal species
Penicillium sp. and was found to have the ability to kill S. aureus, a bacterium
responsible for causing skin infections. Other antibiotics found in the same period, and
shown in Table 1-2, include the sulfonamides and streptomycin which were used to
combat a wide range of bacterial infections. 19

Table 1-2 Evolution of resistance to antibiotics20
Antibiotic

Year deployed

Resistance observed

Sulfonam ides

1930s

1940s

Penicillin

1943

1946

Streptom ycin

1943

1959

C hloram phenicol

1947

1959

T etracyclin

1948

1953

Erythrom ycin

1952

1988

V ancom ycin

1956

1988

M ethicillin

1960

1961

A m picillin

1961

1973

C ephalosporins

1960s

late 1960s

The discovery of successful antibiotics encouraged scientists to research and
develop new antibiotics.

However, pathogenic microbes also have tried to develop

intrinsic self-protection to combat these antibiotics resulting in the emergence of
bacterial resistance (Table 1-2). Antibiotic resistant bacteria have now become a major
worldwide health problem.

During the past six to seven decades, over 100

antibiotics/antibacterial agents have been discovered and developed. The major classes
of antibacterial agents are (3-lactams (e.g. penicillin, methicillin, cephalosporins),
aminoglycosides,

tetracyclines,

sulfonamides,

macrolides

(e.g.

erythromycin),
7

quinolones and glycopeptides (e.g. vancomycin). These antibiotic classes are grouped
according to their targets at the surface of the bacterial cell or inside the cell.21 One of
the most significant antibiotic resistance problems observed in clinical practice is the
increase in the number of the isolates of methicillin-resistant S. aureus (MRSA) strains.
MRSA is the most common antibiotic-resistant organism in hospitals, and ranks as the
most frequently isolated pathogen associated with blood stream infections in North
America between 1997-2001.22 Several variations of multidrug resistance (MDR) have
been found in MRSA isolates, with resistances to macrolide-lincosamide-streptogramin
B (MLSB) antibiotics, fluoroquinolones and other antibiotics. Vancomycin was the last
line of defence against serious infections caused by MRSA, but the emergence of
vancomycin resistance of S. aureus was reported in Japan in 1996,23 and subsequently
in many other countries.

Similarly, Enterococcal strains are also commonly isolated

pathogens in blood steam infections in North America.22 Many Enterococcus faecium
isolates are now vancomycin-resistant and E. faecalis isolates also showed resistance to
aminoglycosides and β-lactams. Unfortunately, the dual drug quinupristin-dalfopristin
(SynercidTM, a new drug that has activity against MDR S. aureus and has been
introduced into hospital use) does not control E. faecalis.24,25 Clearly, new drugs are
urgently needed to overcome the serious multidrug resistance problem in pathogenic
bacteria.

1.3 Mechanisms of antimicrobial resistance
Antibacterial agents can kill bacteria or stop their growth by attacking three main
targets in bacterial systems: bacterial cell wall biosynthesis, bacterial protein synthesis,
and bacterial DNA replication and repair.26 In response, bacteria have developed a
number of resistance mechanisms to protect themselves from antibacterial agents.
8

These bacterial survival strategies fall into three major types, as outlined in the
following sub-sections.

1.3.1 Resistance by antibacterial alteration
Resistance to a wide range of antibacterial agents can be achieved by modification
of the antibacterial agents. This mechanism results in destruction of the antibacterials
by deactivating the drugs to inactive forms. For example, deactivation of penicillin and
cephalosporin antibiotics can be caused by (3-lactamase enzymes, which are produced
by resistant bacteria (Figure 1-2). The strained four-membered p-lactam ring, the active
structural moiety in the penicillin antibiotics, can be opened by p-lactamase to give
•

•

•

•

•

penicilloic acid, which is inactive as an antibiotic.

97

Figure 1-2 Antibiotic destruction by enzymes produced by resistant bacteria (Figure from reference
26)

1.3.2 Resistance by bacterial target modification
This mechanism involves modification of the drug target to such an extent that it
is insensitive to the antibiotic, whilst still keeping its essential cellular function. An
example of this occurs in vancomycin-resistant Enterococci (VRE). The mode of action
of vancomycin involves the disrupting of bacterial cell wall synthesis.
9

Peptidoglycan is an im portant protein in bacterial cell wall synthesis.

Cross-

linking o f peptidoglycans occurs at the D-Ala-D-A la term inus o f peptidoglycan and this
is im portant for cell wall strength.

V ancom ycin acts by binding to the D-Ala-D-Ala

terminus o f the peptidoglycan and preventing this essential cross-linking by the
transpeptidase enzyme. The vanHA genes o f E. fa eciu m encode a new pathway o f cell
biosynthesis which involves a change in the D -Ala term inus to an ester linkage with Dlactate (Figure 1-3) that results in a poor binding o f vancom ycin to the modified
peptidoglycan term inus o f jV-acyl-D-Ala-D-lactate and allows the VRE to survive .28,29

^ V r V
W-acyl-OAIa-D-Aia

A/-acyM> Ala-D- Lac

Figure 1-3 Binding o f vancomycin to D-Ala-D-Ala as peptidoglycan models (Figure from reference
26)

1.3.3 Resistance by reducing antibacterial permeability
This resistance m echanism reduces the intracellular accum ulation o f antibacterial
agents in bacterial cells through transm em brane proteins.

The action o f membrane-

based efflux pum ps has been shown to play an im portant role in the recent developm ent
of multidrug resistance to antibiotics .30,31 Basically, the developm ent o f efflux-m ediated
resistance occurs through the up-regulation o f genes encoding transporters that
efficiently extrude drugs from the bacterial cell and result in a low ineffective
10

concentration o f the drugs in the cell.

For exam ple, tetracycline and erythrom ycin

antibiotics are pum ped out from bacterial cells (e.g. E. coli) via efflux pump protein
(Figure 1-4). The pum p exports these drugs from the bacterial cell faster than the drug
diffuses into the cell, so the intracellular drug concentration is not high enough to
destroy the cell.
Antibiotic

Resistance mechanism

• Eiythromycins
•Tetracyclines

Bacteria manufacture protein pumps that pump
the antibiotic out so that it does not accumulate
to a high enough internal concentration to block
protein synthesis

Figure 1-4 Drugs are pumped out of bacterial cells via efflux pump proteins (Figure from reference
26)

1.4 Bacterial efflux pum p classification
To date, five families o f bacterial drug efflux pum ps have been identified based
on the energy source used for extruding substrates and on sequence similarity (Table 13).

Bacteria can possess efflux proteins from one or more families.

The M ajor

Facilitator Superfam ily (M FS), Resistance-Nodulation Division Family (RND), Small
Multidrug Resistance Family (SM R), and M ultidrug and Toxic Compound Extrusion
Family (M ATE) use a proton m otive force (PM F), pH gradient and electrochemical
formation to efflux antibacterial agents in exchange for protons.

The ATP-Binding

Cassette Superfamily (ABC) o f transporter proteins derive their energy from ATP
hydrolysis .30
MFS transporters contain about 400 amino acids and have been classified into two
subfamilies, which have 12 and 14 transm em brane helices (Figure 1-5).

The pumps
11

with 14-helix transporters are QacA, EmrB from E.coli, TetK from S. aureus, TetL from
Bacillus stearothermophilus, and TcmA from Streptomyces glaucescens. Others having
12-helix transporters are Bit and Bmr from Bacillus subtilis, EmeD from E. coli, and
NorA from S. aureus. The substrates of this family are a variety of organic cations,
including quaternary ammonium compounds such as benzalkonium chlorides, which are
pumped out by QacA, plus uncharged drugs such as chloramphenicol which is extruded
by NorA and Bmr.32
Table 1-3 Antibacterial Resistance Efflux Families, Biochemical Characteristics, Efflux Substrates
and Bacteria Hosts33
Family

Biochemical Characteristics Chemical Substrates

Bacterial Hosts (genera)

M ajor Facilitator

12 or 14-m em brane

antibiotics, quaternary

Mycobacterium

Superfam ily

spanning segm ents

am m onium com pounds

Lactobacillus

basic dyes,

Staphylococcus

phosphonium ions

Bacillus

(M FS)

Escherichia
Streptococcus
Vibrio
Resistance N odule

M ulti-com ponent

basic dyes, detergents

Escherichia

Cell D ivision

segm ents: m em brane

antibiotics, fatty acids

Pseudomonas

(RND)

protein

Neisseria
Haemophilus

Small M ultidrug

A pproxim ately 100-120

antibiotics, quaternary

Bacillus

Resistance Fam ily

am ino acids in prim ary

am m onium com pounds

Escherichia

(SM R)

structure, 4 helices

antiseptics, tertraphenyl Mycobacterium
phosphonium , ethidium Staphylococcus

M ultidrug and Toxic

12-putative m em brane

Com pound Extrusion spanning segm ents
Family (A B C)

dyes, fluoroquinolones

Haemophilus

am inoglycosides

Vibrio
Bacillus

SMR transporters are the smallest known translocases with about 110 amino
acids, and only 4 transmembrane domains; an example is the EmrE transporter from E.
coli. The substrates are similar to the MFS, namely hydrophobic cations, but the range
12

is narrow er than that o f the MFS transorters .34 M any m ultidrug transporters o f the MFS
and SM R families have acidic residues at a sim ilar position in helix 1, suggesting that
they are using a sim ilar mechanism to bind to sim ilar substrates .35
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\
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II

X
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MFP

12 or 14helices

TetA, E. coli

AcrB, £ coli

FmrAB, E. coli

Figure 1-5 Diagram o f the membrane topology of proton-driven drug pumps in Gram-negative
bacteria35

RND transporters contain about 1000 amino acids, which make them much bigger
than

the

MFS

transporters,

w ith

a

sim ilar

12-helical

structure

except

extracytoplasmic dom ains between helices 1 and 2 and between helices 7 and

8

for

(Figure

1-5). A m utation o f the pum ps in this family leads to susceptibility to a wide range o f
substrates, which carry positive, negative or no charge, suggesting that the pumps can
capture their substrates, which are only partially inserted into the m em brane lipid
bilayer .36 Recently, the crystal structures o f outer m em brane TolC 37 and inner
(cytoplasmic) m em brane AcrB 38 transporter proteins in E. coli have been solved while
13

that o f AcrA protein is still unknown (Figure 1-6). The structures o f TolC and AcrB
proteins were predicted to line up to from one continuous channel, which is connected
together w ith the AcrA protein. This system exports a wide range o f substrates from
both cytoplasm and periplasm to the outside o f the bacterial cells. This double
protection system confers resistance to antibiotics and makes E. coli dangerous
pathogenic bacterium.

Cytoplasm

Figure 1-6 Proposed model o f the AcrB-AcrA-TolC drug export complex in E. coli3*

MATE

transporters

were

the

m ost

recently

identified

family,

with

12

transmembrane helices containing a total o f 450 amino acids. The N orM transporter
from Vibrio parahaem olyticus has been characterized as a m ultidrug N a+- antiporter,
which confers

resistance

to

cationic

com pounds,

dyes,

fluoroquinolones,

and

am inoglycosides .39 N o proposed m echanism has been reported.
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Figure 1-7 Diagram o f the membrane topology o f drug transporters belonging to the ABC
superfamily

ABC transporters represent a minority o f efflux pumps.

They derive their

transport energy from ATP hydrolysis and have two sim ilar halves, each containing two
parts o f twelve transm em brane dom ains arranged into six a-helices, and a nucleotidebinding dom ain (NBD) (Figure 1-7).

The w ide range o f substrates o f this family

includes dyes, ionophoric peptides, lipids and steroids. Recently, the MacB transporter
from E. coli has been identified as being involved in the extrusion o f macrolide
antibiotics .35 The proposed general mechanism o f the pumps in this family can be
described by the process involved in the LmrA pum p from Lactococcus lactis, which is
a multidrug transporter with structural and functional identity with the P-glycoprotein
(P'Pg) pump in hum ans (Figure 1-8). The interconversion o f two conformational forms
o f the protein is induced by ATP, w hich have a high-affm ity transport-com petency in
°ne intracellular site, and a low-affmity drug-release site in an extracellular region.
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Figure 1-8 Simple model of P-gp transport
“The NBDs are represented in yellow and the membrane-spanning domains in green. Step 1: binding of
ATP to the NBD of one half of the transporter triggers drug binding to a high-affinity intracellular drugbinding site. Step 2-3: ATP is hydrolysed, occluding the drug-binding site. Step 3-4: release of the
generated Pi leads to the exposure of the drug at an extracellular-facing, low-affinity drug-binding site on
the same domain. At this point the drug can be released. As a result of the remaining ADP and cooperative interaction between the two NBDs, ATP is likely to bind to the non-liganded NBD. Step 4-5:
further conformational changes are likely to result in the exposure of a high-affinity drug-binding site on
the intracellular side of the membrane domain that is associated with the liganded NBD. Step 5-6: drug
binding at this site results in ATP hydrolysis and the drug-binding site becomes occluded. Step 7-1:
release of Pi exposes a low-affinity drug-binding site at the extracellular side and the drug is released.
Release of the drug and ADP allows the return of the transporter to the original conformation, and the
cycle can begin again.”35

1.5 Bacterial MDR pump inhibitors
There are a few proposed mechanisms of inhibitor action against MDR
transporters: these include direct binding of the inhibitor to the binding sites of the
pump protein causing no drug transport,40 destruction of the pumps’ energy by
16

inhibiting binding of ATP and modifying protein structure by an inhibitor interaction
with the cell membrane.29,41
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Figure 1-9 Inhibitors of MDR pumps

A number of potential inhibitors of bacterial efflux pumps have been discovered,
such as MC-207,110, a broad-range inhibitor and the first inhibitor active against
multiple RND transporters in Gram-negative bacteria, which was produced by
Microcide Pharmaceuticals.42 It is an aminonaphthalene derivative of a phenylalaninearginine dipeptide (Figure 1-9), and it was found to possess superior activity to inhibit
RND multidrug pumps of P. aeruginosa, Enterobacteriacea, Haemophilus influenza
and Stenotrophomonas maltophilia, which potentiates the effects of fluoroquinolone
antibiotics.42-44 Several semisynthetic tetracycline analogues have been synthesised, of
which the most potent analogue with ability to inhibit the TetB protein, is 13cyclopentylthio-5-hydroxytetracycline (13-CPTC, Figure 1-9).

This compound has

been shown to inhibit tetracycline efflux in E. coli.45 INF 392, the most potent synthetic
NorA pump inhibitor of a series of INF analogues (Figure 1-9), has been shown to
potentiate the bacteriocidal activity of ciprofloxacin or ethidium bromide in S. aureus;
INF392 also reduced the number of spontaneous mutants in S. aureus to ciprofloxacin
17

by 50-fold or more.33,46 5´-Methoxyhydnocarpin-D (5´-MHC-D, which had originally
been given the name 5´-methoxyhydnocarpin, 5´-MHC),47-49 a natural potent inhibitor
of the NorA pump, was found in a leaf extract of Barberry (Berberis fremontii) and was
found to potentiate the activity of typical substrates of the NorA pump, such as:
berberine, ethidium bromide, and triphenylphosphonium ion.47 Some inhibitors of the
NorA pump will be discussed further in Chapter 3 as part of this thesis.

1.6 Definitions of dual action prodrugs and dual action drugs
Dual action prodrugs, also known as mutual prodrugs, are pharmacological
derivatives of two different but generally synergistic drug molecules, combined together
with a covalent linkage, which requires spontaneous or enzymatic transformation within
the body to release the two active compounds.50,51 Over the past two decades, the
prodrug concept has been optimized in an attempt to solve some problems found in a
large number of existing drugs, and has also become an integral part of the new drug
design process. The application of a prodrug approach has been successful in the
enhancement of the parent drug activity, for example, with dual action antibiotic hybrids
of cephalosporins and quinolones that attack bacteria with two completely different
modes of action. Cephalosporins are active against Streptococci and belong to the βlactam class of antibiotics, and quinolones are active against β-lactam-resistant strains.
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Figure 1-10 Release of quinolone on hydrolysis of a cephalosporin-quinolone ester prodrug

For a quinolone to be microbiologically active then its 3-carboxyl group must be
free. The 3-carboxyl group of the quinolone is combined to a cephalosporin nucleus at
18

position 3 via an ester link (Figure 1-10). Quinolone activity is generated by one of
three mechanisms.

Firstly, when the prodrug is in the presence of an active β-

lactamase, which catalyzes the hydrolysis of the amide bond in the β-lactam ring,
resulting in ring opening and subsequent release of the quinolone carboxylic acid;
secondly, when the prodrug undergoes spontaneous hydrolysis; and thirdly, when the
penicillin-binding proteins (PBPs) in the cytoplasmic membrane of bacteria are acylated
by the cephalosporin causing inhibition of cell-wall synthesis and cell death via the
standard mode of action of β-lactam antibiotics. Therefore, the dual action prodrug
cephalosporin-quinolone esters act as cephasporins and also as prodrugs for
quinolones.52-54
Dual action drugs (or hybrid drugs) are pharmacological derivatives of two
different drug molecules attached to each other and do not require biotransformations to
release the two active compounds.50 The dual action prodrug and dual action drug
approaches of parent compounds A and B can be illustrated as shown in Figure 1-11.

Dual action prodrug

A

Cleavable
Linker

B

Enzymatic or Non-enzymatic
Biotranformation

A

Target 1

+

B

Target 2

Dual action drug

A

Non-cleavable
Linker

B

No biotransformation

Target 1

A

B
+

A

B

Target 2

A and B are different pharmacological drugs

Figure 1-11 Diagram illustrating dual action prodrug and drug approaches

The main aim of the work in this thesis was to attempt to overcome the
antibacterial resistance problem in certain bacteria using compounds based on both the
dual action prodrug and dual action drug concepts. Both design concepts were to
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incorporate two molecular components having different biochemical targets, and were
to be delivered to the target sites in the bacterial cell in effective concentrations. Some
of the advantages and disadvantages of dual action drugs and dual action prodrugs are
summarized in Table 1-4, and a comparison made with the administration of two
separate drugs (dual drug approach). This last approach has been used successfully in
antibacterial therapy, for example with Augmentin (amoxicillin (antibacterial) and
potassium clavulanate (β-lactamase inhibitor)).55 A key potential advantage of the dual
action drugs or prodrugs was the synchronous (or near synchronous) delivery in high
concentration of active components to different bacterial target sites.

Table 1-4 Comparison of dual action drugs and dual action prodrugs with two separate drugs (dual
drugs).

Type
Dual Drugs

Dual Action
Drugs

Dual Action
Prodrugs

Advantages
• Known components administered

Disadvantages
• Formulation; administration
• Different pharmacokinetics of
each drug
• Drug may not synchronously
accumulate at bacterial sites
• More side effects
• Synchronous delivery to different bacterial • Each activity may be reduced
target sites and in high concentrations
(e.g. steric reasons)
• Slower development of resistance
• Molecular weight high
• Improved formulation
• Improved chemical stability
• Decreased toxicity
• Synchronous or near synchronous delivery • Synthetic difficulties
of active agents
• Slower development of resistance?
• Molecular weight high
• Improved formulation
• Improved chemical stability
• Decreased toxicity
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1.6.1 Design principles of dual action antimicrobials
One of the three resistance mechanisms of bacteria to antibiotics, as mentioned
above, is mediated through reducing antibacterial permeability. Recently, there has
been a report by Stermitz et al.47 on the synergistic antibacterial activity in components
of a medicinal plant, Berberis fremontii, involving the alkaloid berberine (1) and the
flavonolignan 5´-MHC-D (Figure 1-9). Berberine possesses a planar aromatic cationic
center that is thought to provide the antimicrobial activity and also to serve as a
recognition site by efflux pump proteins in the microbial cells; berberine is pumped out
from the cells thus reducing its potency. 5´-MHC-D flavonolignan is not a typical
MDR substrate or antibacterial agent, but it can potentiate the activity of berberine by
blocking the MDR (NorA) pump in S. aureus as shown in Figure 1-12.

Figure 1-12 "A model of the synergistic action of berberine and an MDR inhibitor that are both
produced by B. fremontii. Berberine accumulates in the cell driven by the membrane potential.
The NorA pump extrudes berberine. The MDR inhibitor 5'-MHC, which has been renamed to 5'MHC-D and confirmed its structure by HMBC NMR spectroscopic data,49 blocks the NorA pump,
potentiating the antibiotic action of berberine."47
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This knowledge could be adapted to attack resistant strains of pathogenic bacteria
by using an MDR pump inhibitor in combination with an antimicrobial agent which is
normally effluxed by this pump. Thus, the design of dual action prodrugs and dual
action drugs to combat antibacterial resistance by reducing this antibacterial
permeability mechanism could be achieved potentially via a combination of
antibacterial agent and MDR pump inhibitor in the same molecule.

The linkage

between the two moieties could be designed to cleave under bacterial enzymatic action
(e.g. ester or amide hydrolysis) for dual action prodrugs, or to be a non-cleavable under
enzymatic action for dual action drugs. The prodrugs should deliver synchronously (or
near synchronously) the antibacterial agent and the MDR pump inhibitor in high
concentration at or near the appropriate bacterial sites, and a dual mode of action would
be exerted.

Additionally, this approach could help to eliminate the undesirable

properties associated with administering the two parent molecules separately (dual
drugs) as summarized in Table 1-4.

Similar considerations could apply to the

development of novel antimalarial agents.
O
O

O

OH
OCH3
OH

O2N

R
N
H

O

5,7-Deoxyhydnocarpin-D

2-Aryl-5-nitro-1H-indole derivatives

There are a variety of antimicrobial agents and many types of MDR pump
inhibitors. In this project the antimicrobial agent of interest was the alkaloid berberine,
which has a range of antimicrobial activity, and the MDR pump inhibitor was focussed
on the flavonolignan 5,7-deoxyhydnocarpin-D,56 the most potent synthetic NorA pump
inhibitor, and on the simpler 2-aryl-5-nitro-1H-indole NorA pump inhibitor derivatives.
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Berberine

Linker

Cleavable linker
(ester or amide bond)

Antibacterial Berberine derivative

Pump Inhibitor
Non-cleavable linker
(C-C bond)

Dual action drug

+

Pump inbibitor
(Dual action prodrug)
Figure 1-13 Diagram illustrating the dual action prodrug and dual action drug designs

As shown in Figure 1-13, the dual action prodrugs and dual action drugs of efflux
pump inhibitor-berberine prodrugs are formed to enhance a drug’s utility. Once inside
the bacterial cell the dual action efflux pump inhibitor-berberine prodrugs with
cleavable linkages should revert to the antibacterial berberine derivative and efflux
pump inhibitor at the same time by an enzymatic or non-enzymatic process, and then
show their activities when they reach the target sites in high concentration. The dual
action efflux pump inhibitor-berberine hybrids with a non-cleavable linkage are similar
to the ones with cleavable linkage, but would not require a post-barrier transformation
process to release the two parent moieties.
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1.7 Aims of project
The aims of this project were:
1. To design new antimicrobial agents of berberine-based derivatives based on the
dual action prodrug and dual action drug concepts.
O
N

O

Potent Pump Inhibitor

Linker

13

XOMe
OMe

Model of dual action agents

2. To develop a synthetic route to the dual action agents.
3. To synthesize variants on the dual action agents with different enzyme-sensitive
linking groups (substituted ester; amide), and enzyme-insensitive linking groups.
4. To assess the antibacterial potency (and spectrum of activity) and antimalarial
activity of the new derivatives produced, and to define structure-activity
relationships.
5. To identify leads for further drug development.
6. To measure MDR inhibition of the new efflux pump inhibitors in the NorA efflux
pump.
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2

Chapter2: Synthesis of berberine derivatives

On the basis of the SARs of berberine analogues discussed in Chapter 1, substitution
at C-13 of berberine can increase the antibacterial activity. Thus, a combination of an
efflux pump inhibitor via the 13-position of berberine, based upon the dual action
prodrug and dual action drug concepts, formed the basis for the synthetic targets in this
study. The inhibitor was expected to act synergistically by preventing the expulsion of
the berberine-based pump substrate.
A number of 13-substitued berberine derivatives were thus prepared from
berberine chloride in 3 steps via dihydroberberine (Scheme 2-1) or in 2 steps via 8acetonyldihydroberberine derivatives (Scheme 2-2).9,57,58
O

O
N

O

OCH3

Berberine (1)

N

O

OCH3

Reduction

OCH3

dihydroberberine (2)

OCH3

Enamine alkylation
O

O
N

O
R

N

O

Oxidation
OCH3

OCH3

R

OCH3

OCH3
13-substituted berberine

Scheme

2-1

Preparation

of

13-substituted

13-substituted dihydroberberine

berberine

derivatives

from

berberine

via

dihydroberberine (Note: for simplicity the counterion for the salts is omitted in this Scheme and, on
occasion, also in subsequent Schemes)

In the first synthetic approach, berberine (1) was reduced with sodium
borohydride59 and potassium carbonate in methanol57 to afford dihydroberberine (2),
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followed by enamine alkylation with electrophiles (R-X), and subsequent oxidation with
N-chlorosuccinimide (NCS) or N-bromosuccinimide (NBS) to give the 13-substitued
berberine salt derivatives. The target compounds were also prepared in 2 steps (Scheme
2-2) by treatment of 1 with acetone and aqueous sodium hydroxide solution to afford 8acetonyldihydroberberine and subsequent enamine alkylation with electrophiles (R-X)
followed by elimination of acetone to afford the salt derivatives.

One problem

associated with the 8-acetonyldihydroberberine route is that the berberine salt (1) can be
regenerated quite readily by elimination.60

O

O
N

O

OCH3

Berberine (1)

N

O

CH2COCH3
OCH3

Mannich reaction

OCH3

OCH3
8-acetonyldihydroberberine
1. Enamine alkylation
2. Elimination
O
N

O
R

OCH3
OCH3

13-substituted berberine

Scheme 2-2 Preparation of 13-substituted berberines in 2 steps via 8-actonyldihydroberberine

2.1 Retrosynthesis of efflux pump inhibitor-berberine dual action
agents
The preparation of efflux pump inhibitor-berberine dual action agents with a
cleavable linker can be achieved via the DCC coupling of berberine acid derivative with
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a range of pump inhibitors. The alcohol derivative of the pump inhibitors can be
attached to a berberine acid derivative via an ester linkage.

Similarly, the amine

derivatives of pump blockers can be attached to a berberine acid derivative to form an
amide linkage (Model study 1). Alternatively, the dual action agents may be achieved
via enamine alkylation of dihydroberberine derivatives with an inhibitor containing an
alkyl halide group to give products both with cleavable and non-cleavable linkages
(Model study 2). The general retrosynthetic analysis with respect to the two model
studies is shown in Scheme 2-3.

O
N

O

Pump Inhibitor

Linker

OMe

13

OMe

Linker = CH2OCOCH2,
CH2NHCOCH2, CH2
(a) Making Linker
(Model study 1)

(b) Linker Attached
(Model study 2)
O

O
N

O

N

O

OMe

OMe

+
Pump Inhibitor
Y = OH, NH

COOH
CH2Y

+

OMe

OMe

Pump Inhibitor

Z

Z = CH2OCOCH2X, CH2NHCOCH2X,
CH2X
X = Halogen

Scheme 2-3 General retrosynthetic analysis of efflux pump inhibitor-berberine dual action agents
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2.2 Synthetic strategies
2.2.1 Model Study 1
In this model study, in summary, the tetrahydroberberine acid derivative 4 was
prepared (Scheme 2-4), and then coupled with benzyl alcohol as an MDR inhibitor
model. Subsequent oxidation then gave the berberine salt (7).
Preparation of the model target compound 7 began from commercially available
berberine chloride (1), which was reduced with sodium borohydride to give
dihydroberberine (2). Enamine alkylation of 2 with ethyl bromoactetate produced the
13-substituted iminium salt (2a) as an unstable product, which was reduced immediately
with sodium borohydride in methanol to afford the 13-substituted tetrahydroberberine
(3). Hydrolysis of 3 with an aqueous solution of lithium hydroxide in methanol gave
the tetrahydroberberine acid (4). DCC coupling of 4 with benzyl alcohol then afforded
the benzyl ester (5), followed by oxidation with NBS to yield the model target
compound (7). A detailed discussion of these steps is given in the following subsections.
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O
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O
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5

OCH3

DCC coupling
PhCH2OH

N
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OCH3
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Hydrolysis

OCH3

EtOOCH2C

3

OCH3

4

N

O

OCH3

Oxidation
O
N+

O
PhH2COOCH2C

7

BrOCH3
OCH3

Scheme 2-4 Synthetic strategy for preparation of efflux pump inhibitor-berberine prodrug via DCC
coupling.

2.2.1.1 Reduction of berberine chloride
Berberine chloride (1) has been reported to be reduced to its enamine (2) in high
yield using NaBH4 in an aprotic solvent (e.g. pyridine) or in a protic solvent (e.g.
MeOH) in the presence of K2CO3, the yield of 2 were 73%59 and 98%57, respectively.
In the present work, compound 2 was prepared by both methods. Reaction of 1 with
NaBH4 in pyridine (Scheme 2-5) was found in the present study to afford a higher yield
(96%) of 2 than from NaBH4 and MeOH in the presence of K2CO3 (53%, Scheme 2-6).
A possible mechanism for the latter reagent conditions is via a hydride transfer to C-8,
and then abstraction of the proton at C-13 by carbonate (Scheme 2-6). This method was
easier to handle than the NaBH4/pyridine method which required anhydrous conditions,
and the unpleasant solvent, pyridine.
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OCH3

96%
OCH3
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Scheme 2-5 Preparation of dihydroberberine (2) using NaBH4 in pyridine
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Scheme 2-6 Preparation of dihydroberberine (2) using NaBH4 in MeOH and K2CO3
O
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OCH3

H2O
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OH-
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Scheme 2-7 Possible by-product berberine hydroxide generated in the presence of strong base

In the NaBH4/MeOH reaction, a possible by-product could be formed from
MeOH in the presence of strong base, which can generate a methoxide ion. The
methoxide ion could attack at the C-8 atom of 1 to form an 8-methoxy enamine.
Subsequently, the enamine formed might be protonated by water in the reaction and
followed by washing successively the crude product with water (a stronger acid than
methanol), leading to elimination of methanol and formation ultimately of the hydroxide
(rather than methoxide) of 1 (Scheme 2-7).61
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2.2.1.2 Enamine alkylation and reduction
The alkylation of enamine 2 with ethyl bromoacetate produced the non-purified
iminium salt intermediate a in high yield (Scheme 2-8).

Scheme 2-8 Preparation of 13-ethylethanoate tetrahydroberberine (3)

Under various anhydrous reaction conditions, the highest yield of a obtained was
96% using neat ethyl bromoacetate and a reaction temperature of 100°C. Initially, the
reaction was tried using a solvent, e.g. toluene, to dissolve the starting enamine

2

first,

then an excess of dry ethyl bromoactate was added to the solution, and the reaction was
then carried out at 80°C. The yields obtained were in the range of 60-70%, with many
low polarity by-products being observed on TLC. Fortunately, the by-products were
easily removed by trituration with toluene.

As a result of the instability of the

intermediate a, it was reduced immediately by NaBH 4 in EtOH at room temperature to
yield the ester 3 in

88%

yield.

The structure o f 3 was confirmed by the *H NMR

spectrum, which showed the loss of the signal attributed to H-13, but a signal assigned
to H-13a as a broad singlet at

8

3.72 was observed instead. In addition, the data showed

a set of signals assigned to the methylene protons at 5 2.30 (1H), 2.44 (1H), and 3.98
(2H), which were attributed to the CH2CO and OCH 2 groups respectively, together with
a triplet signal ascribed to the methyl substituent of the ethyl ester at 5 1.15. MS (Cl)
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showed the molecular ion peak at m/z 426. All the spectroscopic data was consistent
with the addition of an ethyl ethanoate substituent to the dihydroberberine at C-13.

2.2.1.3 Ester hydrolysis
The hydrolysis of ester 3 was attempted in both acidic and basic conditions. In
the case of acidic hydrolysis, 2M HCl and 1M H2SO4 did not hydrolyze ester 3 at room
temperature. Monitoring of the reaction by TLC before work-up of the reaction showed
the disappearance of the starting ester 3 and the presence of a more polar component
than ester 3. After neutralization with NaHCO3, and extraction with EtOAc, the product
spot on TLC (silica gel) reverted back to the same Rf as the starting ester 3. It is likely
that 3 was protonated on the nitrogen atom by the acid without hydrolysis occurring,
and then the free base of 3 was produced after neutralization. In contrast to the acidic
hydrolysis, the hydrolysis of 3 under basic conditions proceeded smoothly. Thus,
reaction of 3 with 2% LiOH in MeOH at 60oC62 gave the carboxylic acid 4 in 95% yield
(Scheme 2-9) after acidification. The 1H NMR and

13

C NMR spectra confirmed the

structure of acid 4 with the absence of ethyl group signals, and the presence of a
carboxylic acid carbonyl signal at δ 173.6 in the

13

C NMR, together with the MS (EI)

spectrum which showed a molecular ion peak at m/z 397 consistent with this product.

O
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O

2% LiOH (aq),
MeOH
OCH3

EtOOCH2C

3

OCH3

95%

N

O

OCH3

HOOCH2C

4

OCH3

Scheme 2-9 Preparation of acid derivative 4
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2.2.1.4 Esterification

The esterification of carboxylic acid 3 with benzyl alcohol was accomplished in
the presence of DCC and DMAP under anhydrous conditions. Attempts to esterify the
acid 4 with benzyl alcohol using EDCI with DMAP or DCC with HOBt in anhydrous
DMF were not successful. The benzyl ester 5 was obtained in 32% yield (Scheme 2-10)
with DCC and DMAP in DMF.

O

O
N

O

PhCH2OH, DMF
OCH3

HOOCH2C

4

DCC, DMAP,
32%

N

O
PhH2COOCH2C

OCH3

5

OCH3
OCH3

Scheme 2-10 Preparation of the benzyl ester berberine derivative 5

Initially the esterification was attempted using 1.5 eq of benzyl alcohol, 1.0 eq of
acid 4 in DMF in the presence of DCC and DMAP and heating at 40oC for 5 days. The
reaction was monitored by TLC (silica gel) until no starting acid 4 could be detected,
and then the reaction mixture was concentrated by distillation at 110oC to remove the
DMF.

Removal of the excess benzyl alcohol required increasing the distillation

temperature to 150oC, which gave many unwanted by-products.

However, using

exactly 1 equivalent of benzyl alcohol overcame this difficulty.

In the 1H NMR

spectrum of 5, signals assigned to five aromatic protons at δ 7.19-7.35 were apparent,
together with signals at δ 2.37 and 2.52 that were assigned to the CH2CO protons, and at
δ 4.97 which was ascribed to the OCH2 protons.
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2.2.1.5 Oxidation
The oxidation of tetrahydroberberines to their berberine salt derivatives was
achieved using an oxidizing agent, such as I2 in EtOH and NBS in CHCl3. Following a
literature procedure,63 an initial trial oxidation reaction of ester 3 was performed using I2
in EtOH. The iodide salt 6a was produced in 97% yield (Scheme 2-11).

O

O
N

O
R

OCH3

I2, EtOH or
NBS, CHCl3

N+

O

X-

R

OCH3
(3) R = CH2COOCH2Et
(5) R = CH2COOCH2Ph

OCH3
OCH3

(6a) X = I, R = CH2COOCH2Et, 97%
(7a) X = I, R = CH2COOCH2Ph, 16%
(7b) X = Br, R = CH2COOCH2Ph, 85%

Scheme 2-11 Oxidation of tetrahydroberberines to their berberine salt derivatives

Under similar conditions to those used for the oxidation of 6a, the ester 5 was
oxidized to produce 7 in low yield. Unlike the oxidation of 3, the oxidation of 5 did not
give any insoluble product material after the addition of Na2SO3 to destroy the excess I2.
Thus, the reaction mixture was evaporated and chromatographed on silica gel, but due
to the very strong interaction between the silica gel and product 7a, purification was
quite difficult. In a modified procedure, a large volume of EtOH was used in the
oxidation reaction, and purification on alumina gave 7a in 16% yield. Following a
general literature procedure,57 the oxidation of ester 5 was also carried out with NBS in
chloroform to afford the bromide salt 7b in high yield (85%). This method was milder
and quicker than that of iodine in EtOH. Moreover, the purification of product 7b did
not require recourse to chromatography. The structure of 7b was confirmed by the
presence of a singlet signal in the 1H NMR ascribed to H-8, which moved dramatically
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downfield from δ 3.50 and 4.18 (2H, in 5) to 10.56 (1H, in 7). Additionally, two proton
signals assigned to H-8 and H-13a in the starting material 5 were absent in the 1H NMR
spectrum of the product 7b. The MS (ES) showed a positive ion peak at m/z 484, which
corresponded to the molecular weight of compound 7.

2.2.2 Model Study 2
The basic synthetic strategy was to prepare the enamine (9) first, followed by
alkylation to the 13-substituted berberinium salts. A brief discussion on the two-step
preparation of the model target compounds 6b, 7b, 10-11 began from the commercially
available berberine chloride (1). Compound 1 was reacted with allyltributyltin to give
8-allyldihydroberberine (9). Subsequent enamine alkylation of 9 with a range of
alkylating agents produced the model targets (6b, 7b, 10-11) in moderate yield. The
detailed discussion is given in the following sub-sections.
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OCH3
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OCH3

Allylation

OCH3

1
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Enamine alkylation

+
OCH3

R

OCH3

OCH3

9

6b, 7b, 10-11

Scheme 2-12 Synthetic strategy for preparation of model efflux pump inhibitor-berberine prodrugs
via enamine alkylation.
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2.2.2.1 Allylation
α-Allylation of isoquinoline alkaloids can be accomplished by reaction with
allyltin reagents, resulting in high yields of product.

Commercially available

allyltributyltin was used as the allylating agent in the preparation of the enamine 9.
Based on an adapted literature procedure,64 the reaction was achieved by simply adding
excess allyltributyltin to a suspension of berberine chloride (1) in DCM in a sealed tube
and heating at 100oC for 8 hours. The product 9 was then obtained in 92% yield.

O
N+

O

O

Cl -

OCH3
OCH3

CH2=CHCH2SnBu3
dry DCM

O

N
OCH3

sealed tube
92%, 100oC

1

OCH3

9

Scheme 2-13 Preparation of 8-allyldihydroberberine 9

The structure of 9 was confirmed by the presence of a characteristic signal pattern
attributed to the allyl substituent in the 1H NMR spectrum. It showed two groups of
multiplet signals at δ 4.83-4.92 (2H) and 5.74-5.88 (1H), which were characteristic of
methylene and methine protons attached to an sp2 carbon (CH2=CH-). A multiplet
signal at δ 4.83-4.92 (2H) was assigned to the allylic methylene protons of the allyl
substituent. In addition, the signal ascribed to H-8 moved dramatically upfield from δ
9.76 in the chloride salt of 1 to δ 4.83-4.92 in the enamine 9, with an accompanying
change in multiplicity from a singlet in 1 to a multiplet in 9 due to the coupling between
H-8 and the allylic sp3 methylene group. The MS CI) showed a molecular ion signal at
m/z 378, which matched the molecular weight of compound 9.
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2.2.2.2 Enamine alkylation
13-Substituted berberine derivatives can be accessed by C-alkylation of 8acetonyldihydroberberine as mentioned above in Scheme 2-2. The problem with the 8acetonyldihydroberberine route is that the berberine salt (1) itself can be regenerated via
a retro-Mannich reaction, which is competitive with the enamine alkylation to generate
13-substitued berberine derivatives.60 To avoid this problem, the new 8allyldihydroberberine 9 route was utilized. Heating of enamine 9 with a variety of
bromide derivatives (ethyl bromoacetate, benzyl bromoacetate, phenacyl bromide and
benzyl bromide) at 100oC afforded the 13-substituted salts (6b, 7b, 10-11) in moderate
yield (scheme 2-14). It was found that using neat bromide alkylating agent derivatives
gave better yields than with an added solvent except in the case of phenacyl bromide,
for which a solution in acetonitrile was preferable.
O
O

O
N

Br N

O
OCH3

RBr
100oC

R

OCH3

9

+
OCH3
OCH3

(6b) R = CH2CO2CH2CH3, 59%
(7) R = CH2CO2CH2Ph, 57%
(10) R = CH2COPh, 55%
(11) R = CH2Ph, 62%

Scheme 2-14 Preparation of 13-substituted berberine salt derivatives

Mechanistically (Scheme 2-15), the formation of the salts may be rationalized in
terms of initial enamine alkylation of 9 to give the intermidiate 9a, followed by a [3,3]sigmatropic rearrangement to 9b and a subsequent retro-ene reaction65 to afford the salts

6b, 7b, 10-11 and propene. The alternative step of direct elimination of propene from
9a cannot be excluded however. While the acetonyldihydroberberine route to 13substituted berberinium salts may also involve a [3,3]-sigmatropic rearrangement of a
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tautomeric enol intermediate, this is considered less likely in view of the very low enol
concentration expected; the driving force again would be the eventual formation of the
aromatic ring in the berberine.
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Scheme 2-15 Proposed mechanism of formation of 13-substituted berberine salt derivatives

The structures of the 13-substituted berberine salts were confirmed by NMR
spectroscopic analysis and mass spectrometry. The 1H NMR spectrum of 6b, 7b, 10
and 11 revealed the loss of the allyl group with no signals present that could be ascribed
to this substituent. The presence of a signal assigned to the H-8 proton appeared in the
region of δ 10.46-10.61 as a singlet, while a triplet in the range of δ 2.9-3.2 was ascribed
to the C5 protons. A broad signal at δ 4.6-5.0 was ascribed to the C-6 protons, which
the methoxy group signals appeared at δ 3.8-4.2 and four aromatic methine proton
signals were also apparent. In addition, a signal ascribed to the methine carbon of C-8
in the region of δ 145-148 was observed in the 13C NMR of the products. Besides the
characteristic signal pattern attributed to the berberinium salt nucleus, the expected ethyl
ethanoate substituent signals of compound 6b were seen in the 1H NMR spectrum at δ
1.37 (3H) as a triplet, 4.36 (2H) as a quartet and 4.27 (2H) as a singlet. The MS (ES)
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showed a positive ion signal at m/z 422 which was consistent with the molecular ion of

6b. Compound 10 was also confirmed by a singlet signal attributed to the methylene
protons attached to the carbonyl function at δ 5.07, and a signal integrating for five
aromatic protons in the aromatic region. Moreover, the presence of a signal assigned to
the CO in the

13

C NMR spectrum was observed at δ 196.7 and MS (ES) showed a

positive ion peak at m/z 454 [MH]+, which was consistent with the molecular ion of 10.
The 1H and

13

C NMR spectra of compound 11 were broadly similar to those of 10

except for the absence of a carbonyl group signal in the

13

C NMR spectrum in the

former compound.
In summary, the “model study 2” provided a concise new route to access 13substituted berberine salts and it was chosen over “model study 1” for the later
preparation of the berberine-pump inhibitor dual action agents. In order to use this
route, it was necessary to prepare a variety of alkyl halide derivatives of the pump
inhibitors. The efflux pump inhibitors and their synthesis are discussed in the following
sub-sections.
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3

Chapter3: Synthesis of Efflux pump inhibitors

3.1 NorA efflux pump
NorA protein is a major multidrug transport protein in the human pathogenic
bacterium S. aureus, an organism which possesses several multidrug efflux pump
proteins.66 The NorA pump is a member of the Major Facilitator (MF) Superfamily
having 12 transmembrane-spanning segments and is dependant on the transmembrane
proton gradient to transport potentially harmful compounds out of the bacterial cell, and
is driven by the proton motive force as a source of energy. The NorA protein is located
in the cytoplasmic membrane and is encoded by the naturally occurring chromosomal
norA gene, conferring an intrinsic resistance to a variety of structurally unrelated
antibiotics.67 The mechanism by which the NorA efflux protein recognizes multiple
structurally dissimilar substrates is still unclear.

3.2 Substrates of the NorA efflux pump
As noted above, the NorA efflux pump actively exports a wide variety of
compounds that are all structurally very different from each other, making it a powerful
first line of defence for S. aureus against toxic molecules. Both naturally occurring and
synthetic compounds can be pump substrates, including hydrophilic fluoroquinolones
and monocationic organic compounds such as berberine, ethidium bromide,
tetraphenylphosphonium, benzalkonium, chlorhexidine, pentamidine, norfloxacin and
others (Figure 3-1).66,68 The precise mechanism of multidrug recognition of the NorA
pump is unclear due to the difficulty of performing high-resolution X-ray structural
analysis on integral membrane proteins.

Unfortunately none of the efflux pump

proteins belonging to the MF superfamily have been crystallized with bound substrates,
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which would provide a better understanding of how the efflux pump proteins can bind
and transport a wide range of structurally dissimilar substrates. Recently, the structures
of the first few homologous transporters to MFS-type multidrug efflux transporters,
lactose permease LacY and glycerol-3-phosphate transporter GlpT, which are not
multidrug efflux transporters per se, have been solved. These structures confirmed the
proposal that their hydrophilic substrates were bound to the MF superfamily
transporters within an intramembranous cavity.69-71
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Figure 3-1 Chemical structures of some NorA substrates
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3.3 Inhibitors of the NorA efflux pump
Recently, efflux pump inhibitors of the NorA efflux pump have been investigated
in order to potentiate the activity of antibiotics which are substrates of the efflux pump.
A variety of natural product and synthetic inhibitors of the NorA efflux pump have been
reported.
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Figure 3-2 Chemical structures of NorA inhibitors

Reserpine (Figure 3-2), an indole alkaloid obtained from root extracts of
Rauwolfia serpentina, was the first compound identified68 as a potential inhibitor of
NorA, which, when combined with a hydrophilic fluoroquinolone antibiotic, can
potentiate the antibiotic potency. Reserpine enhanced the activity of ciprofloxacin (MIC
= 8 µg/mL) against a fluoroquinolone-resistant strain of S. aureus SA-1199B, a strain
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that overexpresses NorA, by eight-fold at a concentration of 20 µg/mL.72 Reserpine also
prevented emergence of fluoroquinolone resistance in S. aureus73 and S. pneumoniae.74
Since reserpine is neurotoxic to humans at the concentration required for NorA
inhibition it cannot be used clinically as a NorA inhibitor.46 This lead to a search for
other compounds with more selective activity.

A number of structurally different inhibitors of NorA, such as the synthetic INF
analogues, have been reported by Influx Inc. (Chicago, IL) (Figure 3-2). Screening of a
chemical library containing 9600 compounds for NorA inhibitor activity resulted in 399
compounds (4%) which were structurally unrelated, and which had inhibitory activity
which was at least equipotent to that of reserpine. The chemical inhibitor library was
divided into several groups. The first group consisted of indole derivatives, of which
30 compounds were found to be active, and 7 of these were nitroindoles. The second
active group included compounds containing trichloromethylaminal functionality.
However, it was considered likely that compounds with this group would be toxic to
humans and therefore no further characterization of this group was conducted. The
third group contained biphenyl urea derivatives, with 11 compounds present in this
library being found to be active.

The last group contained structurally dissimilar

compounds including INF392, INF277, and INF 240 (Figure 3-2). Five of the most
potent INF analogue inhibitors were tested in combination with ciprofloxacin against
Staphylococcus aureus strain SA-1199B and found to act synergistically and also
reversed ciprofloxacin resistance four-fold (MIC of ciprofloxacin 2 versus 8 µg/mL) at
a concentration of 0.2, 0.4, 0.8, 1.5 and 1.5 µg/mL for INF392, INF240, INF277,
INF271, and INF55, respectively.46 The most potent inhibitor of all the INF analogues
was INF392, which was more potent than reserpine by fifty-fold. Also, INF392 reduced
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the MIC values of ethidium bromide and ciprofloxacin by eight-fold against SA-1199B
at a concentration of 0.4 µg/mL.75
A synthetic inhibitor of P-glycoprotein-mediated mammalian tumour multidrug
resistance, GG918 (Figure 3-2), was discovered to be a NorA inhibitor and was
equipotent to reserpine in potentiating the activity of norfloxacin and ciprofloxacin
against some strains of S. aureus. In combination with ciprofloxacin, GG918 reduced
the MIC of ciprofloxacin against SA-1199B eight-fold at a concentration of 10 µg/mL,
but did not show synergistic activity at the same concentration against the RN4220
strain of S. aureus, which carries a gene encoding the MsrA macrolide efflux protein.
Moreover, GG918 enhanced the activity of norfloxacin eight-fold against SA-1199B
and by four-fold against RN4220 at a concentration of 10 µg/mL.72

There was no

significant inhibitory activity of GG918 in combination with moxifloxacin against all
tested strains.
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Figure 3-3 Naturally occurring NorA inhibitors from Berberis species

Berberine-producing plants from Berberis species have been found to produce
potent NorA inhibitors, including porphyrin pheophorbide a and the flavonolignan 5´MHC-D,47-49 that act synergistically with the antibacterial berberine against S. aureus.
Berberine contains a planar aromatic cationic center which is recognized by efflux
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proteins in bacterial cells, resulting in its extrusion from the bacterial cells.
Pheophorbide a, and 5´-MHC-D, have no antibacterial activity alone but have been
shown to boost the activity of an ineffective antibiotic such as berberine against a NorAproducing strain of S. aureus. These results may help explain why Berberis plants are
relatively free of bacterial plant infections. The MIC of pheophorbide a and 5´-MHC-D
were 0.5 and 1.2 µg/mL, respectively, in the presence of 30 µg/mL of berberine a
concentration (which is one-eighth of its MIC against wild-type S. aureus RN4222).48
Many synthetic flavonolignans and simple flavones were synthesized in order to
determine structure-activity relationships (SARs) for synergistic activity with berberine
against S. aureus RN4222. Many of those compounds showed a synergistic action with
a sub-inhibitory concentration of berberine (30 µg/mL, 1/8 of the MIC) in the MIC
range of 0.08-163 µg/mL. The most potent flavonolignan-based NorA inhibitor was
5,7-deoxyhydnocarpin-D and the most potent flavone-based inhibitor was 4´-npropoxyflavone (Figure 3-4) with MIC values of 0.08 and 0.4 µg/ml, respectively, in
combination with a sub-inhibitory concentration of berberine in S. aureus. The results
revealed that the free hydroxy groups in ring A were not necessary for NorA inhibitory
activity.56 The effect of stereochemistry on activity was not reported for the 5,7deoxyhydnocarpin-D flavonolignan.
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Figure 3-4 The most potent synthetic flavonolignan (relative configuration shown) and flavone of
NorA inhibitors
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Recently, some naturally occurring flavonol

and isoflavone NorA inhibitors

(Figure 3-5) have been identified. A weak antibacterial, α-linolenic acid (MIC, 62.5
µg/mL against S. aureus wild-type 8325-4), was isolated from the leaf and stem extracts
of Lupinus argenteus, along with the flavonoids chrysoplenetin and biochanin A which
potentiated the antibacterial activity of that acid.
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Figure 3-5 Natural flavonol and isoflavone NorA inhibitors, and the antibacterial, α-linolenic acid

Biochanin A was the most potent inhibitor in this plant, and it was shown to
completely inhibit S. aureus and B. megaterium (11561, M. Cannon) growth at a
concentration of 6.25 µg/mL in combination with a sub-inhibitory concentration of
berberine (30 µg/mL) or a sub-inhibitory concentration of α-linolenic acid (30 µg/mL).
Moreover, a SAR study of the flavone series found that the monomethoxy B-ring
derivatives of isoflavones were more potent than disubstitued B-ring derivatives.56,76
Additionally, in either the flavonolignans or flavonols, it was found that
compounds bearing a free hydroxy group at C-3 in ring C did not show efflux pump
inhibitory activity.

In contrast, compounds bearing a methoxy group at the same

position showed inhibitory activity in S. aureus.

For example, a combination of

chrysoplenetin, a natural flavonol extracted from Artemisa annua, at a concentration of
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6.25 µg/mL with a sub-inhibitory dose of berberine, completely inhibited the growth of
S. aureus 8325-4.77
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More recently, a new antibacterial flavonoid and six known phenolic compounds
(Figure 3-6) were isolated78 from the plant, Dalea versicolor, and they showed direct or
synergistic activities against S. aureus and B. cereus.

Both the methoxychalcone

derivative and stilbene derivative were equally the most potent inhibitors in this plant at
a concentration of 3.3 µg/mL in combination with a sub-inhibitory concentration of
berberine against S. aureus 8325-4, whereas dalversinol and the tetrahydroxyflavanone
derivative (Figure 3-6) had direct activity with MICs of 31.3 and 7.8 µg/mL,
respectively. Typically, medicinal plants produce efflux pump inhibitors to potentiate
their own weak antibiotics. However, Dalea versicolor was the first plant reported in
the literature that produced both strong antibacterials and efflux pump inhibitors. It is
likely that dalversinol and the tetrahydroxyflavanone derivative, which have a flavanone
nucleus, might not be NorA pump substrates.
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Polyacylated neohesperidosides (Figure 3-7) isolated from Geranium caespitosum
were found to potentiate the antibacterial activity of berberine, rhein (an anthraquinone),
ciprofloxacin and norfloxacin against S. aureus 8325-4. Neither the monoester nor
diester derivatives showed potentiation activity with berberine, whereas the tetraester
and pentaester derivatives did with MIC values of 3.12-6.25 µg/mL in the presence of a
sub-inhibitory concentration of berberine.79
From all the literature data, the synthetic NorA inhibitor 5,7-deoxyhydnocarpinD,56 with an MIC value of 0.08 µg/mL, is the most potent inhibitor discovered so far. In
comparison to reserpine having efflux pump inhibitory activity at a concentration of 20
µg/mL in combination with a sub-inhibitory dose of berberine,77 it was found that 5,7deoxyhydnocarpin-D was more active than reserpine by 250-fold against S. aureus
8325-4. Thus, in the present study this inhibitor was chosen initially for synthesis and
ultimately for combination with berberine to make dual action prodrugs and dual action
antibacterials.

3.3.1 Synthesis of 5,7-deoxyhydnocarpin-D (12)
Following a literature procedure,56 commercially available coniferyl alcohol and
3´,4´-dihydroxyflavone were oxidatively coupled using Ag2CO3. Either Ag2CO3 or
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horseradish peroxide (HRP) was used previously56 for the preparation of 12 and 14
yielding a mixture of different regioisomers. The silver reactions gave 12 as a major
regioisomer, having ring D at C-13 with the beta position, whereas the HRP reactions
gave 14 as the major regioisomer product having ring D at C-12 with the alpha position.

OH

5'

OH

6'
8

O

OH

Ag2CO3

OCH3

+
O

coniferyl alcohol

A

O

12

O

13

3
5

OH
2''

2'

C

6

Acetone, Benzene
12%

OH

3',4'-dihydroxyflavone

7

O

B

6''
5''

12

O

O
O

O

OCH3

or

13

OH
O
O

12

13

OH
O

OH

+

OH
12

OCH3

D

13a

OH
OCH3

+

O

12

O

13

OCH3
OH

OH

13b

O

O

14

Scheme 3-1 Preparation of flavonolignan 12

The reaction with Ag2CO3 was performed in a solvent mixture of 2:1
benzene/acetone at 60oC for 10h.

Purification of the crude product by column

chromatography gave only one major fraction, which was shown to be a mixture of
regio- and stereoisomers on the basis of the 1H NMR spectroscopic data. Further
purification of the fraction was performed by PLC with multiple development, resulting
in 7 product bands with similar Rf values. Three of these bands were processed to
afford the regiopure compound 12 as a major product, and two minor products, 13(a or

b) and 14 (Scheme 3-1), which were confirmed by NMR spectroscopic analysis. Guz et
al.49,56 were not able to separate a mixture of 12 and 14 using HPLC methods. As
acetylation of the mixture 12/14 facilitated an easier separation of the mixed products,
49

the NMR spectroscopic data of the peracetate derivative of 12 were reported by these
authors.
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Scheme 3-2 Free radical mechanism for the formation of 12 and 14

Mechanistically, the coupling of coniferyl alcohol and 3´,4´-dihydroxyflavone is
likely to proceed via the corresponding phenoxy radicals and phenoxide anions, which
then react via an intermolecular Michael-type addition of the phenoxide anion a or b on
the oxidation product c, followed by intramolecular free radical coupling80 to give either

12 or 14 (Scheme 3-2). The formation of 12 and 14 depended on whether anions a or b
were formed, with anion a being the precursor of product 12 and anion b being the
precursor of product 14.81
The structure of 12 was confirmed by NMR spectroscopic analysis and mass
spectrometry. In the 1H NMR spectrum, the four ring A aromatic protons gave signals
in the aromatic region (δ 7.06-8.20), which appeared as two doublet of doublets (dd)
attributed to H-5 and H-8, and two doublet of doublet of doublets (ddd) were ascribed to
H-6 and H-7. Three aromatic proton signals ascribed to those of ring B were also in a
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similar region to those of ring A and they appeared as a meta-coupled doublet assigned
to H-2´, and an ortho-coupled doublet assigned to H-5´ and H-6´. A singlet signal
attributed to H-3 of ring C appeared at δ 6.72. Three aromatic proton signals for ring D
appeared as an ortho-coupled doublet assigned to H-5´´ and H-6´´ at δ 6.95 (2H), and as
a singlet attributed to H-2´´, as well as methoxy and hydroxy signals at δ 3.92 and 5.83
as a singlet and broad singlet, respectively. The hydroxymethyl proton signals appeared
at δ 3.58 and 3.85 as two doublet of doublets sets, and the presence of signals at δ 5.00
(d, J = 8.4 Hz) and δ 4.08-4.14 (m), for the methine protons H12/H13; these could
correspond to either isomer 12a or 12b (Figure 3-8).
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Figure 3-8 Possible structures of 12 and 14

Connectivities in structure 12 were established from the HMBC experiment, and
the upfield chemical shift value of H-13 (δ 5.00, d) (relative to the value for H-12 at δ
5.03 (d) in 14) confirmed49 the regioisomer shown (12

12a; Figure 3-8).

The structure of the regioisomer 14 was confirmed by 1H NMR spectroscopic
analysis, in which the 1H NMR spectrum was almost identical to that of 12 including a
characteristic doublet signal at δ 5.03 (d, J = 8.4 Hz) for H-12ax-H-13ax coupling. The
chemical shift of the signal for H-12 (in 14) was slightly more downfield than that of H13 (in 12). Thus, the isomer 14 was assigned as 12b (Figure 3-8).
The 1H NMR spectrum of 13 was similar to that of 12 and 14 except for the
presence of signals attributed to H-12 and H-13 at δ 5.27 (d, J = 3.0 Hz) and δ 4.57-4.63
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(m) corresponding to either structure 13a or 13b (Scheme 3-1). Therefore, if 13 was a
mixture of 12 and 14, two sets of doublet signals in the region of δ 4.9-5.0 with a vicinal
coupling constant for diaxial protons H-12, H-13 (Jax,ax ~ 8-13 Hz ) would be expected
in the 1H NMR spectrum. On the contrary, the 1H NMR spectrum of 13 revealed a
single doublet signal at δ 5.27 (d, J = 3.0 Hz) indicating a vicinal coupling of axial and
equatorial protons (Jax,eq ~ 2-6 Hz) or of diequatorial protons (Jeq,eq ~ 2-5 Hz).82
Therefore 13, therefore, is tentatively assigned as one of the isomers as shown in
Scheme 3-3.
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Unfortunately no spectroscopic data for compounds 12, 13, and 14 were reported
in the literature. The data for the peracetate derivative of 12 were reported however and
thus acetylation of this compound was undertaken.

3.3.1.1 Acetylation of the regioisomer 12
Acetylation of 12 was preformed using standard acetic anhydride/pyridine
conditions. The structure of the diacetate product 15 was confirmed by NMR
spectroscopic analysis and mass spectrometry.
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Table 3-1 A comparison of 1H NMR spectroscopic data for 14 with those reported56 for the
peracetate of 5,7-deoxyhydnocarpin-D
1

H

15 (δ ppm, CDCl3)

Report Data56 (δ ppm, CDCl3)

OAc

2.06 (s)

2.09 (s)

OAc
OCH3
H-11
H-12
H-11
H-13
H-3
H-6''
H-2''
H-5''
H-8
H-7
H-5'
H-6'
H-2'
H-6
H-5

2.31 (s)
3.85 (s)
4.02 (dd, 12.3, 4.2)
4.26-4.36 (m)
4.38 (dd, 12.2, 3.2)
4.98 (d, 7.8)
6.73 (s)
6.97 (dd, 7.8, 1.5)
6.99 (s)
7.09 (d, 8.4)
7.09 (d, 8.4)
7.39 (br.t, 8.1)
7.48-7.54 (m)
7.48-7.54 (m)
7.58 (d, 2.1)
7.63-7.70 (m)
8.20 (dd, 7.8, 1.5)

2.35 (s)
3.89 (s)
4.04 (dd, 12.4, 4.4)
4.36 (m)
4.42 (dd, 12.4, 3.2)
5.01 (d, 8.0)
6.76 (s)
7.02 (m)
7.00 (d, 2.0)
7.12 (d, 8.0)
7.12 (d, 8.0)
7.42 (ddd, 8.2, 6.8, 0.8)
7.54 (dd, 8.4, 1.6)
7.63 (dd, 8.0, 2.0)
7.61 (d, 2.0)
7.70 (ddd, 8.6, 7.0, 1.6)
8.23 (dd, 8.4, 1.6)

NMR spectroscopic data for 15 was almost the same as that for the peracetate of
5,7-deoxyhydnocarpin-D reported in the literature (Table 3-1).56

Unfortunately, the

key correlation of H-13 to C-3´ was not seen in the HMBC spectrum as expected. Thus,
the identity of 15 with the peracetate of 5,7-deoxyhydnocarpin-D would not be
confirmed. Due to the difficulties experienced, further work on compound 12 and its
coupling to a berberine acid derivative, was not pursued.
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3.3.2 Syn thesis o f 2 -a r y l-5 -n itr o -l//-in d o le s
Synthetically more accessible efflux pump inhibitors were then investigated. INF
55,

one of the most active synthetic NorA efflux pump inhibitors amongst the indole

analogues, was the inhibitor of choice (Figure 3-2). At a concentration of 1.5 |J.g/mL,
INF55 potentiated the activity of ciprofloxacin four-fold against S. aureus SA1199-B.
Thus, the next target pump inhibitors were designed to modify INF55 (5-nitro-2-phenyll//-indole) in order to provide a linking functionality in the new target molecule, which
could be attached to the antibacterial berberine based on the dual action prodrug and
dual action drug concepts.

2-(2-methoxyphenyl)-5-nitro-l//-indole

2-(4-methoxyphenyl)-5-nitro-l//-indole

Figure 3-9 Related INF55 derivatives were predicted to possess NorA inhibitory activity83

Some related 2-aryl-5-nitro-l//-indole derivatives (Figure 3-9) have been
predicted83 by CoMFA (3D-QSAR) analysis to have pump blocking activity.

In

particular, 2-(2-methoxyphenyl)-5-nitro-l//-indole was predicted to show comparable
activity to INF55, with ort/jo-substitution on the 2-phenyl ring, while 2-(4methoxyphenyl)-5-nitro-l//-indole, with ^ara-substitution on the 2-phenyl ring was
predicted to be less active than INF55. Therefore, the linking functionality for the 2aryl-5-nitro-l//-indole derivatives in the present study was designed to be preferentially
at the orr/zo-position on the 2-phenyl ring. Subsequently, simple lipophilic groups such
as OCH3 and OCH 2Ph, which could also act as H-bond acceptors, were added as
substituents in the me/a-position on the

2 -aryl

ring in order to investigate structure54

activity relationships.

However, preparation of the linking functionality for these

designed compounds at the para-position on the 2-phenyl ring was not ruled out and an
attempt to access these via the Fischer indole synthesis was also undertaken (Section
3.3.3).
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Scheme 3-5 Designed INF55 derivatives to access the dual action prodrugs and dual action drugs

Following the model study 1 (Section 2.2.1), an alcohol derivative of INF55
(Scheme 3-5) was eventually chosen as the first functionalised pump inhibitor target in
order to access ultimately the dual action prodrug with a cleavable ester linkage.
Subsequently, the alcohol derivative was converted to an amine for making the dual
action prodrug with a potentially cleavable amide linkage. Alternatively, the alcohol
could be converted to a variety of halide derivatives, such as; bromoacetate,
bromoacetamide, and bromide derivatives, in order to access the dual action ester and
amide prodrugs, and dual action drugs via the methodology established in model study
2 (Section 2.2.2).

55

3.3.3 Attempted synthesis of 2-aryl-5-nitro-1H-indoles via Fischer
indolization
Prior to the synthesis of the ortho-substituted 2-aryl group analogues of INF55,
some preliminary work was undertaken aimed at para-substituted analogues. Synthesis
of the alcohol derivative 16g of 5-nitro-2-phenyl-1H-indole (Scheme 3-6) was the first
synthetic target in this early phase of the work. It was expected this derivative could be
accessed by the well established Fischer indole route for synthesizing substituted
indoles via arylhydrazones.

It was proposed that using commercially available 4-

nitrophenylhydrazine and 4-acetylbenzonitrile as reagents with an acid catalyst, the
indole 16e could be prepared. Subsequent hydrolysis of the benzonitrile 16e would
afford the benzoic acid 16f, and then selective reduction of the acid would give the
desired benzyl alcohol 16g.
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Scheme 3-6 Synthetic strategy to 4-(5-nitro-1H-indol-2-yl)benzyl alcohol (16g)

The general mechanism84for the Fisher indolisation reaction is shown in Scheme
3-7. Proton-tautomerization of hydrazone 16, which is simply prepared by the treatment
of 4-nitrophenylhydrazine and 4-acetylbenzonitrile with an acid catalyst, generates the
enehydrazine 16a. A subsequent [3,3]-sigmatropic rearrangement, the key step of the
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mechanism, gives 16b and then elimination of ammonia affords the desired indole 16e.
An acid catalyst is necessary to accelerate the formation of the enehydrazine 16a from
the proton-tautomerization of hydrazone 16.

A variety of acid catalysts can be

employed, for example metal halides (zinc chloride is the most frequently used),
mineral acids (hydrochloric, sulfuric, and polyphosphoric acids), and organic acids
(actetic acid).85-88 Moreover, microwave irradiation has been used to facilitate this
reaction.89
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Scheme 3-7 Mechanism for the Fischer indole synthesis of 16e

The Fischer indole synthesis of 16e from 4-nitrophenylhydrazine and 4acetylbenzonitrile was attempted a number of times with various types of acid catalysts
such as p-toluenesulfonic acid, glacial acetic acid, hydrochloric acid, phosphoric acid,
polyphosphoric acid and BF3-etherate.

All reactions gave the same product, the

hydrazone 16, which was confirmed by 1H NMR and MS spectroscopic data. The 1H
NMR spectrum of 16 in CDCl3 showed four doublet signals which integrated for eight
aromatic protons with ortho-coupling at δ 7.40 (2H) and 8.15 (2H) which were
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attributed to H-2, H-6 and H-3, H-5 on the aromatic ring bearing the para-nitro
substituent, and at δ 7.86 (2H) and 8.00 (2H) ascribed to H-2´, H-6´ and H-3´, H-5´ on
the aromatic ring bearing the para-cyano substituent. A singlet signal at δ 3.35 (3H)
was assigned to the methyl group adjacent to the imine functionality together with a
singlet signal at δ 10.43 attributed to the hydrazone NH proton. The MS (EI) spectrum
showed a signal at m/z 280, which represented the molecular ion of compound 16. Both
the 1H NMR and MS spectroscopic data were consistent with the hydrazone 16 and not
consistent with the indole 16e for which a characteristic signal (δ 6.5–7.0) for the H-3
proton of the indole would be expected. The problem associated with this method was
the inability to access the key [3,3]-sigmatropic rearrangement (16a to 16b) (Scheme 38) possibly due to the presence of electron-withdrawing substituents (-NO2 and –CN
groups) on both aromatic rings, which may hinder the protonation step and
rearrangement.

CN

CN
O2N

O2N

16a

N
H

NH

H

+

H

NH2
NH

16b

Scheme 3-8 Effect of electron-withdrawing groups on the [3,3]-sigmatropic rearrangement of 16a

More severe conditions were then investigated involving microwave irradiation at
high energy levels with short heating periods. The reactions were carried out under acid
conditions using either formic acid or neat ZnCl2.90 Unfortunately, none of the desired
product 16b was observed, and only hydrazone 16 was detected in formic acid reaction.
With neat ZnCl2 the conditions were too severe and no products were isolated.
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Therefore, alternative methods for the synthesis of 5-nitro-2-phenyl-1H-indole
derivatives bearing alcohol functionality were considered and the Fischer indole
synthesis strategy was abandoned.
Several routes have been described for the synthesis of 5-nitro-2-phenyl-1Hindole (Scheme 3-9), including a palladium-assisted reaction of 4-nitro-2-bromoaniline
and α-piperidinostyrene,91 the Fischer indole synthesis of acetophenone with
phenylhydrazine and subsequent nitration,92 and reaction of 4-nitroaniline and dimethyl(2-oxo-2-phenyl-ethyl)-sulfonium bromide followed by cyclisation.93 However, there
are limitations with respect to functional group tolerances and selective introduction of
functionalities at desired positions in these approaches.

With the commercial

availability of 5-nitro-1H-indole in mind, particular attention in the alternative
approaches focussed on preformed indoles and introduction of an ortho-substituted aryl
group at the indolic C2 position.
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Scheme 3-9 Preparation of 5-nitro-2-phenyl-1H-indole (INF55)
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3.3.4 S yn thetic strategy for 2 -a r y l-5 -n itr o -l//-in d o Ie derivatives via
palladium cyclization
A regioselective synthesis of 2-arylindoles from indole was reported by
Itahara.94,95 His work involved the synthesis o f 2-(o-indolyl)benzoic acids via ring
closure of 1-aroylindoles using palladium acetate followed by hydrolysis (Scheme 3-

*

in d o le

V /

l- a r o y lin d o le s

~R

O

6 - o \o - 6 I I - is o in d o lo |2 ,l- a |in d o lc s

R = H, 47%
= CH3, 42%
= Cl, 43%

o -(2 -in d o ly l)b e n z o ic a c id s

R = H, 75%
= CH3, 74%
= Cl, 70%

Scheme 3-10 Preparation of o-(2-indolyl)benzoic acids via intramolecular ring closure of 1aroylindoles 94,95

Itahara’s approach was of interest as it was a regioselective and concise three-step
method with potential for the introduction of a range of substituents. It was expected
that the

2 -(o-indolyl)benzoic

acids produced could be easily reduced to the desired

primary alcohols, and the latter then converted to other substituted derivatives. Thus,
the general method of Itahara was adapted in the current work using commercially
available 5-nitro-l//-indole (17) as a starting material for the synthesis of 2-(oindolyl)benzyl alcohols as shown in Scheme 3-11.

60

O2N

N-acylation

O2N

Ring closure

N
H

O2N

R

N

17

N

O

R

O

18; R = H

33; R = H
Hydrolysis

O2N

BrH2C

HOH2C

Bromination O N
2

N
H

53; R = H

N
H

R

41; R = H

Reduction

O2N

O2N

45; R = H

38; R = H

R

O-alkylation

H2NH2C
N
H

N
H

R

Amination

HOOC

O2N

R

BrH2COCOH2C
N
H

51; R = H

R

N-alkylation

O2N

BrH2COCHNH2C
N
H

49; R = H

Proposed substituents ;
R = OCH3, OCH2Ph
R

Scheme 3-11 Synthetic strategy for 5-nitro-2-phenyl-1H-indole derivatives

The basic synthetic strategy was to initially prepare N-benzoyl-5-nitroindole (18)
by N-acylation of the commercially available 5-nitro-1H-indole (17), followed by an
intramolecular oxidative ring-closure by palladium cyclisation, then ring-opening by
amide hydrolysis and subsequent specific reduction of the benzoic acid 38 to afford the
benzyl alcohol 41 which could then be converted into various alkylating agents 49, 51
and 53. The bromoacetate 51 was prepared from 41 in one-step by O-alkylation and the
benzyl bromide 53 was also prepared from 41 in one-step by bromination, whereas the
bromoacetamide 49 was prepared from the benzylamine 45 obtained in turn from
amination of 41. Similarly, the other methoxy and benzyloxy derivatives of alcohol 41
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were to be prepared and then the various alkylating agents also would be synthesized
following the same synthetic strategy.

3.3.4.1 N-acylation of indoles
The N-acylation of indoles is a well established reaction that is used to protect the
indolic nitrogen with an acyl group96,97 which can then be easily removed by base
hydrolysis98, and also to provide precursors for intramolecular cyclization.99 The most
common N-acylation method requires the generation of an indole anion (by addition of
a base, e.g. BuLi,100 NaH,101,102 KOH,102 and K2CO3103) followed by nucleophilic attack
on an acyl halide. N-acetylation of indoles can be achieved in high yields using acetic
anhydride in combination with TEA and a catalytic amount of DMAP.104 Also direct Nacylation of indole with carboxylic acids catalyzed by boric acid affords N-acylated
indoles in moderate yield.105
In the present work, a variety of N-acylated indoles (Scheme 3-12) were prepared
via the acid chloride method with strong bases, NaH (method A) or n-BuLi (method B),
at low temperature, together with the direct coupling method with carboxylic acids and
boric acid (method C). Additionally, a new method using carboxylic acids with DCC
A) R1COCl, NaH
B) R1COCl, n-BuLi

R
N
H

R = H, OCH3, NO2, F

C) R1COOH, B(OH)3
D) R1COOH, DMAP, DCC

R
N
O

R1

(18-32)
24 R = H, R1 = Ph
25 R = H, R1 = Ph-p-OCH3
26 R = H, R1 =Ph-o-OCH3
27 R = OCH3, R1 = Ph
28 R = OCH3, R1 = Ph-p-OCH3
18 R = NO2, R1 = Ph
19 R = NO2, R1 = Ph-p-OCH3

32 R = NO2, R1 =Ph-o-OCH3
22 R = NO2, R1 =Ph-p-OBn
23 R = NO2, R1 = CH2Ph
29 R = F, R1 = Ph
30 R = F, R1 = Ph-p-OCH3
31 R = F, R1 = Ph-o-OCH3

Scheme 3-12 Methods for N-acylation of indoles
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and DMAP as carboxylate activators at room temperature (method D) was explored. It
was found the NaH and n-BuLi methods under low temperature conditions worked well
with commercially available benzoyl chlorides only, leading to the desired N-acylated
indole products in high yields except for 22 with the 4-benzyloxybenzoyl chloride,
which was very sensitive to moisture.

To avoid the use of acid chlorides, direct

coupling of carboxylic acids to the indoles using boric acid in mesitylene at reflux was
trialled, but only low yields of N-acylated products were obtained. Thus, investigation
of a simpler and milder new method for the direct acylation of indoles with carboxylic
acids using DCC as the coupling agent was developed in this project. High yields were
obtained when an electron-withdrawing group was present at C-5, however this method
was less effective with a C-5 electron donating group (Table 3-2).
A variety of N-acylated products of indoles bearing electron-donating and
electron-withdrawing groups were synthesized by methods A-D (Scheme 3-12) in order
to compare yields and to find the optimal approaches. The results from Table 3-1
revealed the most efficient methods for the N-acylation of indole and its derivatives
bearing an electron-donating group at C-5 were methods A and B using the highly
flammable NaH and n-BuLi, respectively, and the appropriate acid chlorides. Method B
(using n-BuLi) required a shorter reaction time and less reaction steps than method A.
In the case of indoles with electron-withdrawing groups at C-5, the simple and efficient
method for N-acylation was method D using carboxylic acids and DCC/DMAP at room
temperature, which involved milder conditions and avoided the extra step of acid
chloride preparation when they were not available commercially.
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Table 3-2 Percentage yields of N-acylated products of indoles
Product
24

Method
A

N

C

Yield (%)
88
45104
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32

O
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D
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N

D

89

N

D

87

D

85

N
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O

N

25

Method

Product

N

D

46

OCH3

O

O2N

23

O

D

34

A

7295

D

15

H3CO

N
O

F

27

N
O

H3CO

31
O

F
N

28

D

9

30

O

O
OCH3

O2N

18

A

N
O

O2N

19

N

OCH3

F

89

D

91

B

44

D

95

31

N

OCH3

O

O

OCH3

3.3.4.1.1 Discussion of the N-acylation of indole
The preparation of N-benzoyl indole 24 was carried out via methods A and D and
yields were compared with the yield reported for method C.105 Method A required
reaction of indole with NaH for 2 h to ensure complete formation of the indole sodium
salt. Subsequent alkylation of the deprotonated indole with benzoyl chloride at –60oC
to 70oC then afforded the desired product 24, which had almost the same Rf value as the
starting indole, resulting in a difficult purification by chromatography since some
starting material remained. Recrystallization of 24 from warm ethanol afforded 24 in
88% yield. In comparison, method D involved a direct acylation of indole with benzoic
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acid using the dehydrating agent DCC in the presence of DMAP to afford 24 in low
yield (32%) together with unreacted indole. In this case the low yield is probably a
result of incomplete deprotonation of the indolic NH (pKa ~ 17) by the DMAP, since
the indolide anion is presumably involved in the key penultimate nucleophilic attack on
the acid-DCC intermediate (Scheme 3-13). In general terms, the carboxylic acid forms
an adduct with DCC which then acts as a good leaving group, on subsequent
nucleophilic attack by the indolide anion (generated by DMAP deprotonation) to afford
the desired amide and dicyclohexylurea. An additional preparation of 24 via direct
acylation of indole with benzoic acid in the presence of boric acid has been reported
previously by Terashima and afforded 24 in 45% yield.105 The role of boric acid in this
reaction is unclear.
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+
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+

Cyc-NH-CO-NH-Cyc
DHU
Scheme 3-13 Mechanism of the DCC coupling of indole and carboxylic acid in the presence of
DMAP

The preparation of 25 was also achieved by method D using indole and 4methoxybenzoic acid with DCC/DMAP. The reaction was carried out overnight at
room temperature to afford 25 in 46% yield. The amide 25 had also been made
previously by Welstead in 75% yield96 by method A using NaH and 4-methoxybenzoyl
chloride. Thus in this case method A was again better than method D.
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The preparation of 26 was accomplished by method D using indole with 2methoxybenzoic acid and DCC/DMAP. The reaction was carried out for 3 days giving

26 in 34% yield. The structure of 26 was confirmed by NMR spectroscopy and mass
spectrometry. The 1H NMR spectrum revealed the absence of a broad singlet signal
near δ 8.00 which could be assigned to the indolic NH. The presence of a 3-proton
singlet at δ 3.79 was attributed to the aromatic methoxy group. A broad doublet signal
at δ 8.44 was assigned to H-7. The broad signal for H-7 appeared to be associated with
partial conformational restriction in the acylated region of the molecule.

Signals

attributed to H-3´, 4´, 5´ and 6´ in the o-methoxybenzoyl moiety appeared as multiplets
in the region of δ 7.00-7.60. Additionally, in the 13C NMR spectrum a signal at δ 167.2
was assigned to the carbonyl carbon, while the HRMS (EI) spectrum supported the
supported the molecular formula of 26.

3.3.4.1.2 Discussion of the N-acylation of 5-methoxyindole
The preparation of 27 (Table 3-2) was achieved by method D using 5methoxyindole with benzoic acid and DCC/DMAP. The reaction mixture was stirred at
room temperature overnight to afford 27 in 32% yield, whereas the preparation of 27
has been reported in 72% yield by method A using 5-methoxyindole with benzoyl
chloride and a strong base (NaH).96 With an electron-donating group at C-5 in the
indole, product formation in method D proceeded generally in low yield, and was not
successful in the attempted synthesis of acylated product from 5-methoxyindole and 2methoxybenzoic acid. Since the methoxy substituent is an electron-donating group, it
would increase electron density adjacent to the indole nitrogen in the para position
reducing the acidity of the 5-methoxyindole and hence retarding indolide anion
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formation via reaction with DMAP. The structure of 27 was confirmed by 1H NMR
spectroscopic data and mass spectrometry. The 1H NMR spectrum showed the presence
of a singlet signal ascribed to the methoxy group at δ 3.88 and the absence of a broad
singlet signal which could be attributed to an indolic proton. Two sets of multiplets
between δ 7.48-7.75, integrating for a total of 5 protons, were attributed to the aromatic
protons of the benzoyl moiety. Additional confirmation of the structure was provided
by the HRMS (EI) spectrum, which showed a molecular ion signal at m/z 251.0950,
consistent with the molecular formula of 27. In a similar result to that of 27, application
of method D to the reaction of 5-methoxyindole and 4-methoxybenzoic acid afforded
the N-acyl product 28 in only 9% yield.

3.3.4.1.3 Discussion of the N-acylation of 5-nitroindole
In contrast to the results with 5-methoxyindole, the preparation of 18 (Table 3-2)
was successful using both method A and D from 5-nitroindole and benzoic acid,
resulting in high yields (89-91%) without chromatographic purification, whereas this
compound previously has been prepared in only moderate yield by Cho et al. in a study
of selective cyclooxygenase-2 inhibitors.103 Cho’s method involved reaction of 5nitroindole and benzoyl chloride with potassium carbonate in DMF to afford 18 in 43%
yield. In the current study, the structure of 18 was confirmed by NMR spectroscopic
analysis and mass spectrometry. The 1H NMR spectrum showed a multiplet signal (δ
7.54-7.80) integrating for five protons which was attributed to the aromatic protons of
the benzoyl moiety. Additional confirmation of the structure was provided by the
HRMS (EI) spectrum with a signal at m/z 266.0688, which was consistent with the
molecular ion of compound 18.
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In the attempt to explore the effects of DMAP, DCC and carboxylic acid
concentrations on the reaction outcome, 5-nitroindole and 4-methoxybenzoic acid were
reacted using varying amounts of DMAP, DCC and the carboxylic acid. All reactions
gave product 19 in high yields (91-97%) as shown in Table 3-3. Taking into account
reaction time, the preferred conditions were those for entry 1.

Table 3-3 A variety of reagent amounts for the synthesis of 19 via method D

Entry 5-nitroindole
(eq)
1
2
3

1
1
1

acid
(eq)

DCC
(eq)

DMAP
(eq)

reaction time
(h)

yield
(%)

2
1.3
2

2
1.3
2

1
0.1
0.1

4
72
6

95
97
91

Moreover, the preparation of 19 was carried out from 5-nitroindole and 4methoxybenzoyl chloride via n-BuLi (method B) to afforded 19 in moderate yield
(44%).

Confirmation of the structure of 19 was provided by NMR spectroscopic

analysis and mass spectrometry. The 1H NMR spectrum revealed a singlet at δ 3.92
which integrated for three protons and was attributed to the methoxy protons. The
appearance of two equivalent signals integrating for two protons each at δ 7.05 and 7.77
were attributed to the aromatic protons in the para-substituted benzoyl moiety.
Furthermore, a signal ascribed to the carbonyl carbon was seen in the

13

C NMR

spectrum at δ 167.9, and in the HRMS (EI) a molecular ion peak was observed at m/z
296.0796 which corresponded to the molecular weight of 19.
Following the optimal conditions established for the synthesis of 19 via method

D, compound 32 was prepared from 5-nitroindole and 2-methoxybenzoic acid to afford
32 in 80% yield after recrystallization. The structure of 32 was confirmed by NMR
spectroscopic analysis and mass spectrometry.
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Scheme 3-14 Preparation of 4-benzyloxybenzoyl chloride

The first attempted preparation of the amide 22 was carried out by method B
using 5-nitroindole and the moisture-sensitive 4-benzyloxybenzoyl chloride.

The

preparation of 4-benzyloxybenzoyl chloride (Scheme 3-14) was based on a literature
procedure106 using 4-hydroxybenzoic acid and benzyl bromide in K2CO3 to generate 20
in 81% yield. Subsequent hydrolysis of the ester 20 using KOH afforded the acid 21 in
91% yield, followed by reaction with oxalyl chloride under anhydrous conditions to
afford the corresponding acid chloride. The acid chloride was found to be unstable due
to moisture sensitivity and could not be chromatographed, and thus the yield of the
subsequent acylated indolic product 22 was low (30%). Following the procedure used
to prepare 19 by method D, 22 was prepared from 5-nitroindole and the acid 21. The
reaction was carried out at 40oC in order to accelerate the reaction. However, the result
was different from what was expected. The reaction was monitored by TLC for 5 days,
and a consistent ratio of 1 to 1 of starting indole and product 22 was observed after day
2 of the reaction.

The reaction was stopped after 5 days and the mixture

chromatographed to afford 22 in 52% yield. It is likely that the N-acylated product 22
was partially hydrolyzed under the prolonged basic conditions regenerating some of the
5-nitroindole. The structure of 22 was confirmed by NMR spectroscopy and mass
spectrometry. The 1H NMR spectra of 22 were similar to 19 with the same signal
pattern above 6 ppm except for additional aromatic multiplet signals (δ 7.36-7.48)
integrating for five protons attributed to the five aromatic protons of the benzyl
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substituent. The 13C NMR spectrum also showed an additional five aromatic signals in
the range of δ 127.5-135.8 when compared to the spectrum for 19. Moreover, the 1H
NMR spectrum showed a distinct signal at δ 5.19 integrating for two protons, which
was ascribed to the methylene protons of the benzyloxy substituent and a methylene
carbon signal was also seen in the

13

C NMR at δ 70.3. The molecular formula of 22

was established by HRMS (EI).
Following the procedure described by Terashima105 (method C), the reaction of 5nitroindole and phenylacetic acid and boric acid in mesitylene at 185oC was investigated
for the preparation of 23 (Table 3-2). However, the N-acylated product 23 was only
obtained in very low yield (4%). Similarly, with method A using 5-nitroindole and
phenyl acetyl chloride with NaH in DMF at –60 to 70oC overnight, amide 23 was again
obtained in only low yield (19%).

The structure of 23 was confirmed by NMR

spectroscopic analysis and mass spectrometry. The 1H NMR spectrum showed a signal
integrating for two protons at δ 4.29 which was attributed to the methylene protons of
the phenyl acetyl moiety. An aromatic signal integrating for five protons was seen at δ
7.29-7.42 as a multiplet and was ascribed to the five aromatic protons of the phenyl
acetyl moiety. Additionally, the

13

C NMR spectrum showed a signal attributed to the

carbonyl carbon at δ 164.9 while the HRMS (CI) data was consistent with the molecular
formula of 23.

3.3.4.1.4 Discussion of the N-acylation of 5-fluoroindole
The preparation of a series of N-acylated products (29-31) (Table 3-2) of 5fluoroindole with various carboxylic acids (benzoic acid, 4-methoxybenzoic acid and 2methoxybenzoic acid) was carried out by method D. Compounds 29-31were obtained
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in high yield (85-89%) after chromatography. The structures of 29-31 were confirmed
by NMR spectroscopic analysis and mass spectrometry. The 1H NMR spectra of those
compounds revealed the absence of a signal attributable to an indolic NH proton. The
1

H NMR spectrum of 29 showed the presence of aromatic signals (δ 7.40-7.65 as

multiplets) integrating for five protons consistent with the presence of the benzoyl
moiety. Further confirmation was provided in the 13C NMR spectrum through a signal
attributed to the carbonyl carbon at δ 168.5 as well as by the HRMS (EI) spectrum
which gave a molecular ion peak at m/z 239.0738, consistent with the molecular
formula of 29.
The 1H NMR spectrum of 30 was very similar to that of 29 except for the loss of
one aromatic signal around δ 6.90-7.80 and the presence of a singlet signal (δ 3.91)
integrating for three protons assigned to the methoxy protons.

The HRMS (EI)

spectrum afforded a molecular ion peak at m/z 269.0854, consistent with the molecular
formula of 29.
All spectroscopic data for 31 were closely comparable to those of 30, with a small
difference in splitting pattern of the signals attributed to the aromatic protons of the
benzoyl moiety in a range of δ 6.90-7.80, and the signal assigned to H-7 at δ 8.44
appeared as a broadened multiplet in 31. The HRMS (EI) spectrum showed a signal at
m/z 269.0854, representing the molecular ion of 31.

3.3.4.2 Cyclization of the N-acylated indoles
The cyclisation of the N-acylated indoles 18, 19 and 22 was accomplished via a
palladium(II)-promoted oxidative intramolecular reaction. Accordingly, following a
method for the intramolecular reaction of 1-aroylindoles by palladium acetate which has
71

been reported previously by Itahara94 and shown in Scheme 3-10, the N-acylated indole

18 (Scheme 3-15) was reacted with one equivalent of palladium(II) acetate in glacial
acetic acid. The reaction was carried out at 110oC to afford the expected ring-closed
product 33.
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N
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O
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11

R
N
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18; R =H
19; R = OCH3
22; R = OCH2Ph
37; R = OH, 35%

33; R =H, 50%
34; R = OCH3, 74%
35; R = OCH2Ph, 20%
36; R = OH, 22%

Scheme 3-15 Intramolecular ring-closure of the N-acylated indoles

The reaction mixture, which still contained some of the starting indole 18, was
separated by flash chromatography. The separation was very difficult however due to
the very similar chromatographic properties of 33 and 18 and the tendency of 33 to elute
very slowly from the column. Thus, the separation by flash chromatography was
changed to vacuum liquid chromatography (VLC) which used reduced pressure and this
then gave a more rapid separation. Additionally, 33 had unusual solubility properties, in
that it was only partially soluble in various solvents such as DCM, DCM/MeOH,
PS/EtOAc and DMSO. After chromatography, 33 was obtained in 50% yield. The 1H
NMR spectrum of 33 revealed the loss of the doublet signal at δ 7.50 which could be
ascribed to H-2 in the starting material, together with the loss of an aromatic proton
signal. The characteristic signal attributed to H-11 appeared at δ 6.79 as a singlet,
which strongly supported the structure of 18.
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Mechanistically,107,108 the oxidative cyclization of the N-acylated product 18
probably involves initial indole C-2 palladation to form an σ−indolylpalladium(II)
complex 18a, which would be promoted by protonation of the acetate ligand of
Pd(OAc)2 by acetic acid (Scheme 3-16). Subsequently, complex 18a could undergo an
intramolecular insertion into the benzoyl ring to give 18b, followed by β-hydride
elimination of 18b to afford the ring-closed product 33.
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Scheme 3-16 Mechanism for the palladium(II)-promoted oxidative cyclization

As this reaction consumed one equivalent of Pd(OAc)2, which is expensive and
could not be recovered, the cyclization was then attempted using a catalytic amount of
Pd(OAc)2. Following a literature procedure109,110 using cupric acetate to reoxidize Pd(0)
to Pd(II), a solution of acetic acid solution containing 18, 0.1 equivalents of Pd(OAc)2
and 2.6 equivalents of Cu(OAc)2.H2O was heated under an air atmosphere at 95oC for 5
days to give 33 in 29% yield, with over 50% of the starting material 18 still remaining.
The attempted reoxidation of the Pd metal back to Pd(II) by Cu(OAc)2 was thus
unsuccessful and hence one equivalent of Pd(II) was still required for the preparation of
derivatives of 18.
In further work, the N-acylated product 19 was reacted with 1.0 equivalent of
Pd(OAc)2 in glacial acetic acid to afford the ring-closed product 34 in high yield (74%,
Scheme 3-15). It is likely that the electron releasing para-substitutent of 18a (R =
73

OCH3) would facilitate the insertion step for ring closure (Scheme 3-16). Confirmation
of the structure of 34 was again provided by NMR spectroscopic analysis and mass
spectrometry. The 1H NMR showed a characteristic signal for ring-closed product at δ
6.77 as a singlet attributed to H-11 and which had no correlation with any nearby proton
in the gCOSY spectrum. The absence of the signal which could be ascribed to H-2
around δ 7.55 was also noted. Further support for the structure was provided by the
HRMS (EI) with a signal at m/z 294.0648, indicating the molecular formula of
compound 34.
Another derivative of 22 (R = OCH2Ph, Scheme 3-15) was prepared by reaction
of the N-acylated product 22 and Pd(OAc)2 in glacial acetic acid to afford the ringclosed product 35 in 20% yield and the unexpected products 36 and 37 in 20 and 35%
yields, respectively (Scheme 3-15). Debenzylation can be readily accomplished under
acidic conditions at reflux.111 Therefore, the cleavage of the benzyloxy subsituent in 22
and 35 could both occur together with the cyclization of 22. The mixture was purified
by VLC and 35 was easily removed from the chromatographically inseparable mixture
of 36 and 37.

Fortunately, the components of 36 and 37 had different solubility

properties, as 37 was completely soluble in 2% MeOH in DCM but 36 was not. Thus, a
suspension of the mixture of 36 and 37 in 2% MeOH in DCM was filtered to give the
ring-closed product 36 as a solid and 37 was retained in the filtrate. The phenol 36
could be converted to 35 in good yield by benzylation of the phenoxide anion with
benzyl bromide (Scheme 3-17).
O 2N

OH
N

PhCH2Br, CsCO3
DMF, 80oC
74%

O2N

OCH2Ph
N

O

O

36

35

Scheme 3-17 Benzylation of compound 35 with benzyl bromide
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In the 1H NMR of 35 a diagnostic singlet at δ 6.79 was assigned to H-11.
Unfortunately, the

13

C NMR spectrum in CDCl3 as solvent revealed only

methine/methylene carbon signals and the quaternary carbon signals were not seen.
Due to the partial solubility of compound 35 in CDCl3, the concentration of 35 was too
dilute for the quaternary carbon signals to be detected. The

13

C NMR spectrum was

reattempted in DMSO-d6, and in a solvent mix of CDCl3/CD3OD, in which the
solubility of 35 was much higher. The 13C NMR experiments were carried out at 25oC
overnight, however the same problem arose as with the CDCl3 spectrum with no
quaternary carbon signals being seen and some of 35 precipitated in the NMR tube. The
mass spectral data indicated cyclisation to 35 had occurred.
The structure of 36 was also confirmed by NMR spectroscopic analysis. The 1H
NMR revealed a characteristic singlet signal assigned to H-11 at δ 7.07. The absence of
a signal which could be ascribed to the methylene protons of the benzyloxy substituent
around δ 5.20 was also noted.
The structure of 37 was confirmed similarly by 1H NMR spectroscopic analysis.
The 1H NMR showed the loss of signals which could be assigned to the methylene
protons and the five aromatic protons of benzyloxy substituent. A doublet signal at δ
6.72 was attributed to H-3 and the gCOSY spectrum showed it was coupled to a doublet
signal at δ 7.53, which was thus assigned to H-2. The HRMS (EI) spectrum showed a
molecular ion peak at m/z 282.0638, indicating the molecular formula of 37 to be
C15H10N2O4.

75

3.3.4.3 Amide hydrolysis of the cyclized products
N, N-Disubstituted amides can be hydrolysed under acidic or alkaline conditions.
Based on the method of Itahara,95 alkaline hydrolysis of the cyclized products 33-35
was achieved at 82oC using t-BuOK in t-BuOH containing a small amount of H2O. The
amide hydrolysis was unsuccessful under normal conditions with either HCl/MeOH in
the presence of H2O or NaOH/MeOH in the presence of H2O.

O2N
N
O

COOH

O2N

R

t-BuOK, t-BuOH/H2O
82oC

33; R = H
34; R = OCH3
35; R = OCH2Ph

N
H
R

38; R = H, 95%
39; R = OCH3, 94%
40; R = OCH2Ph, 96%

Scheme 3-18 Amide hydrolysis of the cyclized products 33-35

On TLC analysis of the first attempted hydrolysis of 33, with t-BuOK in t-BuOH
(82oC, N2) for 12h only one clean product spot could be detected and none of the
starting material 33.

The reaction was then stopped and the literature work-up

procedure was followed. The reaction mixture was evaporated and diluted with a large
amount of water. The mixture was then carefully neutralized with dilute HCl and
extracted with diethyl ether. The ether extracts were dried with sodium sulfate and
evaporated to give a brown semicrystalline residue which was triturated with
ether/hexane to give the desired product 38 but, surprisingly, in very low yield (11%).
It was suspected the work-up procedure might be the problem and thus it was
reconsidered. The hydrolysis of 33 was reattempted with t-BuOK in t-BuOH containing
a small amount of H2O at 82oC, and after 12h, the reaction mixture was concentrated
and then added to a large amount of ice water. The reaction mixture was then acidified
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to pH1 using dilute HCl to give a yellow suspension. The suspension was saturated
with solid NaCl and then vigorously stirred until the yellow suspension changed to a
yellow solution. The reaction solution was then extracted with diethyl ether to afford
the desired acid 38 in high yield (95%). Presumably the effect of the NaCl was
important in reducing acid solubility in the aqueous phase and thus assisting extraction
of the product into the diethyl ether. Structural confirmation of 38 was provided by
NMR spectroscopic analysis and mass spectrometry. The 1H NMR spectrum showed a
similar signal pattern to the 1H NMR spectrum of the starting cyclized product 33.
However, the

13

C NMR spectrum displayed a downfield signal attributed to the

carbonyl carbon of a carboxylic acid at δ 171.7, while the HRMS (EI) spectrum
supported the molecular formula of 38.
Following the modified work-up procedure, the other two acid derivatives 39 and

40 were prepared from 34 and 35 in the same manner, and were obtained in 94% and
96% yields, respectively. The structure confirmation of 39 and 40 was provided by
NMR spectroscopic analysis and mass spectrometry. The 1H NMR spectrum of 39
showed a similar spectrum to the starting material 34 but with additional signal which
could be attributed to the indolic proton at δ 12.07 and this was confirmed by gHMBC
analysis. The 13C NMR spectrum revealed a signal ascribed to the carbonyl carbon of
the acid at δ 167.9 and the HRMS (EI) spectrum had a molecular ion peak at m/z
312.0749, supportive of the molecular formula of 39. The 1H NMR spectra of 40
showed similar signals to those of 39, together with extra signals which could be
assigned to the benzylic ether group.
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3.3.4.4 Reduction of acids to alcohols
Carboxylic acids are easily reduced to primary alcohol by LiAlH4 which is a
powerful but non-selective reagent. Alternative reagents were thus considered and
selective reduction of benzoic acid derivatives 38-40 in the presence of the nitro
substituent to the corresponding alcohols was accomplished with borane in
tetrahydrofuran without disturbing the reducible nitro substituent.

Moreover, the

reaction was remarkably facile and proceeded in high yield. A possible mechanism
involves the formation of an acyloxyborane in the first step (Scheme 3-19).
Subsequently, this moiety can undergo further reaction with borane and eventually
hydrolysis to the corresponding alcohol and boric acid.112,113

RCOOH + BH3

THF

RCOOBH2

RCH2OB

H2O

RCH2OH + B(OH)3

Scheme 3-19 Possible mechanism for reduction of carboxylic acids with borane in tetrahydrofuran
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CH2OH

O2N
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41; R = H, 99%
42; R = OCH3, 95%
43; R = OCH2Ph, 85%

Scheme 3-20 Selective reduction of the benzoic acid derivatives in the presence of a nitro
substituent

The benzoic acid 38 was reacted112 with excess borane-tetrahydrofuran complex
to afford the corresponding alcohol 41 in high yield (99%) (Scheme 3-20).

The

aromatic nitro group is inert toward borane. In the 1H NMR spectrum of 41 the
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presence of the new hydroxymethyl group was confirmed by a signal integrating for two
protons at δ 4.77. A signal for this methylene carbon was also apparent at δ 65.1 in the
13

C NMR spectrum, and this assignment was confirmed by a DEPT experiment..
The other benzyl alcohol derivatives 42 and 43 were prepared similarly from their

benzoic acid derivatives 39 and 40 in 95% and 85% yield, respectively (Scheme 3-20).
The 1H NMR analysis of 42 confirmed the formation of the benzyl alcohol derivative
with the presence of a signal ascribed to the methylene protons at δ 4.70. The presence
of a signal attributed to a methylene carbon at δ 64.6 and the absence of a carbonyl
group signal was noted in the 13C NMR spectrum. Correspondingly, the structure of 43
was confirmed by the disappearance of the signal assigned to the carbonyl carbon at δ
167.9 in the starting material 40 and the appearance of a signal attributed to the
methylene carbon at δ 70.2 in the

13

C NMR spectrum. Further confirmation of the

structure of the benzyl alcohol derivative 43 was provided by the presence of a two
proton singlet signal attributed to a methylene proton at δ 5.08 in the 1H NMR
spectrum; an M+ signal at m/z 374.1256 in the HRMS (EI) spectrum was consistent with
the molecular formula C22H18N2O4.

3.3.4.5 Attempted conversion of alcohols to amines
Typical methods to convert primary alcohols to primary amines involve a threestep procedure via the transformation of the alcohol to the corresponding halide or
sulfonate, which then undergoes nucleophilic substitution by the azide anion to afford
an alkyl azide and subsequent reduction of the azide to the desired primary amine.114-116
Alternatively the conversion of an alcohol to such an amine can be achieved in a facile
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one-pot process by a combination of reactions. An alcohol may be converted to the
corresponding azide/amine by using NaN3 and PPh3 in 20% CCl4 in DMF.117

PPh3 (1eq)
NaN3

R-OH

CCl4-DMF (1:4)

via azide
PPh3 (>2eq)

R-N3

PPh3

R-N=N-N=PPh3
-N2

(phosphazide)

R-N=PPh3
(iminophosphorane)
H2O

R-NH2
Scheme 3-21 A facile one pot methodology for the conversion of alcohols to azides or amines

Treatment of alcohols with NaN3 and two equivalents of PPh3 in CCl4-DMF (1:4)
at 90oC afforded their corresponding amines117 (Staudinger reaction) in excellent yield
(85-95%).

Using one equivalent of PPh3 in the same manner117 afforded the

corresponding azides. Azide formation occurs with the first equivalent of PPh3, and the
azide can then react with the second equivalent of PPh3 producing the
iminophosphorane intermediate (via the phosphazide), which can then be converted to
the amine by hydrolysis with water (Scheme 3-21). Thus treatment of alcohol 41 with
NaN3 and PPh3 (2 equivalents) in 25% CCl4 in DMF at 90oC, followed by the addition
of excess water to hydrolyze the expected iminophosphorane intermediate 44a, afforded
the undesired azide 44 without any of the desired amine 45 (or intermediate 44a). The
azide 44 was obtained in 74% yield.
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Scheme 3-22 Attempted preparation of the benzylamines 45 and 48

The reaction was reattempted in the same manner as previously except that the
reaction time was extended to ensure that the azide 44 had sufficient time to react with
the second equivalent of PPh3. Water was then added to the reaction with warming at
50oC overnight as suggested in the literature,117,118 however neither intermediate 44a nor
amine 45 were observed. After chromatography, only the azide 44 was obtained in 74%
yield. The 1H NMR spectrum of 44 showed a distinct 2-proton singlet at δ 4.40 which
was attributed to the methylene protons, the signal position being upfield relative to the
corresponding signal in the starting alcohol 41. The 13C NMR spectrum also displayed
a signal ascribed to the methylene carbon at δ 54.0, which was consistent with a CH2
which is shielded by a neighbouring azide group. Additionally, the HRMS (EI)
spectrum revealed a molecular ion signal at m/z 294.0987, consistent with the molecular
formula C15H12N5O2.
The azide derivative 47 was also prepared in the same manner as for 44, from
treatment of the alcohol 42 with NaN3 and 2 equivalents of PPh3 at 90oC. It is possible
that with both 44 and 47, the temperature was not sufficiently high for the phosphazide
81

intermediate formation and hence formation of 44a and 47a.

Alternative azide

reduction methods were then investigated.

3.3.4.6 Reduction of azides to amines
Azides can be reduced easily to primary amines by a number of reducing agents,
including NaBH4, which usually gives poor yields but is selective.

However, the

reducing power of NaBH4 is augmented by using either THF or t-BuOH as a solvent
with dropwise addition of MeOH. Following a general literature procedure,119 the azide

44 was reduced with NaBH4 in THF-MeOH at reflux with stirring for 2 days. TLC
analysis of the reaction mixture indicated some of the starting material 44 still remained
together with the formation of two new products, one at a lower Rf than the azide 44 and
another as a streak from the baseline. After separation of the former product, NMR
analysis and mass spectrometry suggested that it was the cyclized product 46. The 1H
NMR spectrum revealed the loss of the signal previously ascribed to the indolic NH
proton and the appearance of a downfield singlet integrating for two protons at δ 5.12,
which was attributed to the methylene protons. The HRMS (EI) spectrum, which
showed a molecular ion signal at m/z 250.0732, was also consistent with the molecular
formula of the cyclized product 46. It is possible that 46 forms from the amine 45 via
its borane complex, followed by nucleophilic attack on a methylene carbon by an
indolide anion which may be generated in the basic conditions (Scheme 3-23). The
other product, which was observed as a streak from the baseline on TLC, was predicted
to be the desired amine 45, which would bind strongly to the acidic silica gel. The
amine 45 was separated by column chromatography with an eluting solvent mix of
DCM in MeOH plus triethylamine.
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Scheme 3-23 Reduction of the azide 44 to amine 45 with NaBH4 in THF with dropwise addition of
MeOH

The 'H NMR spectrum of 45 showed an upfield singlet signal integrating for two
protons at 8 3.99 which was assigned to the methylene protons adjacent to the amino
group, and a signal ascribed to the indolic NH was apparent at 5 13.63. The HRMS (El)
data was consistent with the molecular formula o f 45.

R C H 2,N
1N3

r c h 2n h

2

Scheme 3-24 General scheme for the conversion of azides to amines using NaBH4 and 1,3propanedithiol as a catalyst

The azide reduction was reattempted following a method described by Pei120 using
NaBH4 and 1,3-propanedithiol as a catalyst in /-PrOH and TEA at room temperature.
Azides may be selectively reduced to amines by 1,3-propanedithiol which is oxidized to
the cyclic disulfide (Scheme 3-24). Sodium borohydride can then be used to reduce the
cyclic disulfide back to the 1,3-propanedithiol thus reducing the amount of 1,3propanedithiol required for complete reduction.

Unfortunately, the reduction of the

azide 44 still gave a 3:1 mixture of the amine 45 and the unwanted cyclized product 46.
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Lk1ft

To avoid this unwanted cyclization, the reaction was undertaken at a lower
temperature for a shorter time. The azide 44 was then successfully reduced by 1,3propanedithiol (3 eq.) and NaBH4 (15 eq.) in 35% MeOH in i-PrOH and TEA at 0oC for
130 min to afford the amine 45 in 90% yield.
The other benzylamine derivative 48 was obtained from the benzyl azide 47 in
91% yield in the same manner as for 45 (Scheme 3-25). In the 1H NMR spectrum of 48,
the methylene protons were assigned to the signal at δ 3.91, further upfield from the
corresponding signal (δ 4.26) in the starting azide 47.
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45; R = H, 90%
48; R = OCH3, 91%

Scheme 3-25 Reduction of the azides 44 and 47 to the amines 45 and 48, respectively

Since the palladium-induced oxidative cyclization of 22 gave 35 in low yield and
two by-products 36 and 37, the synthesis of benzyloxy analogues of azide and amine
derivatives was thus omitted. Although the by-product 36 can be converted to 35, there
is an extra step involved.

3.3.4.7 Preparation of α-bromoacetamides
The final step in the preparation of the required alkylating agents was adapted
from a literature precedent.121 The amine 45 was reacted with bromoacetyl chloride in
DCM and TEA to afford the bromoacetamide 49 in 62% yield (Scheme 3-26). The 1H
NMR spectrum of 49 revealed the presence of two singlet signals integrating for two
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protons each at δ 3.85 and 4.45 which were attributed to two groups of methylene
protons in the molecule. Further confirmation of the structure was obtained by the
appearance of a signal ascribed to a carbonyl carbon at δ 167.2 in the

13

C NMR

spectrum, together with the HRMS (EI) spectrum which showed a molecular ion peak at
m/z 389.0197, consistent with the molecular formula of 49.
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Scheme 3-26 Preparation of bromoacetamides 49 and 50

The bromoactamide derivative 50 was prepared in 64% yield from the amine 48 in
the same manner as for 49. Analysis of the 1H NMR spectrum of 50 revealed two
methylene proton signals as two singlets at δ 3.91 and 4.44, and the 13C NMR spectrum
confirmed the presence of a carbonyl carbon signal at δ 167.1. HRMS (EI) spectral
analysis indicated a molecular ion at m/z 417.0332, supporting the molecular formula of

50.

3.3.4.8 Preparation of α-bromoesters
The α-bromoester derivatives 51 and 52 (Scheme 3-27) were prepared from the
corresponding alcohol derivatives 41 and 42, respectively.

Following a literature

procedure,122 the alcohol 41 was reacted with bromoacetyl chloride in TEA and THF at
0oC for 2h. As the formation of the desired bromoester 51 was not observed by TLC
85

analysis, the reaction was heated at 50oC for 5h to then afford 51 in 70% yield. The 1H
NMR spectrum of 51 revealed two singlet signals attributed to two groups of methylene
protons at δ 3.97 and 5.31, together with a distinct signal ascribed to the carbonyl
carbon in the

13

C NMR at δ 167.0. The mass spectral analysis HRMS (EI) showed a

molecular ion at m/z 338.0056, consistent with the structure of 51.
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Scheme 3-27 Preparation of bromoesters 51 and 52

The α-bromoester 52 was prepared in the same manner as the α-bromoacetamides

49 and 50. The desired product 52 was obtained in 39% yield with some starting
material 42 still being present. The 1H NMR spectrum of 52 showed a downfield
singlet signal integrating for two protons at δ 5.17, which was attributed to the benzylic
methylene protons, and a new signal integrating for two protons at δ 3.88 which was
assigned to the bromomethyl group. The

13

C NMR spectrum of 52 had a signal at δ

166.8 which was consistent with an ester carbonyl group.

3.3.4.9 Preparation of indole benzyl bromide derivatives from the alcohols
Various methods for the conversion of alcohols into their corresponding alkyl
bromides are known. The most commonly used preparative route is the reaction of an
alcohol with triphenylphosphine and carbon tetrabromide (Scheme 3-28).123,124 Thus the
86

preparation o f benzyl bromide 53 was conducted 125 in anhydrous diethyl ether at room
temperature for 2 days, but no reaction occurred. The reaction was therefore repeated at
a higher temperature (40°C, 2 days) to push the bromination to completion. The desired
benzyl bromide 53 was obtained in 41% yield together with triphenylphosphine oxide as
a by-product (Scheme 3-29).

ROH

Ph3P + CBr4

------- -

+

Ph3PBr
CBr3

l

----- ►

+

Ph3POR + CHBr3
Br’
RBr + Ph3P = 0

Scheme 3-28 General scheme for the bromination of alcohols using carbon tetrabromide and
triphenylphosphine126

The structure of 53 was confirmed by NMR spectroscopy, with the spectra being
similar to the starting alcohol 41, while the formula was established from the HRMS
(El) data.

Scheme 3-29 Bromination of the alcohol 41 into the benzyl bromide 53
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In contrast, attempted bromination of alcohol 42 in the same manner as for the
reaction with 41 (Scheme 3-29) failed to furnish the desired benzyl bromide 42a.
Instead, the benzylphosphonium salt 54 was only obtained. In the 1H NMR of 54, 15
aromatic protons at δ 7.18-7.97 were present, plus two signal ascribed to methylene
protons at δ 5.17. The presence of a very weak singlet signal at δ 29.2 in the 13C NMR
spectrum was attributed to the methylene carbon, although a doublet would be
expected127 for this signal from coupling with the adjacent phosphorus atom. This
signal assignment was confirmed, by gHSQC and DEPT spectral analysis.

High

resolution mass spectral analysis (ES) revealed a positive ion at m/z 543.1838,
corresponding to the formula of the cation in the salt 54. It is likely that the desired
product 42a (Scheme 3-29) was formed in the reaction, but this then proceeded readily
to give 54 on reaction with an excess of triphenylphosphine. The bromide 42a would be
further activated towards such a reaction by the para-methoxy group in the benzylic
bromide. Although undesired in this reaction, these conditions are common for making
a phosphonium salt from an alkyl halide and phosphine. Thus it was decided to make
the undesired phosphonium salt 54 into a potentially useful alkene 55 (for cross
metathesis reactions) via the Wittig reaction.
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Scheme 3-30 Preparation of the alkene 55 via the Wittig reaction

The phosphonium salt 54 was treated with NaOH to generate ylid 54a, which was
then reacted with formaldehyde to give the alkene 55 (Scheme 3-30). Unfortunately,
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the desired alkene 55 was obtained in only 3% yield together with an undesired alkyl
derivative 56 as a major product in 49% yield.
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Scheme 3-31 Possible mechanism for the formation of 56

The normal Wittig reaction (Scheme 3-30) would proceed via the phosphorus
ylide 54a, being generated in turn by reaction of the phosphonium salt 54 with sodium
hydroxide. Subsequent reaction with formaldehyde would give 55. It is proposed that
an alternative pathway from 54 and sodium hydroxide could also occur via the indolyl
anion 54c, which is stabilized by the electron-withdrawing nitro group. Elimination of
triphenylphosphine from 54c would afford 54d, which could be the re-aromatized to
give product 56 via hydride transfer (from H2C(OH)O- formed in turn from HCHO and
OH-). A non-nucleophilic base could obviate this last step but this reaction was not
examined further.

3.3.4.10 Attempted N-protection of indole 42
In order to attempt to prevent the formation of undesired products during the
formation of the benzylic bromide from 42, protection of the indolic nitrogen of 42 was
investigated. It was hoped to Boc protect the indolic nitrogen and thus deactivate the
ring before the bromination. Accordingly, direct N-boc protection was attempted using
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the alcohol 42 with (Boc)2O and DMAP.128 NMR spectroscopic analysis and mass
spectrometry revealed that the O-acylated compound 58 (Scheme 3-32) was the major
product, together with a small amount of 57, with no N-boc product.
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Scheme 3-32 Attempted N-boc protection of 42

The 1H NMR spectrum of 58 showed the presence of a singlet signal at δ 1.52
integrating for nine protons which was attributed to the t-butyl group. A distinct singlet
signal assigned to the NH proton at δ 9.99 confirmed that 58 was the O-boc and not the
N-boc product. In addition, the correlation of a methylene proton signal at δ 5.11 to a
carbonyl carbon signal at δ 153.5 was seen in the gHMBC spectrum and mass spectral
(CI) analysis confirmed the molecular ion peak at m/z 399 (C21H23N2O6, [MH]+),
consistent with the molecular formula of 58.
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Scheme 3-33 Possible formation of the cyclized product 57
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As the alcohol 42 contains two acidic protons (NH and OH) with similar pKa
values, which would be competitively deprotonated, the minor product 57 might be
formed from an intermediate 58a and/or 58b (Scheme 3-33). The 1H NMR spectrum of
the minor product 57 showed a signal integrating for two protons at δ 4.91 as a broad
doublet and this was attributed to the ring methylene group. Mass spectral (CI) analysis
confirmed the molecular formula of 57 via a base peak at m/z 325 (C17H13N2O5, [MH]+).
The N-protection of 42 was reattempted with a sulfonamide derivative which is
less susceptible to nucleophilic attack than the carbamate type protecting groups.129
However, reaction of the alcohol 42 with benzenesulfonyl chloride and n-BuLi at room
temperature afforded only 59 in 8% yield (Scheme 3-34), without any of the desired Nsulfonyl product.
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Scheme 3-34 Attempted N-sulfonyl group protection of 42

Due to the unsuccessful selective N-protection of 42, the subsequent bromination
step to achieve the alkyl bromide derivative 42a (Scheme 3-29) was not pursued further.
It was decided to make a dual action drug 65 (Chapter 4, Scheme 4-5) in the next step
using the alcohol 42 instead of 42a, as discussed in Chapter 4.
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4

Chapter4:

Synthesis of the berberine-indole dual action agents
O
O2N

N+

O
13

Y

OMe
OMe

N
H
R

R = H, OCH3

Dual action prodrugs; Y = CH2OCOCH2-(C13), CH2NHCOCH2-(C13)
Dual action drugs;
Y = CH2

Figure 4-1 The structures of the desired dual action agents

The aim of the synthetic work in this chapter was to synthesize berberine-indole
dual action agents (Figure 4-1) based on the dual action prodrug and dual action drug
concepts. The hybrids consisted of berberine linked at its C-13 position by an ester,
amide or alkyl group to a 2-aryl-5-nitroindole analogue. Before the berberine and the
indole derivatives were combined, a series of model compounds were produced, of
which the first was 13-benzylberberine (Chapter 2, Section 2.2.2.2), with the benzyl
group representing the 2-aryl-5-nitroindole moiety. Eventually, synthesis of the desired
berberine-indole molecules was achieved based on the two-step strategy of “model
study 2” (Chapter 2, Section 2.2.2) as described in the following sections.

4.1 Synthesis of the berberine-indole prodrugs with a cleavable
linkage
The dual action prodrugs containing berberine and an indole were designed to link
the berberine and indole moieties together via an ester or amide group. These linkers
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were expected to cleave under enzymatic action (by esterases or amidases) in the
bacterial cells resulting in synchronous release in high concentration near the bacterial
target sites. The synthesis of the ester and amide-linked prodrugs is discussed in the
following sections.

4.1.1 Synthesis of the ester prodrug (60)
The ester bromide derivative of indole 51 was combined with the enamine 9
following the “model study 2” coupling procedure (Chapter 2, Section 2.2.2). The
enamine 9, which was discussed in Chapter 2, was reacted with the bromoester 51 in
dry CH3CN at 100oC for 2 days (Scheme 4-2). Analysis of the crude reaction mixture
by TLC (silica gel, 8% MeOH in DCM) showed product was formed which streaked up
from the baseline. The pure ester prodrug 60 was isolated in 19% yield after multiple
preparative layer chromatography and recrystallization from 1% MeOH in DCM. It is
likely that some product was lost in the purification process due to it strong adsorption
on silica gel.
O

O
N

O

O
OCH3

+

OCH3

CH2OCOCH2Br

O2N

N+

Br OMe

CH3CN
O

100oC, 19%

OMe

O

9
N
H

HN

51

NO2

60

Scheme 4-2 Preparation of a dual action prodrug 60 with an ester linkage

The structure of the ester prodrug 60 was confirmed by NMR spectroscopic
analysis and mass spectrometry. The 1H NMR spectrum in CDCl3 revealed the loss of
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the signals attributed to the allyl substituent protons and the C-13 proton in the starting
enamine 9, and the presence of a singlet signal ascribed to the C-8 proton appeared at δ
9.91. The 1H NMR spectrum also verified the presence of the indole moiety, with a
singlet signal attributed to the indolic NH proton at δ 12.19, the expected set of signals
integrating for seven protons ascribed to the aromatic protons of the indole, and a
characteristic singlet signal assigned to the C-3΄ proton at δ 6.74. In addition, two
singlet signals attributed to the methylene protons of the ester linking group at δ 4.48
(CH2CO) and 5.39 (CH2O) were observed. The carbonyl carbon of the ester group was
confirmed by a signal in the 13C NMR spectrum at δ 170.3, and a downfield signal at δ
145.8 was ascribed to the C-8 methine carbon in the berberine moiety. Further support
for the structural assignment was provided by HRMS (ES) with a signal at m/z
664.2034, consistent with the formula of the quaternary ammonium ion component of

60.

4.1.2 Synthesis of the ester prodrug (61)
Under the same reaction conditions as for 60, the ester prodrug 61 was produced
from enamine 9 and the bromoester 52 in CH3CN at 100oC for 2 days. The ester 61 was
obtained in 20% yield after extensive chromatographic treatment of the reaction
mixture. The 1H and 13C NMR spectra of 61 were similar to those of the ester 60 except
for the absence of an aromatic proton signal attributed to the C-4΄΄ proton in the latter.
Moreover, the presence of a signal at δ 3.84 integrating for three protons and attributed
to the methoxy groups was observed in the 1H NMR spectrum, and for the methoxy
carbon at δ 55.6 in the 13C NMR spectrum. The HRMS (ES) spectrum showed a signal
at m/z 674.2134, which was consistent with the positive ion component of compound

61.
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Scheme 4-3 Preparation of the dual action prodrug 61 with an ester linkage

4.1.3 Synthesis of the amide prodrug (62)
The reaction conditions for the formation of the amide prodrug 62 were the same
as those used to synthesize the ester prodrugs (60, 61) and the same purification
problems, including the loss of some of the product 62, occurred due to the polarity of
the molecule. The enamine 9 was reacted with the bromoacetamide indole derivative 49
in dry CH3CN at 100oC for 2 days. The amide 62 was obtained in only 10% yield after
recrystallization.
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Scheme 4-4 Preparation of dual-action prodrug 62 with an amide linkage

The 1H and 13C NMR spectra in CD3OD of amide 62 were almost the same as those for
the ester 60, except for an upfield singlet signal attributed to the methylene protons
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adjacent to the amide at δ 4.69 (CH2NH). In the 13C NMR spectrum, an upfield signal
at δ 42.0 was ascribed to the methylene carbon adjacent to the amide nitrogen atom.
The HRMS (ES) showed a signal at m/z 643.2184, representing the positive ion
component of compound 62.

4.1.4 Synthesis of the amide prodrug (63)
A mixture of the enamine 9 and the bromoacetamide indole derivative 50 in dry
CH3CN was heated at 100oC for 2 days. After multiple chromatographic purification
and recrystallization, 63 was obtained in 20% yield.
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Scheme 4-5 Preparation of the dual-action prodrug 63 with an amide linkage

Characteristic peaks in the 1H and

13

C NMR spectra of 63 included an extra signal

integrating for three protons at δ 3.87 ascribed to the methoxy group in the indole
portion, as well as a further signal at δ 56.0 in the

13

C NMR attributed to this group.

The HRMS (ES) showed a peak at m/z 673.2305, representing the positive ion of
compound 63.
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4.1.5 Synthesis of the dual action drug (64)
The preparation of the dual action drug 64 used the same reaction conditions as
those used in the synthesis of the other ester and amide prodrugs. The enamine 9 and
the bromide 53 in dry CH3CN were heated at 100oC for 1 day, to afford 64 in 34%
yield.

The product was separated chromatographically but multiple development

preparative layer chromatography was not required. The structure of compound 64 was
elucidated by NMR spectroscopy and mass spectrometry. The 1H and 13C NMR spectra
in CD3OD had signals representative of the berberine and 2-aryl-5-nitroindole moieties.
In addition, signals attributed to the methylene linking group for those two moieties
were observed at δ 4.84 in the 1H NMR spectrum and at δ 36.4 in the 13C spectrum. The
HRMS (ES) spectrum provided further evidence with a signal at m/z 586.1984, which
was consistent with the positive ion component of compound 64.
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Br OMe
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N
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53
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Scheme 4-6 Preparation of the dual action drug 64

4.1.6 Synthesis of the dual action drug (65)
Due to problems in the preparation of the para-methoxybenzyl bromide 5nitroindole derivative from 42 (Chapter 3), one pot procedures for the formation of 65
from the alcohol 42 were investigated. The first attempted synthesis of 65 (Scheme 4-7)
was based on triphenylphosphine-carbon tetrabromide as the reagent combination to
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generate the alkyl bromide in situ from the alcohol 42 in the first step, and then attack
by the enamine 9 to ultimately afford the bromide salt of 65. This reaction was carried
out at 90oC for 20 hours and produced many products as indicated by TLC analysis.
The only product isolated was the unwanted berberinium bromide (1) in 12% yield.
Unfortunately there was no evidence for the expected bromide salt 65. It seemed likely
that the alkyl bromide derivative had been generated from the benzyl alcohol 42 and
immediately cyclized to 46 (Scheme3-23; Section 3.3.4.6) instead of reacting with the
enamine 9.

Hydrogen bromide, which may be generated in this reaction, could

protonate the enamine 9 and then propene elimination would give the bromide salt 1.

O
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CBr4 -DMF (1:4)
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OCH3
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O
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O

BrOMe

1

OMe

Scheme 4-7 Attempted synthesis of the dual action drug 65

A further reaction was then attempted with the less reactive carbon tetrachloride
in place of carbon tetrabromide.

A mixture of alcohol 42, enamine 9, and

triphenylphosphine in CCl4 and DMF was heated at 90oC for 12 hours (Scheme 4-8).
The crude reaction mixture was purified by multiple preparative layer chromatography
and the product recrystallized to give the chloride salt 65 in 4% yield. The 1H and 13C
NMR spectra in CD3OD of 65 were similar to those of 64 except for one less aromatic
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proton signal and the presence of signals which could be ascribed to the aromatic
methoxy group (δ 3.83 in the 1H NMR; δ 56.0 in the

13

C NMR). The HRMS (ES)

spectrum showed a signal at m/z 616.2090, which is consistent with the positive ion
component of compound 65.
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Scheme 4-8 Preparation of the dual action drug 65

4.2 Attempted linking group expansion of berberine-indole
hybrids
The purpose of expanding the length of the linking group of the berberine-indole
hybrid was to create increased flexibility between the two moieties in the dual action
drugs. This would hopefully allow more successful attack on the bacterial target sites
and hence increased antimicrobial activity.
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4.2.1 A ttem p ted synth esis o f a b erberin e-ind ole hybrid via a cross
m etath esis reaction
Cross metathesis is an important reaction in organic synthesis, in which two
independent alkenes are combined into one molecule using appropriate catalysts (e.g.
molybdenum, or ruthenium complexes ) . 130,131 When two terminal alkenes are treated
with a transition metal catalyst with the ability to catalyze the exchange of alkylidene
groups of two independent alkenes, they produce a new compound linked via an alkene
with the loss of ethylene.

Scheme 4-9 Schematic representation of the Ru-based cross metathesis mechanism132

The catalytic mechanism cycle proceeds via initial [2+2] cycloaddition and
consequent cycloreversion to give the desired product (Scheme 4-9). Initially, the cycle
is initiated by coordination of an alkene to the ruthenium metal to form a ruthenacycle
(step A) which rapidly releases ethylene gas and gives a newly substituted alkylidene
(step B).

Then a cycloaddition reaction of the second alkene (step C) with the

alkylidine from step B gives a metallacyclobutane in step D l, or D which is more
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preferred.

Cycloreversion of the metallacyclobutane results in the desired cross-

metathesis product and the active catalytic species is regenerated (step E).
Cross metathesis of alkenes with a ruthenium complex catalyst was chosen to
carry out the linking group expansion in the berberine-indole hybrids.

Thus, the

synthetic plan proposed the coupling of 13-allylberberine bromide 66 to the vinyl
substituted 2-aryl-5-nitroindole analogue 55 via a cross metathesis reaction induced by
polymer bound benzylidene-bis (tricyclohexylphosphine)-dichlororuthenium (Grubbs’ I
catalyst) (Scheme 4-10). The Grubbs’ II catalyst was not investigated due to time
constraints.
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Scheme 4-10 Attempted linking group expansion of the berberine-indole hybrid

The

starting

allyl

berberine

66

was

prepared

by

reaction

of

8-

allyldihydroberberine 9 and excess neat allyl bromide at 100oC for 2 hours (Scheme 411). After chromatography, the allyl berberine 66 was obtained in 52% yield. This
compound had been made previously by Ikekawa et al., but they did not give any
spectroscopic data in their patent.133 Confirmation of the structure of 66 was provided
by NMR spectroscopic analysis and mass spectrometry. The 1H and 13C NMR spectra
showed the characteristic signals of 13-substituted berberinium salts as observed in
compounds 60-65. Additionally, the 1H NMR spectrum showed a set of distinctive
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signals attributed to the allyl group at δ 3.90-4.01 (CH2CH=CH2) as a multiplet, 4.91
and 5.43 (CH2CH=CH2) as broad doublets, and 6.31-6.42 (CH2CH=CH2) as a multiplet.
The 13C NMR spectrum had signals that confirmed the structure of 66 including a set of
signals attributed to an allyl group at δ 34.7 (CH2CH=CH2), 120.8 (CH2CH=CH2), and
135.1 (CH2CH=CH2). The HRMS (ES) spectrum provided additional evidence with a
signal consistent with the positive ion of 66 at m/z 376.1548.
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O
O

N

CH2=CHCH2Br
OCH3

9

O

N

BrOCH3

100 oC, 52%

OCH3

66

OCH3

Scheme 4-11 Preparation of the allyl berberine salt 66

The other alkene component, 55 was prepared as discussed in Chapter 3 (Section
3.3.4.9). The cross metathesis reaction of 66 and 55 was catalyzed by 10 mol% of
Grubbs’ I ruthenium catalyst (polymer bound) in dry DCM with heating at reflux for 2
days under a nitrogen atmosphere. After chromatography, two unidentified products
were isolated and some of the starting materials 66 and 55 were also recovered.
Unfortunately, none of the expected indole-berberine cross metathesis product was
obtained and only trace amounts of the two isolated products were obtained which did
not permit full spectroscopic identification. The MS (CI) spectrum of the unknown
products showed molecular ion peaks at m/z 208 in the first case and at m/z 313 in the
second case. These peaks did not correspond to possible homodimeric products.
The cross metathesis reaction shown in Scheme 4-10 was tested by changing the
alkene 55 to another alkene derivative. It was proposed that the vinyl group in 55 may
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be too short, thus causing difficulty in coupling to 66 on steric grounds. Thus, the allyl
derivative 42a was designed to replace 55 for use in a cross metathesis reaction with 66.
O

CH2OH

O2 N
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NaH, DMF
80oC, overnight

N
H

42

O2N
N
H

OCH3

OCH3

42a

CH2OH

O2N
N

67

OCH3

Scheme 4-12 Unsuccessful O-alkylation of alcohol 42

In the attempted preparation of 42a, allyl bromide was used as the alkylating
reagent, dry THF as a solvent, and TEA as a base to abstract the hydroxyl group proton
in 42.

The reaction mixture was heated at 50oC for 30 hours under a nitrogen

atmosphere, but none of the product 42a was obtained. After chromatogryphy, only the
starting alcohol 42 was recovered. It seems likely that the electron-donating paramethoxy substituent on the benzyl alcohol moiety decreased the acidity of the benzylic
hydroxy proton. Thus, a stronger base was indicated and NaH was used instead of TEA
in the next trial. Alcohol 42 was heated for 12 hours at 80oC in DMF with 1.3 mole
equivalents of allyl bromide and 1.0 mole equivalent of NaH101 (Scheme 4-12). After
chromatography, the N-allyl product 67 was obtained in 21% yield together with two
unidentified products which were lower in polarity than 67 (from TLC analysis). It is
likely that the indolic NH proton is more acidic than the benzylic hydroxy proton due to
the presence of the 5-nitro group (electron withdrawing group). The nitro group would
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stabilize the indolyl anion through delocalization of the negative charge (Scheme 4-13),
and hence N-alkylation would be preferred over O-alkylation.
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Scheme 4-13 Resonance stabilization of 5-nitroindolyl anion

The 1H NMR spectrum of 67 consisted of six aromatic proton signals with the expected
splitting patterns, a singlet at δ 6.71 attributed to the C-3 proton of the indole nucleus, a
singlet at δ 3.83 integrating for three protons ascribed to the methoxy group, and a
singlet at δ 4.48 integrating for two protons and assigned to the methylene group.
Moreover, the presence of an allyl group was indicated by characteristic signals at δ
4.61 (CH2CH=CH2) as a doublet, 4.85 and 5.16 (CH2CH=CH2) as two doublets, and
5.78-5.91 (CH2CH=CH2) as a multiplet; no signal which could be ascribed to the
indolic NH proton was observed. The

13

C NMR spectrum and 2D analysis provided

additional confirmation of the structure of 67. The HMBC experimental data indicated
that the methylene proton signal observed at δ 3.60 (allyl group) correlated with the
signal at δ 139.6 (C-7a) and it also correlated with the signal at δ 131.3 (C-2). This
clearly indicated that the allyl group was attached to the nitrogen of the indole nucleus.
The HRMS (CI) showed a signal at m/z 339.1349, consistent with the molecular ion of
compound 67.
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Scheme 4-14 Proposed alternative synthesis of a berberine-indole hybrid with an expanded linking
group

At this point an alternative route to the more flexible hybrid molecules was
devised based on an enamine alkylation reaction of 9 with 2-aryl-5-nitroindole
derivatives containing longer side chains and a bromo substituent to act as an alkylating
agent (Scheme 4-14). The initial target was the bromide 55c. The synthetic plan for

55c (Scheme 4-15) involved a selective monoprotection of ethylene glycol (as its
TBDMS ether), subsequent O-alkylation with the bromide 55 to produce 55a, then
deprotection to give the free alcohol 55b, and bromination to eventually afford the
bromide 55c.
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Scheme 4-15 Proposed synthesis of 55c
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4.2.2 Synthesis of 2-(tert-butyldimethylsilanyloxy)ethanol (68)
The selective monosilylation of ethylene glycol was achieved following a
literature procedure which described the synthesis of this compound.134 Ethylene glycol
was treated with 1 equiv. of NaH to form a monosodium salt as an opaque white
precipitate, and then

silylating with TBDMSCl.

After chromatography, the silyl

alcohol 68 was obtained in 33% yield.
TBDMSCl
OHCH2CH2OSiMe2But
OHCH2CH2OH NaH, THF [OHCH2CH2Na]
RT
RT, 33%
68
Scheme 4-16 Monosilylation of ethylene glycol

4.2.3 Attempted O-alkylation of 55a
The alkylation of 2-(tert-butyldimethylsilanyloxy)ethanol (68) with the previously
prepared alkylating agent 55 was carried out using similar reaction conditions to those
used for the synthesis of 67 (Scheme 4-12). The monosilylated ethanol in DMF was
treated with NaH to form a sodium alkoxide salt, and then the bromide 55 was added
and the mixture heated at 80oC for 2 days. The major product obtained (69% yield) was
the cyclised compound 46 (see Chapter 3, Scheme 3-23); none of the required
compound 55a was observed. Due to time constraints, no further work on the extended
linking chains was undertaken.
O 2N

CH2Br

O2N

NaH, DMF
N
H

55

N

80oC, 2days

46

OHCH2CH2OSiMe2But

68

Scheme 4-17 Attempted O-alkylation of 2-(tert-butyldimethylsilanyloxy)ethanol (68)
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4.3 Hydrolysis of the ester linked berberine-indole prodrug
An enzymatic hydrolysis experiment was undertaken only on the berberine-indole
prodrug with an ester linkage, which was a model dual-action prodrug compound for
enzymatic hydrolysis. The enzyme used was the commercially available porcine liver
carboxyl esterase (EC 3.1.1.1). This experiment investigated the prodrug concept that
two parent drugs would be released after enzymatic ester cleavage of the prodrug.
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Figure 4-18 Enzymatic hydrolysis of ester prodrug 60

Following a general literature procedure,135 the ester prodrug 60 in DMSO was
reacted with the porcine liver carboxyl esterase (EC 3.1.1.1) in the presence of Tris-HCl
buffer solution (pH 7.2) at 37oC for 1 day. After this time, organic products were
extracted with DCM. TLC analysis of this concentrated extract indicated the presence
of trace amounts of the alcohol 41. It is likely that the solubility of prodrug 60 in
DMSO-Tris-HCl buffer solution may have been a problem, since formation of a
suspension was noted after addition of the buffer solution to a solution of the ester 60 in
DMSO. When acetone was used instead of DMSO in the enzymatic reaction, a small
amount of 41 was again detected. These results provided some indication that the ester
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prodrug 60 does hydrolyse in the presence of esterase or undergoes spontaneous
hydrolysis slowly with time. Further studies are needed to confirm these using bacterial
esterases. Also, the hydrolysis of the amide prodrug with hydrolases136 still needs to be
investigated.
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5

Chapter5: Biological test results

The biological activities of the test compounds were determined by antimicrobial
assays against various microorganisms including bacteria, yeasts and a protozoan, but
mainly bacteria. Subsequently, the most active compounds were assessed for
cytotoxicity against human cancer cells. The antibacterial testing was divided into two
phases. The first phase of testing was performed in the University of Wollongong to
assess the initial antibacterial activity.

The second phase was performed in the

Department of Biology, Northeastern University, Boston, USA, in collaboration with
Prof. Kim Lewis and Mr. Anthony Ball, for more detailed systematic studies of both
antibacterial and MDR pump inhibitory activities. Additional antibacterial testing of a
few active compounds was also done by Avexa Ltd., Melbourne, and antimalarial
testing (protozoan; Plasmodium falciparum) of the most active antibacterial compound
was done by Dr. Sumalee Kamchonwongpaisan, Protein-Ligand Engineering and
Antimalarial Screening Laboratories, National Centre for Genetic Engineering and
Biotechnology, National Science and Technology Development Agency (BIOTEC),
Bangkok, Thailand. Limited testing against the yeast, Saccharomyces cereavaesiae and
the yeast-like fungus Candida albicans was also undertaken at Northeastern University.
Details of the testing methodologies are given in Appendices I-V.
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5.1 Preliminary antibacterial testing results against
Staphylococcus aureus ACM844 and Escherichia coli
ACM845 using a combination of FDA and antimicrobial (cell
lysis/cell stasis) assays

The initial results of antibacterial testing of 7 berberine derivatives (3, 5-8, 10-11),
2 indoles (38, 41), a potential dual action prodrug 60 and a dual action drug 64, together
with MDR inhibitory testing of a mixture of 11 and 38, and 11 and 41, provided
valuable initial information about the antibacterial activity against Gram-positive (S.
aureus ACM844) and Gram-negative (E. coli ACM845) human pathogenic bacteria
using a combination of fluorescein diacetate (FDA) and antimicrobial (cell lysis/cell
stasis) assays137 (Table 5-1). With the FDA assay, it is not possible to distinguish
whether antimicrobial agents cause cell death or cell stasis, and thus the antimicrobial
(cell lysis/cell stasis) assay was used after completion of the FDA assay to assess the
ability of the cells to recover. Therefore, the combination of both assays produced an
accurate assessment of antimicrobial activity.137 The antimicrobial activity in the cell
lysis/cell stasis assay was determined as the lowest concentration that caused over 90%
cells unable to recover and is defined as the minimum inhibitory concentration (MIC).
This value is given in µg/mL and in µM concentrations in Table 5-1.
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Table 5-1 Minimum Inhibitory Concentration (MIC) values of berberine bromide, berberine
derivatives, indole derivatives and a mixture of indole and berberine derivatives against S. aureus
ACM844 and E.coli ACM845 using the combination of FDA and antimicrobial (cell lysis/cell stasis)
assays. NT indicates the sample was not tested. * indicates result of antibacterial screening.

MIC, µg/mL (µM)
S. aureus ACM844
E. coli ACM845

Entry

Compound

1

1, Br

75.00(180.33)

NT

2

3

100.00(235.03)

NT

3

5

>100.00(>205.11)

100.00(205.11)

4

6a

100.00(182.03)

NT

5

7

100.00(177.28)

100.00(177.28)

6

8

100.00(191.82)

100.00(191.82)

7

10

50.00(93.62)

NT

8

11

50.00(98.80)

NT

9

38

100.00(354.28)

100.00(354.28)

10

41

50.00(186.38)

<10.00(<37.28)

11

11+38 (1:1 weight ratio )

50.00

NT

12*

11+41 (1:1 weight ratio )
41 in the presence
of 11 at 0.5 MIC

10.00-25.00

NT

10.00

NT

14*

60

10.00-100.00(13.80-137.97)

NT

15

64

10.00(15.00)

NT

13

The antibacterial activity results (Table 5-1) showed that compounds 3 and 5 had
low antibacterial activity, and both were less active than 1.

Since it has been

established11 that aromaticity in ring C is essential for protoberberine alkaloids to
exhibit high antimicrobial activity (as discussed in Chapter 1, section 1.1), the low
activity of tetrahydroberberines 3 and 5 was not unexpected although other variables
could be involved. Moreover, it has been reported that introduction of an ester group at
the C-13 position (ring C) of 1 resulted in a decrease in the activity.9 Therefore, it was
not surprising that the activities of 3 and 5 were lower than that of 1.

Similarly,

compound 6a and 7 were slightly less active than 1 probably as the effect of the
lipophilic ester group was introduced at the C-13 position.
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Introduction of a carboxylic acid group at the C-13 position of 1 caused a decrease
in antibacterial activity (comparing 8 with 1). Substitution of hydrogen at the C-13
position of 1 by a lipophilic phenacyl group (10) or benzyl group (11) resulted in an
increase in the activity.
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The related 13-substituted berberine derivatives 60 and 64, which were expected
to have dual antimicrobial and MDR pump inhibitory activities, were both more active
than 1, although the MIC for 60 was not accurately determined in these preliminary
studies. Compound 64, at least, was also more active than the benzyl analogue 11. This
evidence indicated that there was a significant advantage associated with a 2-phenyl-5nitro-1H-indole substituent at the C-13 position.
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The 2-phenyl-5-nitro-1H-indole analogues 38 and 41 had inherent antibacterial
activity, with 38 being more active than 41. Interestingly, 41 was more active against
Gram-negative bacteria (E. coli ACM845) than Gram-positive bacteria (S. aureus
ACM844). In addition, 38 and 41 were tested in S. aureus in the presence of the
antibacterial agent 11 (entry 11-13), and it was found that 41 was able to potentiate the
antibacterial activity of 11 in line with 41 having MDR pump inhibitory activity.
The FDA and antimicrobial (cell lysis/cell stasis) assays provided preliminary
results for the antibacterial agents (60 and 64) and the potential MDR pump blocking
agents (38 and 41). Therefore, systematic antimicrobial activity testing and MDR pump
inhibitory activity testing of all target compounds were indicated and these tests were
undertaken by microbiologists at Northeastern University, Boston. The detailed results
of the antimicrobial activity and MDR pump inhibitory activity are given in the next
section.

5.2 MDR pump inhibitory testing results
The initial antibacterial activity results in the previous section showed that 2phenyl-5-nitro-1H-indole derivatives may be NorA MDR pump inhibitors and
potentiators of the antibacterial activity of berberine or berberine derivatives in S.
aureus. To confirm and quantify the MDR pump inhibitory activity of the 2-phenyl-5nitro-1H-indole derivatives, a set of these indoles was tested in the presence of a subinhibitory concentration (no effect on bacteria at this concentration) of a NorA MDR
pump-substrate and antibacterial agent which was either berberine (1) chloride or
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ciprofloxacin. The potentiating activity of the 2-phenyl-5-nitro-1H-indole derivatives
on berberine 1 chloride in a wild type S. aureus strain 8325-4 was described by the
fractional inhibitory concentration (FIC) index (Table 5-2), and the MDR pump
inhibitor property was examined using this index as an indication of the activity. In the
case of the potentiating activity of these indoles on ciprofloxacin, the FIC index was not
able to be calculated because the exact MICs for direct activity of the indoles against S.
aureus K2361 (Table 5-4) were not available. The MDR pump inhibitory activity
results for the 2-phenyl-5-nitro-1H-indole derivatives are shown in Tables 5-3 and 5-4,
and the direct activity (antibacterial activity) results for all test compounds (Figure 5-1;
fold out sheet page 128) are shown in Tables 5-5 and 5-6 against strains expressing the
MDR efflux pump in Gram-positive bacteria, Gram-negative bacteria and yeasts. In all
tests berberine 1 was used as its chloride salt.
Table 5-2 Indicator of potentiating activity for 2-aryl-5-nitro-1H-indole derivatives with the
antibacterial agent berberine (1) chloride using wild-type S. aureus 8325-4 which expresses the
NorA MDR pump.

FIC indexa
FIC indexa
Compound Berberine (1) chloride Compound Berberine (1) chloride
38
44
1.12
0.24
39
45
<0.37
0.13
41
47
0.37
<0.14
42
48
<0.37
<0.13
43
56
<0.13
<0.15
a

The fractional inhibitory concentration (FIC) was calculated for each inhibitor and berberine (1)
chloride in combination by using the following formulas: FIC of antibacterial agent = MIC of
antibacterial agent in combination/MIC of antibacterial agent alone, FIC of inhibitor = MIC of inhibitor in
combination/MIC of inhibitor alone, and FIC index = FIC of antibacterial agent + FIC of inhibitor.
Potentiating activity was defined as an FIC index of <0.5.46

Most of the test compounds were synergistic with a sub-inhibitory concentration
of 1. The FIC indices (Table 5-2) for compounds 39, 41-45, 47, 48, and 56 had values
114

less than 0.5, which indicated that these compounds were synergistic in potentiating the
antibacterial activity of 1 while compound 38 was not. It appeared that the use of 1 in
combination with an inhibitor of the MDR pump (41 - 45, 47, 48, and 56) significantly
improved the efficacy of the antibacterial 1 by inhibiting its efflux.
Table 5-3 Minimum Inhibitory Concentration (MIC) value for 2-phenyl-5-nitro-1H-indole
derivatives (MDR pump inhibitory activity) against Gram-positive bacteria: Staphylococcus aureus
K1758 (lacking NorA MDR pump), S. aureus 8325-4 (expressing NorA MDR pump), S. aureus
K2361 (overexpressing the NorA MDR pump), Enterococcus faecalis V583, and E. faecium DO in
the presence of sub-inhibitory concentration of berberine (1) chloride. NT indicates the sample was
not tested. “-” indicates sample showed no activity when tested at a concentration of 50µg/mL.

MIC, µg/mL (µM)
Compound
S. aureus
E. faecalis E. faecium
K1758
8325-4
K2361
V583
DO
+1, 3µg/mL +1, 30µg/mL +1, 30µg/mL +1, 30µg/mL +1, 30µg/mL
38
39
41
42
43
44
45
47
48
56
INF55

-

-

-

-

NT

12.50
(40.03)
6.25
(23.30)
3.13
(10.49)
0.39
(1.04)
0.78
(2.66)
<0.24
(<0.90)
0.39
(1.21)
0.78
(2.62)
0.39
(1.38)
0.78
(3.28)

12.50
(40.03)
12.50
(46.59)
12.50
(41.90)
0.39
(1.04)
6.25
(21.31)
0.39
(1.46)
1.56
(4.83)
0.39
(1.31)
1.56
(5.53)
0.24
(1.01)

12.50
(40.03)
12.50
(46.59)
6.25
(20.95)
0.78
(2.08)
3.13
(10.67)
12.50
(46.77)
1.56
(4.83)
12.50
(42.04)
-

-

NT

-

NT

-

NT

-

NT

-

NT

12.50
(46.77)
-

25.00
(93.53)
NT

25.00
(84.09)
-

12.50
(84.09)
NT

NT

NT

3.13
(13.15)

Note: inhibitors 41 and 44 were chosen for MDR inhibitory activity testing against Salmonella
enterica Serovar Typhimurium SL1344R2 in the presence of either a fixed sub-inhibitory
concentration of 30µg/mL berberine (1) or 50ng/mL ciprofloxacin. The results showed that the
MIC for 41 was 3.13µg/mL (11.67µM) in the presence of 1, but no activity in the presence of
ciprofloxacin. The MICs for 44 were 0.24µg/mL (0.82µM) in the presence of 1, and 3.13µg/mL
(10.67µM) in the presence of ciprofloxacin.
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As shown in Table 5-3, alcohol analogue 43 (with benzyloxy substitution on the
2-phenyl ring) showed the highest MDR inhibitory activity with an MIC of 0.78µg/mL
(over 4-fold more potent than that of the parent INF55) in the presence of 1 against a
mutant strain of S. aureus K2361 which overexpresses the NorA pump, but lower
activity in the presence of ciprofloxacin with an MIC of 50.00µg/mL (Table 5-4). The
lipophilicity of the benzyloxy substituent and the weak acidity of the benzyl alcohol
substituent (pKa ~ 12-13) might be of importance in mediating this synergistic activity.
A similar pattern of synergy was shown with the other inhibitors 41-42, 44-45, 47-48
and 56, which preferably potentiated the activity of 1 over ciprofloxacin (Tables 5-3 and
5-4). This would suggest that, compared to ciprofloxacin, 1 was a more preferred
substrate for the NorA MDR pump, and that the less significant potentiating activity of
those inhibitors with ciprofloxacin might relate to molecular hydrophilicity and
structural characteristics of ciprofloxacin that may reduce recognition and efflux.
The azide analogues 44 and 47 bearing a methoxy substituent in the 2-aryl ring
exhibited a 4- and 2-fold less blocking activity than 43, respectively, against S. aureus
K2361. In addition, the azide 44 was able to completely inhibit the Gram-negative
bacterium Salmonalla enterica Serovar Typhimurium SL1344 R2 at MICs of 0.24 and
3.13µg/mL (see Note, Table 5-3) in the presence of a sub-inhibitory concentration of 1
and ciprofloxacin, respectively. It might be noted that the dipolar azide functionality,
N=N+=N-, seems to be associated with the ability of the molecule to inhibit the bacterial
efflux pumps in both Gram-positive and Gram-negative bacteria. However, one can not
disregard the lipophilicity of the methoxy substituent in the azide 47, since this
compound showed higher activity than 44 (which lacked the methoxy group) against S.
aureus K 2361. This is consistent with the effect of alkoxy substituents in the 2-aryl
group on the activity of the alcohol analogues 41-43. Without the alkoxy substituents
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(41, 44), there was a 2- to 16-fold increase in MICs against S. aureus K 2361.
Therefore, the substitution of a benzyloxy group in the 2-phenyl ring of the azide
analogue might increase its MDR inhibitory activity in both S. aureus and S. enterica,
and this would be of interest for future work.
Interestingly, two amine analogues, 45 and 48, had moderate activity in the
presence of 1 against E. faecalis V583 and E. faecium DO, while the other analogues
had no activity against these bacteria.

In addition, 45 and 48 also moderately

potentiated the activity of either 1 (Table 5-3) or ciprofloxacin (Table 5-4) against S.
aureus K2361.
Table 5-4 Minimum Inhibitory Concentration (MIC) value for 2-phenyl-5-nitro-1H-indole
derivatives (MDR pump inhibitory activity) against S. aureus K1758 (lacking NorA MDR pump), S.
aureus 8325-4 (expressing NorA MDR pump), S. aureus K2361 (overexpressing NorA MDR pump)

in the presence of sub-inhibitory concentration of ciprofloxacin (Cip.). NT indicates the sample was
not tested. “-” indicates the sample showed no activity when tested at a concentration of 50µg/mL.

Compound
K1758

38
39
41
42
43
44
45
47
48
56

MIC, µg/mL (µM)
S. aureus
8325-4
K2361
+Cip., 40ng/mL
+Cip., 500ng/mL

NT

-

-

NT

-

-

NT

-

50.00 (186.38)

NT

-

-

NT

-

50.00 (133.55)

NT

-

12.50 (42.62)

NT

-

25.00 (93.53)

NT

-

-

NT

-

12.50 (42.04)

NT

-

-

Acid analogues 38 and 39 (with a methoxy substituent in the 2-aryl ring), were
either inactive or were only slightly active against all test strains. As shown in Table 5117

2, 38 had no synergistic activity in potentiating the antibacterial activity of either 1 or
ciprofloxacin; it is possible that 38 and 39 are competitive MDR substrates.
Since 43 was the most active NorA MDR inhibitor, a berberine (1) uptake assay
in the presence of inhibitor 43 (5µg/mL) was performed. As berberine is a planar
cationic molecule, it fluoresces when located inside the cell and bound to DNA. The
uptake assay evaluated NorA pump inhibition by 43 through suppressing the berberine
efflux. The rate of berberine uptake (Figure 5-2) as measured by fluorescence emission
showed a sharp increase in berberine accumulation within the cells over a period of 10
minutes when in the presence of 43 compared to the parent NorA MDR inhibitor
INF55. 43 is over 20-fold more active than INF55 over this period, and it potentiated
the uptake of berberine in three strains of S. aureus: the wild-type 8325-4, the NorA
knock out K1754, and the overexpressing NorA K2361.
RFU
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3:36

4:48
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7:12
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Time (min)
A = INF55 (8325-4), B = INF55 (K1754), C = INF55 (K2361), D = 43 (8325-4), E = 43 (K1754), F = 43 (K2361)

Figure 5-2 Uptake of berberine as potentiated by MDR inhibitors, 43 or INF55. Fluorescence is
given in relative fluorescence units (RFU). The inhibitor concentration was 5µg/mL (for INF55 and
43). The background fluorescence of berberine was blanked to zero. Cells were in HEPES buffer
pH7 at OD 0.15. The tests were done with S. aureus 8325-4, S. aureus K1754, and S. aureus K2361.
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5.3 Antimicrobial testing results (Direct activity)
The set of 2-phenyl-5-nitro-1H-indole derivatives, the berberine carboxylic acid
derivative (8), and dual-action prodrugs and dual-action drugs (60-65) (Figure 5-1; page
128) were tested for direct antimicrobial activity against human pathogenic Grampositive and Gram-negative bacteria, and yeasts. The data are shown in Tables 5-5 and
5-6.

5.3.1 Nitroindoles
In general, the 2-phenyl-5-nitroindole derivatives had weak or no intrinsic
antimicrobial activity against S. aureus (Table 5-5). Surprisingly, the amine 48 had
moderate intrinsic antibacterial activity (12.5µg/mL) against the Gram-negative
bacterium E. coli, which has an effective permeability barrier (outer membrane and
MDR pumps) to hinder drug accumulation in its cells and also to transport unwanted
molecules out of the cells. Gram-positive bacteria lack this outer membrane which
would restrict the access of amphipathic compounds into their cells. Gram-negative
bacteria are thus normally harder to kill than the Gram-positive ones.138,139 A similar
result with the other Gram-negative bacterium S. enterica Serovar Typhimurium was
seen with the alcohol derivative 43 (MIC, 12.5µg/mL). This suggested that compounds

43 and 48 might have another mode of antibacterial action in the Gram-negative
bacteria, apart from the MDR pump inhibition and synergistic action with antibiotics.
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All compounds in the indole series were inactive against the Gram-positive
bacterium E. faecalis, the Gram-negative bacterium P. aeruginosa, and the yeast,
Saccharomyces cereavaesiae and the yeast-like fungus Candida albicans, (Table 5-5).

Table 5-5 Minimum Inhibitory Concentration (MIC) value for indole derivatives (direct activity)
against bacteria Gram-positive (Staphylococcus aureus; 3 strains) and Gram-negative (Escherichia
coli, Salmonella enterica), and yeast (Saccharomyces cereavaesiae). NT indicates the sample was not

tested. “-” indicates sample showed no activity tested at concentration 50µg/mL.

Compd
38
39

S. aureus
K1758
8325-4

MIC, µg/mL (µM)
S. enterica
Serovar
Typhimurium S. cerevisiae
E. coli
K 2361 K12
SL1344 R2
BY4742

-

-

-

-

-

NT

-

-

-

-

-

50.00
(186.38)

50.00
(186.38)

-

-

25.00
(93.19)

50.00
(186.38)

-

-

-

-

-

-

43

NT

-

-

-

12.50
(33.39)

-

44

3.13
(10.67)

50.00
(170.48)

-

-

-

-

50.00
(187.07)

50.00
(187.07)

-

-

25.00
(93.53)

-

-

-

-

-

-

-

25.00
(84.09)

-

50.00
(168.17)

12.50
(42.04)

25.00
(84.09)

-

-

-

-

-

-

-

250.00
(1050.42)

250.00
(1050.42)

250.00
(1050.42)

NT

NT

NT

41
42

45
47
48
56
INF55

Note: all compounds in Table 5-5 were additionally tested direct activity against Enterococcus faecalis
V583, Pseudomonas aeruginosa PA1, Candida albicans F5, and Candida albicans F5 M432, which
showed no direct activity at concentration of 50µg/mL.
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5.3.2 Berberine derivatives
The ester prodrugs 60-61, the amide prodrugs 62-63 and the dual action drugs (or
hybrid drugs) 64-65 were synthesized with the aim of increasing antibacterial potency
of berberine or analogues 64 and 65 were obtained from a combination of berberine (1)
and the 2-phenyl-5-nitro-1H-indole derivatives with a methylene linkage. Similarly, the
combination of 1 and the 2-phenyl-5-nitro-1H-indole derivatives with an ester linkage
afforded 60 and 61, and those with an amide linking group also gave 62 and 63.
Esterification of the berberine carboxylic acid derivative 8, which had 5- and 50-fold
greater antibacterial activity than 1 (Table 5-6) against wild-type S. aureus 8325-4 and
S. enterica Serovar Typhimurium, respectively, with the indole alcohol derivative 41 (or

42) led to the corresponding ester prodrugs 60 (or 61). Similarly, amidation of 8 with
the indole amine derivative 45 (or 48) led to the corresponding amide prodrugs 62 (or

63). The prodrugs 60-63 required bacterial enzymatic hydrolysis (esterase and amidase)
to release the MDR pump inhibitor component and berberine derivative 8 at or near
target sites in bacterial cells. These compounds were tested against human pathogenic
bacteria (both Gram-positive and Gram-negative) and yeasts. The data are shown in
Table 5-6.
The ester prodrugs 60 and 61 exhibited moderate antibacterial activity against the
NorA overexpressing strain of S. aureus K2361, with MICs of 25.00µg/mL for 60 and
12.50µg/mL for 61, respectively. The two amide prodrugs 62 and 63 were comparable
in activity and more active than the esters 60 and 61; the amides 62 and 63 showed 2- to
4-fold greater antibacterial activity at the same MIC values of 6.25µg/mL against the
NorA overexpressing S. aureus strain.
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Table 5-6 Minimum Inhibitory Concentration (MIC) value for berberine derivatives, dual action
prodrugs and dual action drugs (direct activity) against Gram-positive (Staphylococcus aureus; 3
strains, and Escherichia coli) and Gram-negative (Salmonella enterica). NT indicates the sample
was not tested. “-” indicates sample showed no activity tested at a concentration of 50µg/mL.

MIC, µg/mL (µM)
Compound
S. aureus
E. faecalis S. enterica Serovar
K1758 8325-4
K2361
V583 Typhimurium SL1344 R2
1.00
(3.00)
250.00
(672.39)
50.00
(95.92)
16.00
(22.07)
6.25
(8.28)
3.13
(4.33)

4.00
(12.00)
500.00
(1344.77)
NT

62

0.24
(0.72)
15.60
(41.96)
50.00
(95.92)
3.13
(4.32)
3.13
(4.15)
3.13
(4.33)

25.00
(34.49)
12.50
(16.57)
6.25
(8.64)

50.00
(68.98)
12.50
(16.57)
-

63

6.25
(8.29)

12.50
(16.59)

6.25
(8.29)

-

3.13
(4.15)

64

1.56
(2.34)

0.97
(1.46)

1.98
(2.97)

1.56
(2.34)

0.78
(1.17)

65

3.13
(4.80)

3.13
(4.80)

6.25
(9.58)

12.50
(19.17)

3.13
(4.80)

Ciprofloxacin
1, Cl
8
60
61

NT
500.00
(1344.77)
-

NT
1250.00
(3361.93)
25.00
(47.96)
1.56
(2.15)
0.78
(1.08)
3.13
(4.33)

Note: all compounds in Table 5-6 were additionally tested direct activity against Gram-negative bacteria
(E. coli K12, Pseudomonas aeruginosa PA1) and yeasts (Saccharomyces cereavaesiae BY4742, Candida
albicans F5, and Candida albicans F5 M432), which showed no direct activity at a concentration of
50µg/mL.

The most active compound against S. aureus was the dual action drug 64 with an
MIC against the mutant strain overexpressing the NorA pump at clinically useful
concentrations (1.98µg/mL, over 250-fold more potent than the parent antibiotic 1).
With this compound, it appeared that it had both strong NorA pump blocking activity as
well as separate direct antibacterial potency. A similar result was observed with the
dual action drug 65, although it was 3-fold less active than 64 against the S. aureus
strain K2361. It seemed that the presence of a methoxy substituent in the aryl ring of
the inhibitor moiety of 65, resulted in a decrease in the activity against S. aureus. The
MICs for 60-65 against S. aureus K2361 (the strain overexpressing the NorA pump)
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compared with K1754 (the strain lacking the NorA pump) indicated that compounds 62-

65 completely inhibited the efflux activity of NorA pump in this bacterium as the MICs
for these compounds in both strains were the same or similar (note that there was only a
2-fold difference in the MICs with both strains, which might not be significant). The
MICs for compounds 60-61 in these two strains were quite different however, indicating
that the NorA pump was partially inhibited by these ester prodrugs.

RFU
8325-4

K2361

K1758

Time (min)

Figure 5-3 Graphs showing the accumulation of compound 64 (5µg/mL) inside Staphylococcus
aureus cells over a period of 10 minutes. Fluorescence is given in relative fluorescence units (RFU).

INF55 at 5µg/mL plus berberine 5µg/mL is not shown but would be represented by a horizontal
line at –30 RFU’s. The background fluorescence of berberine was blanked to zero. Cells were in
HEPES buffer pH7 at OD 0.15. The tests were done with S. aureus 8325-4, S. aureus K1754, and S.
aureus K2361.
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Verification of the dual action of the most active compound 64 was subsequently
achieved by a direct uptake assay in 3 strains of S. aureus.47 The uptake assay measured
the fluorescence generated by 64, a planar cationic species, when it interacted with
DNA in the bacterial cells. Due to the disabling of the MDR pumps, it led to an
accumulation of 64 in the cells. The fluorescence from the complex of 64-DNA (Figure
5-3) was found to be increased compared with that from berberine plus INF55 (known
NorA inhibitor, Figure 5-1 and Table 5-3). This uptake study confirmed that 64 had a
double action of MDR pump inhibition and antibacterial activity.
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Interestingly, with the Gram-positive bacterium E. faecalis, only the hybrid drug

64 was able to completely inhibit the bacterial growth at a clinically useful
concentration of 1.56µg/mL while the others were moderately active (61 and 65 with
MICs of 12.5µg/mL) or inactive (60, 62, and 63).
Unexpectedly, the ester prodrug 61 and the hybrid drug 64 were extremely active
against the Gram-negative bacterium S. enterica Serovar Typhimurium at the same MIC
of 0.78µg/mL (over 1600-fold more potent than berberine 1). The amine prodrugs 62
and 63, and hybrid drug 65 were strongly active at the same concentration of
3.13µg/mL against this bacterium while the ester prodrug 60 was more active at the
concentration of 1.56µg/mL. This data indicated that the ester prodrugs 60-61 had more
specific efficacy for the Gram-negative bacterium S. enterica Serovar Typhimurium
than for S. aureus. The ester prodrug 60 and the hybrid 64 were also tested against the
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other wild-type strain of S. aureus, ATCC 6538P, and 4 strains of Enterococcus
faecium. The hybrid drug 64 was strongly active against S. aureus, whereas the ester
prodrug 60 was only moderately active. As expected, both 60 and 64 were inactive
against all strains of E. faecium, vancomycin resistant Enterococcus (VRE) strains due
to unrelated resistance mechanisms to the MDR pump. The resistance mechanism of
these strains involves modification of the peptidoglycan drug target as discussed in
Chapter1, section 1.3.2. Moreover, 64 was tested for antimalarial activity in vitro
against an anti-folate sensitive strain (TM4) and an anti-folate resistant strain (K1) of
Plasmodium falciparum. The result showed good activity with an IC50 of 1.66µg/mL
against the anti-folate resistant strain, which possesses an efflux-related resistance
phenotype.140

Table 5-7 Additional Minimum Inhibitory Concentration (MIC) values for 60 and 64 (direct
activity) against Staphylococcus aureus ATCC 6538P, 4 strains of Enterococcus faecium (VRE243
and VRE987 are sensitive to vancomycin, and VRE449 and VRE820 are resistant to vancomycin),
and 2 strains of Plasmodium falciparum (TM4 is an anti-folate sensitive strain and K1 is an antifolate resistant strain).

MIC, µg/mL (µM)
IC50, µg/mL (µM)
Compd S. aureus
E. faecium
P. falciparum
ATCC 6538P VRE243 VRE449 VRE820 VRE987 TM4
K1
60
64

31.25
(43.11)
0.98
(1.47)

>125.00
(>172.46)
>125.00
(187.54)

>125.00
(>172.46)
125.00
(187.54)

>125.00
(>172.46)
125.00
(187.54)

>125.00
(>172.46)
>125.00
(>187.54)

NT

NT

7.93
(11.90)

1.66
(2.49)

In summary, all compounds 60-65 showed moderate to strong direct antimicrobial
activity and were much more potent than the parent berberine (1). The MICs of 64 were
near or below 1µg/mL against both S. aureus and S. enterica Serovar Typhimurium,
which are clinically useful concentrations. The hybrid drug 64 was the most potent
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antimicrobial compound developed in this research, substantiating the principle of the
hybrid molecule approach. With the dual action prodrugs 60-63, there is evidence that
antimicrobial berberine acid derivative (8) fragment and the MDR pump inhibitor
fragment were possibly released by bacterial hydrolase enzymes. Also this partial
hydrolytic cleavage had been noted using commercially available pig liver esterase at
pH 7.2 for 24h (Chapter 4, Section 4.3). If it is assumed that the prodrugs 60-63 were
hydrolysed completely by bacterial enzymes then they could release the two fragments
expected in a 1:1 equimolar ratio as shown in Scheme 5-1.
1µmole
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N+
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bacterial enzyme
hydrolysis

60: X = O, R = H
61: X = O, R = OCH3
62: X = NH, R = H
63: X = NH, R = OCH3

Y

+
R
HN

COOH

OMe

8

NO2

41: Y = OH, R = H
42: Y = OH, R = OCH3
45: Y = NH2, R = H
48: Y = NH2, R = OCH3

Scheme 5-1 Potential release of 2 active components from the dual action prodrugs 60-63 by
bacterial esterase or amidase as follows: 8 and 41 released from 60, 8 and 42 released from 61, 8
and 45 released from 62, and 8 and 48 released from 63.

In order to prove the assumption of full hydrolysis, separate mixtures of the
hydrolysis products, the berberine acid 8 and each of the indoles (41, 42, 45 or 47) in a
1:1 ratio, were tested against both wild-type 8325-4 and mutant K1758 strains of S.
aureus. The results are shown in Table 5-8. It should be noted that a 1:1 weight ratio
was used in the testing instead of the more accurate 1:1 molar ratio.
The MIC value for a separate mixture of 8 and 41 in a 1:1 weight ratio in the
antibacterial testing was compared with calculated MICs for the fragments 41 and 8
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which would be generated from the prodrug 60 (MIC, 16.00µg/mL = 22.07µM)
assuming complete bacterial enzymatic hydrolysis (Table 5-8). The calculated MICs
showed that the concentration of 41 and 8 required for wild-type (8325-4) strain growth
inhibition was only 5.92µg/mL (22.07µM) and 11.51µg/mL (22.07µM), respectively.
The 1:1 mixture of 41 and 8 gave an experimental MIC of 6.25µg/mL.

Table 5-8 Comparison of direct activity of co-administration of the MDR pump inhibitor and the
berberine acid derivative 8 in a 1:1 weight ratio, to the dual action prodrugs (60-63).

MIC, µg/mL (µM)
Compd
60
8 + 41
(calcd)
8 + 41
(exp.)
62
8 + 45
(calcd)
8 + 45
(exp.)

S. aureus
8325-4
K1758
16.00 (22.07)

3.13 (4.32)

8 = 11.51 (22.07)
41 = 5.92 (22.07)

8 = 2.25 (4.32)
41 = 1.16 (4.32)

8 = 6.25 (11.99)
41 = 6.25 (23.30)

8 = 3.13 (6.00)
41 = 3.13 (11.67)

3.13 (4.33)

3.13 (4.33)

8 = 2.26 (4.33)
45 = 1.16 (4.33)

8 = 2.26 (4.33)
45 = 1.16 (4.33)

8 = 12.50 (23.98)
45 = 12.50 (46.77)

8 = 12.50 (23.98)
45 = 12.50 (46.77)

MIC, µg/mL (µM)
Compd
61
8 + 42
(calcd)
8 + 42
(exp.)
63
8 + 48
(calcd)
8 + 48
(exp.)

S. aureus

8325-4

K1758

6.25 (8.28)

3.13 (4.15)

8 = 4.32 (8.28)
42 = 2.47 (8.28)

8 = 2.16 (4.15)
42 = 1.24 (4.15)

8 = 6.25 (11.99)
42 = 6.25 (20.95)

8 = 6.25 (11.99)
42 = 6.25 (20.95)

12.50 (16.59)

6.25 (8.29)

8 = 8.65 (16.59)
48 = 4.93 (16.59)

8 = 4.32 (8.29)
48 = 2.46 (8.29)

8 = 12.50 (23.98)
48 = 12.50 (42.04)

8 = 3.13 (6.00)
48 = 3.13 (10.53)

These data indicated that the concentration of a separate mixture of 41 and 8
required for bacterial growth inhibition corresponded approximately to the calculated
maximum concentrations of fragments 41 and 8 which could be released from prodrug

60. Similar results were obtained with the other ester prodrug 61 and the amide prodrug
63.

Therefore, the ester and amide prodrugs 60-61 and 63 seemed to be cleaved by

bacterial hydrolytic enzymes as anticipated. The calculated intracellular concentrations
of the two fragments 8 and 45 released from the amide prodrug 62 were lower than the
actual concentrations of a 1:1 separate mixture of 8 and 45 from antibacterial testing.
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The amide prodrug 62 seemed to be stable in bacterial cells, and might have strong
intrinsic antibacterial activity.
In order to fully establish bacterial esterase or amide hydrolysis in the prodrugs, it
would be necessary to examine the effect of bacterial lysates on these compounds.
Time constraints did not allow this to be undertaken.

5.4 Cytotoxicity results
Only the inhibitor 41, the corresponding ester prodrug 60, and the hybrid drug 64
were tested for cytotoxicity against human histiocytic lymphoma cells (cell line U937)
by

[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl-2-(4-sulfophenyl)-2H

tetrazolium, inner salt (MTS) assay, and the results are shown in Table 5-9.
Table 5-9 Preliminary minimum inhibitory concentration (MIC) of 40, 60, and 64 against human
hystiocytic lymphoma cells (cell line U937).

MIC
µg/mL
(µM)

Compound
41
60
64
>100.00 >100.00 >100.00
(327.76) (137.97) (>150.04)

The MIC value of each compound tested was greater than 100µg/mL, indicating
they were only weakly or non-cytotoxic. There was over 50-fold difference in the MIC
of 60 and 64 for antimicrobial activity versus cytotoxicity.
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Chapter6: Conclusions and Future Directions

6.1 Conclusions
The synthesis of a range of new 2-aryl-5-nitroindole derivatives as potent multidrug
resistance pump (MDR) inhibitors was achieved using a palladium-mediated cyclisation
to establish the crucial indole C2-aryl C bond formation. Biological testing of these
compounds showed that all compounds (39, 41-45, 47-48, and 56) apart from the acid
derivative 38 potentiated the action of the antibacterial
agent berberine (1) by blocking the NorA MDR pump
in S. aureus. The alcohol 43 was the most effective

CH2OH

O2N
N
H

43

O

inhibitor in the 2-aryl-5-nitroindole series against all strains of Staphylococcus aureus,
together with showing a moderate intrinsic activity against Salmonella enterica Serovar
Typhimurium SL1344R2.

The novel alcohol 43 was thus a new dual action

antibacterial agent.
Other novel dual action antibacterial agents were designed and synthesized. The
lead compounds (60, 62, and 64) were based on a combination of berberine (1) and 2phenyl-5-nitroindole derivatives with enzymatically cleavable (ester and amide) and
non-cleavable (methylene) linking groups. The coupling of the two active components
was achieved by a one-step synthesis.

This involved the reaction of 8-

allyldihydroberberine (9) with the appropriate alkylating agent from the 2-phenyl-5nitro-1H-indole derivative via an enamine alkylation/propene elimination strategy to
afford the potential dual action prodrugs (60, 62) and the dual action drug (64) in low to
moderate yields. Similarly, methoxyaryl derivatives (61, 63, and 65) of these leads
were synthesized and investigated for antibacterial activity. Biological testing of the
dual action prodrugs and dual action drugs (60-65) showed that all compounds were
active as antibacterial agents. The dual action drug 64 was the most active antibacterial
129

agent against both Gram-positive and Gram-negative bacteria. Compound 64 exhibited
a 250-fold greater antibacterial activity than the parent antibacterial berberine (1)
against a resistant strain of S. aureus, K2361, which overexpresses the NorA MDR
pump.

Compound 64 also showed a 320-fold greater activity than 1 against

Enterococcus faecalis V583, and a 1600-fold greater activity than 1 against Salmonella
enterica Serovar Typhimurium SL1344R2. The methoxy substituted derivative of 64,
the compound 65, was slightly less active than 64 against all strains tested. Compound

64 also showed good antimalarial activity (Plasmodium falciparum) in vitro.

An

additional uptake assay against S. aureus for compound it was confirmed that 64 had
dual activity as a NorA inhibitor and as an antibacterial.
O
N+

O

O

Br -

N+

O

Br OMe

OMe
N
H

OMe

O

N
H

OMe

O

H3CO
HN

HN

NO2

62

NO2

63

In the series of ester and amide dual action prodrugs 60-63, the amides 62 and 63
had higher activities than the esters 60 and 61 against S. aureus strain K2361. However,
the esters 60 and 61 were more potent than the amides 62 and 63 against S. enterica
Serovar Typhimurium SL1344 R2.
O
N+

O

Br O
OMe

O

O2N

N+

O

OMe

OMe

O

OMe
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The ester 61 was the most active compound against the S. enterica strain SL1344
R2 in the prodrug series, and was comparable in activity to the dual action drug 64
(MIC; 0.78 µg/mL).

It is probable that the prodrugs 60-63 may have intrinsic

antibacterial activity without enzymatic hydrolysis being involved. As an amide bond
has greater stability than an ester bond, the rate of bacterial enzymatic hydrolysis in 62
or 63 might be slower than hydrolysis of the ester 60 or 61, resulting in slightly higher
activities than the ester prodrugs against S. aureus K2361. Thus, the dual action of the
amide prodrugs may not require bacterial enzymatic action to generate the fragment 8
and the corresponding MDR pump inhibitor (45 or 48).

On the other hand, the

microbiological evidence pointed to hydrolysis of the esters 60 and 61 by bacterial
esterase, with the fragments being the antibacterial berberine acid 8 and a corresponding
MDR pump inhibitor (41 or 42) produced synchronously in high concentration. Partial
hydrolysis of 60 was observed in the presence of pig liver esterase.
In summary, a potent dual action drug, 64, was found.

The dual action

mechanism is thus a promising way to combat the problem of antibiotic resistance by
drug efflux. Also, compound 43 is the most potent NorA MDR pump inhibitor against
S. aureus in the 2-aryl-5-nitro-1H-indole series. Therefore, the variety of novel MDR
pump inhibitors, dual action prodrugs and dual action drugs discovered in this project
should provide a useful basis for future antimicrobial drug developments.

6.2 Future directions
To verify ester or amide hydrolysis within bacterial cells, bacterial enzymatic
hydrolysis experiments on the ester and amide prodrugs (60-63) is required in future
work.
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Also, prior to in vivo antibacterial studies, plasma stability studies on the prodrugs
need to be undertaken and modifications to the ester or amide groups made, if
necessary, in order to avoid hydrolysis before delivery to the bacteria.
A combination of the most potent inhibitor 43 with berberine 1 should also be
investigated. Such a compound may be a novel triple action drug against the Gramnegative pathogen Salmonella enterica.
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Chapter7: Experimental

7.1 General
All melting points were determined using a Reichert hot-stage melting point
apparatus and are uncorrected.
1

The H and

13

C NMR were determined at 299.92 and 75.42 MHz with a Varian

Unity-300 spectrometer, and at 499.91 and 125.71 MHz with Varian Inova-500
spectrometer. Unless otherwise stated, the spectra were obtained from solutions in
CDCl3 and referenced to TMS (proton) and the chloroform mid-line (77) (carbon).
1

Chemical shifts of the outer peaks are given for specified multiplet patterns in the HNMR spectra.

The assignments were made by standard gradient correlation

spectroscopy (gCOSY), gradient heteronuclear single quantum correlation (gHSQC)
and gradient heteronuclear multiple bond correlation (gHMBC) spectroscopy. The same
superscript assignments may be reversed for the signals designated in the same
compound. J values for mutually coupled systems were calculated from chemical shift
differences and were the same or very close to being the same; coupling was confirmed
from gCOSY spectra.
MS (CI) and (EI) were obtained using a Shimadzu QP-5000 spectrometer with
isobutane as the ionising gas in the CI mode, and with a source temperature of 250oC.
High resolution (CI) MS (for MH+) and (EI) MS (for M+) were run using a VG
Autospec spectrometer operating at 70 eV and a source temperature of 250oC with PFK
reference and methane as ionising gas in CI mode, and high resolution (ES) MS (for
MH+) with a Micromass Qtof 2 mass spectrometer using a cone voltage of 30V and
polyethylene glycol (PEG) as an internal reference.
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Elemental microanalyses were determined by Mr. G. Blazak at the University of
Queensland.
Berberine chloride was obtained from the Sigma Chemical Company and dried
over phosphorus pentoxide at 80oC under reduced pressure for 8 h before use.59 NBS
was recrystallized from water and dried over phosphorus pentoxide before use.
Solvents were purified and dried by standard techniques.141
Chromatography using Merck Kieselgel 60 silica gel (230-400 mesh) was
performed under medium pressure or by vacuum liquid chromatography (VLC).
Preparative TLC was done on Merck Silica gel 60 F254 and Aluminium oxide F254 with a
thickness of 0.2 mm on aluminium sheet. All chromatographic solvent proportions are
volume for volume. Reactions were monitored by thin-layer chromatography (TLC) on
Merck silica gel 60 F254 and Aluminium oxide F254 on aluminium sheets, and the
compounds were detected by examination under ultraviolet light and by exposure to
iodine vapour.
Organic solvents were dried with anhydrous sodium sulfate and removed under
reduced pressure (in vacuo) by a Büchi rotary evaporator.
Microwave reactions were performed in a Milestone Ethos Sel Microwave
Solvent Extractor, employing Easywave software, and using internal reaction
temperature control.

Sealed Teflon reaction vessels were used and washed with

concentrated nitric acid between uses. Magnetic stirring was used to stir reaction
mixtures.
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7.2 Dihydroberberine route to 13-substituted berberines
(Chapter 2)
7.2.1 P reparation o f 9 ,1 0 -D im eth o x y -5 ,8 -d ih y d ro -6 //-b en zo [g ]-l,3 benzod ioxolo[5,6-a]q u in olizin e (2 )57,59
Method 1\ To a solution o f dry berberine hydrochloride
(1) (3.0g, 8.1mmol) in pyridine (18mL) was added sodium
borohydride (360mg, 9.5mmol) and the mixture stirred at
room temperature for 20min. More sodium borohydride
(300mg, 7.9mmol) was added and stirring was continued for 30min.

The reaction

mixture was then poured into ice water (200mL). The precipitated solid was filtered
and dried to give the enamine 2 (2.6g, 96%) as a yellow solid, m.p. 123-125°C (Lit. 142
157-158°C; recrystallised from DCM-MeOH). 'H-NMR (300MHz, CDC13):

8

2.88 (t, J

= 5.9 Hz, 2H, H-5), 3.13 (t, J = 5.9 Hz, 2H, H-6 ), 3.85 (s, 6 H, OCH3), 4.32 (br.s, 2H, H8 ),

5.94 (s, 2H, 0C H 20 ), 5.95 (s, IH, H-13), 6.58 (br.s, IH, H-11), 6.74 (s, 2H, H-12,

H-4), 7.17 (s, IH, H-14). CIMS: m/z, [MH]+: 338 (50 %).
Method 2: To a solution o f berberine hydrochloride.2.5 H20 (1) (0.7g, 1.7mmol)
in methanol (25mL) was added K2 CO 3 (0.8g, 60mmol), and then sodium borohydride
(24.0mg, 0.64mmol) was slowly added to the suspension which was then stirred at 0°C
for

8

h. The mixture was concentrated and then added to ice water (200mL). The

precipitated solid was filtered and washed thoroughly with water until the washing were
neutral. The solid was then washed with MeOH (50mL) to remove starting material 1,
and dried to give the enamine 2 (0.3g, 53%) as a yellow solid.
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7.2.2 Preparation

of

(9,10-Dimethoxy-5,8,13,13a-tetrahydro-6H-

benzo[g]-1,3-benzodioxolo[5,6-a]quinolizin-13-yl)-acetic acid
ethyl ester (3)
Dry ethyl bromoacetate (30mL, 270.5mmol) was added

O

dropwise with stirring to dihydroberberine 2 (2.62g,

N

O

OCH3

EtOOCH2C

3

OCH3

0.78mmol) at 0oC under a nitrogen atmosphere. The solution
was heated to 100oC for 1h to give a suspension. Dry toluene

(25mL) was added to the suspension, the precipitate filtered and then dried to give the
iminium salt intermediate 2a (3.78g, 96%). The unstable intermediate 2a (3.78g,
8.9mmol) was dissolved in absolute ethanol (50mL) and stirred at 0oC.

Sodium

borohydride (400mg, 10.5mmol) was added to the suspension which was then stirred at
room temperature for 20min. More sodium borohydride (400mg, 10.5mmol) was added
and further stirred for 1h. The mixture was then concentrated by solvent evaporation in
vacuo. Water (200mL) was added to the crude product and the mixture then extracted
with diethyl diethyl ether (3 x 150mL). The combined diethyl ether extract was washed
with water, dried and evaporated. The crude product was chromotographed on silica gel
(DCM) to afford the ester 3 (2.8g, 88%) as a yellow solid, m.p. 103-104oC. 1H-NMR
(300MHz, CDCl3): δ 1.15 (t, J = 7.2 Hz, 3H, CH3), 2.30 (dd, J = 15.6, 8.4 Hz, 1H,
CH2CO), 2.44 (dd, J = 15.6, 8.4 Hz, 1H, CH2CO), 2.50-2.61 (m, 2H, H-5, H-6), 2.993.13 (m, 2H, H-5, H-6), 3.52 (d, J = 16 Hz, 1H, H-8), 3.61-3.68 (m, 1H, H-13), 3.72
(br.s, 1H, C-13a), 3.85 (s, 6H, OCH3), 3.98 (q, J =7 Hz, 2H, CH2CH3), 4.10 (d, J = 16
Hz, 1H, H-8), 5.91 (d, J = 1.3 Hz, 1H, OCH2O), 5.92 (d, J = 1.3 Hz, 1H, OCH2O), 6.58
(s, 1H, H-4), 6.74 (s, 1H, H-14), 5.76 (d, J = 8.4 Hz, 1H, H-11), 7.00 (d, J = 8.4 Hz, 1H,
H-12).

13

C NMR (75MHz, CDCl3): δ 14.11 (CH3), 29.8 (C5), 38.1 (CH2CO), 40.5

(C13), 51.0 (C6), 54.2 (C8), 55.8 (OCH3), 60.0 (OCH3), 60.1 (CH2CH3), 63.0 (C13a),
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100.8 (OCH2O), 105.9 (C4)a, 108.3 (C14)a, 110.6 (C12)b, 124.1 (C11)c, 128.4 (C13b)d,
128.5 (C8a)e, 129.8 (C4a)d, 132.4 (C12a)e, 144.9 (C14a)f, 146.0 (C9), 146.4 (C3a)f,
150.6 (C10), 173.6 (CO). HMRS (EI); m/z calcd for C24H27NO6 [M]+: 425.1838; found:
425.1837.

7.2.3 Preparation of (9,10-Dimethoxy-5,8,13,13a-tetrahydro-6Hbenzo[g]-1,3-benzodioxolo[5,6-a]quinolizin-13-yl)-acetic acid(4)
Method 1: A solution of 3 (18.0mg, 0.04mmol) in 2M

O
N

O

OCH3

HOOCH2C

4

OCH3

HCl (1.5mL) was stirred for 30h at room temperature with
shielding from light, and was then evaporated and added to

ice water (20mL). The mixture was neutralized by saturated NaHCO3 solution and then
extracted with EtOAc (3 x 20mL). The combined EtOAc extracts were washed with
water, dried and evaporated to give only the starting material 3 (18.0mg). The reaction
conditions were, therefore, changed to use 1M H2SO4 in THF under the same procedure
but no hydrolysis was observed.
Method 2: To a solution of 3 (521.0mg, 1.19mmol) in MeOH (30mL) was added a
2% aqueous solution of lithium hydroxide (40mL) and the mixture heated at reflux for 1
h. The cooled reaction mixture was then evaporated. The crude product was added to
ice water (200mL) and acidified to pH 1 with 1M HCl. The precipitate was filtered,
washed with water and dried to afford the acid 4 (460.1mg, 95%) as an opaque white
solid, m.p. 202-205oC.

1

H-NMR (300MHz, CDCl3): δ 2.59-2.85 (m, 4H, H-5, H-6,

CH2CO), 3.18-3.34 (m, 2H, H-5, H-6), 3.42-3.50 (m, 1H, H-13), 3.73 (d, J = 15.6 Hz,
1H, H-8), 3.87 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 4.06 (d, J = 3.3 Hz, 1H, H-13a), 4.32
(d, J = 15.6 Hz, 1H, H-8), 5.98 (s, 2H, OCH2O), 6.60 (s, 1H, H-4)a, 6.64 (s, 1H, H-14)a,
6.86 (d, J = 8.7 Hz, 1H, H-12)b, 7.00 (d, J = 8.7 Hz, 1H, H-11)b.

13

C NMR (75MHz,
137

DMSO-d6): δ 28.2 (C5), 37.8 (CH2CO), 43.3 (C13), 50.1 (C6), 53.0 (C8), 55.7 (OCH3),
59.6 (OCH3), 62.2 (C13a), 100.8 (OCH2O), 105.6 (C4)c, 108.2 (C14)c, 111.6 (C12),
123.9 (C11), 126.3 (C8a)d, 127.1 (C4a)e, 128.7 (C13b)e, 131.0 (C8a)d, 144.3 (C9)f,
145.9 (C3a)g, 146.3 (C14a)g, 150.3 (C10)f, 173.6 (CO). HRMS (EI); m/z calcd for
C22H23NO6 [M]+: 397.1525; found: 397.1516.

7.2.4 Preparation of (9,10-Dimethoxy-5,8,13,13a-tetrahydro-6Hbenzo[g]-1,3-benzodioxolo[5,6-a]quinolizin-13-yl)-acetic acid
benzyl ester (5)
Method 1: To a mixture of the acid 4 (23.0mg,

O
N

O
PhH2COOCH2C

5

0.06mmol), HOBT (2mg, 0.01mmol) and DCC (15.0mg,
OCH3

0.07mmol) was added anhydrous DMF (1mL) at 0oC under a

OCH3

nitrogen atmosphere. The mixture was then stirred at room

temperature for 5 min. A solution of 20% dry benzyl alcohol in anhydrous DMF
(0.15mL, 0.29mmol) was then added and the mixture stirred at room temperature for 2
days. The reaction mixture was monitored by TLC (silica gel, 2%DCM in MeOH), but
no reaction of the starting material 4 was observed.
Method 2: To a mixture of the acid 4 (23.0mg, 0.06mmol), DMAP (7.0mg,
0.06mmol) and EDCI (9.2mg, 0.06mmol) was added anhydrous DMF (1mL) at 0oC
under a nitrogen atmosphere. The mixture was then stirred at room temperature for 5
min. A solution of 5% dry benzyl alcohol in anhydrous DMF (0.15mL, 0.08mmol) was
then added and the mixture stirred at 40oC for 2 days. The mixture was monitored by
TLC (silica gel, 2%DCM in MeOH), but no reaction of the starting material 4 was
observed.
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Method 3: To a mixture of the acid 4 (115.0mg, 0.29mmol), DMAP (5mg,
0.04mmol) and DCC (76.0mg, 0.37mmol) was added anhydrous DMF (1mL) at 0oC
under a nitrogen atmosphere. The mixture was then stirred at room temperature for 5
min. A solution of 20% dry benzyl alcohol in anhydrous DMF (0.15mL, 0.29mmol)
was then added and the mixture stirred at 80oC for 30h. The reaction mixture was
evaporated in vacuo. The residue was chromatographed on silica gel (0.5% MeOH in
DCM) to afford the ester 5 (45.0mg, 32%) as a yellow solid, m.p.104-105oC. 1H-NMR
(300MHz, CDCl3): δ 2.37 (dd, J = 15.5, 4.1 Hz, 1H, CH2CO), 2.52 (dd, J = 15.5, 8.9
Hz, 1H, CH2CO), 2.48-2.60 (m, 2H, H-5, H-6), 2.94-3.32 (m, 2H, H-5, H-6), 3.50 (d, J
= 15.9 Hz, 1H, H-8), 3.63-3.69 (m, 1H, H-13), 3.71 (br.s, 1H, H-13a), 3.83 (s, 3H,
OCH3), 3.84 (s, 3H, OCH3), 4.18 (d, J = 16.2 Hz, 1H, H-8), 4.97 (d, J = 2.1, 2H,
OCH2), 5.88 (d, J = 1.2 Hz, 1H, OCH2O), 5.89 (d, J = 1.5 Hz, 1H, OCH2O), 6.55 (s, 1H,
H-4)a, 6.68 (d, J = 8.7 Hz, 1H, H-11)b, 6.74 (s, 1H, H-14)a, 6.90 (d, J = 8.4 Hz, 1H, H12)b, 7.19-7.35 (m, 5H, ArH).

13

C NMR (75MHz, CDCl3): δ 29.8 (C5), 38.0 (CH2CO),

40.7 (C13), 51.0 (C6), 54.2 (CH2O), 55.7 (OCH3), 60.0 (OCH3), 63.0 (C13a), 65.9
(CH2O), 100.7 (OCH2O), 105.8 (C4)c, 108.2 (C14)c, 110.5 (C11)d, 124.0 (C12)d, 127.4
(C8a)e, 127.8 (ArCH), 127.9 (2C, ArCH), 128.2 (C4a)f, 128.2 (2C, ArCH), 128.3
(C13b)f, 132.0 (C12a)e, 135.9 (ArC), 144.8 (C9)g, 145.8 (C14a)h, 146.3 (C3a)h, 150.5
(C10)g, 173.3 (CO). HRMS (EI): m/z calcd for C29H29NO6 [M]+: 487.1995; found:
487.1988.
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7.2.5 Preparation of 13-(Ethoxycarbonylmethyl)-9,10-dimethoxy-5,6dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide
(6a)58
To a solution of the ester 3 (100.0mg, 0.24mmol) in absolute EtOH (10mL), was
added iodine (179.2mg, 0.71mmol) and the mixture stirred at 60oC for 12 h. More
iodine (100.0mg, 0.39mmol) was then added and the mixture stirred for a further 12 h.
The excess iodine was decomposed by the addition of sodium thiosulfate until the
brown solution was changed to a yellow solution and a

O
N

O

+

I-

white precipitate was formed. The insoluble substance was
OCH3

EtOOCH2C

filtered and the filtrate was then evaporated. The residue

6a

OCH3

was crystallized from warm EtOH to afford the iodide salt 6a (125.5mg, 97%) as a
yellow solid, m.p. 155-157oC (Lit.58 165oC). 1H-NMR (300MHz, CDCl3): δ 1.35 (t, J
= 7.2 Hz, 3H, CH3), 3.26 (br.s, 2H, H-5), 4.04 (s, 3H, OCH3), 4.25 (s, 2H, CH2CO),
4.33 (q, J = 7.2 Hz, 2H, CH2CH3), 4.38 (s, 3H, OCH3), 5.09 (br.s, 2H, H-6), 6.08 (s, 2H,
OCH2O), 6.87 (s, 1H, H-4), 7.21 (s, 1H, H-14), 7.70 (d, J = 9.0 Hz, 1H, H-11), 7.84 (d,
J = 9.3 Hz, 1H, H-12), 10.34 (s, 1H, H-8).

7.2.6 Preparation of 13-Benzyloxycarbonylmethyl-9,10-dimethoxy-5,6dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide
(7a) and bromide (7b)
O
O

+

N

Method 1, Iodide salt:

X-

PhH2COOCH2C

OCH3
OCH3

7a : X = I; 7b: X = Br

To a solution of ester 5

(79.0mg, 0.16mmol) in ethanol (150mL) was added iodine
(80.0mg, 0.32mmol). The solution was heated at reflux for
1h.

The excess iodine was decomposed by addition of
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sodium thiosulfate until the brown solution was changed to a yellow solution and a
white precipitate was formed. The insoluble substance was filtered and the solvent was
then evaporated. The crude product was chromatographed on alumina by PLC (2%
MeOH in DCM) to afford the quinolizinium iodide 7a (15.7mg, 16%) as a yellow solid.
Method 2, Bromide salt: To a mixture of the ester 5 (30mg, 0.06mmol) and NBS
(21.8mg, 0.12mmol) was added dry CHCl3 (2mL) and the solution stirred at room
temperature for 1h. The mixture was then washed with water (50mL). The chloroform
layer was dried and concentrated. The residue was triturated with diethyl ether (10mL)
and then filtered to afford the quinolizinium bromide 7b (38.2mg, 85%) as a yellow
solid, m.p. 124-126oC.

1

H-NMR (300MHz, CDCl3): δ 3.25 (t, J = 5.7 Hz, 2H, H-5),

4.05 (s, 3H, OCH3), 4.31 (s, 2H, CH2CO), 4.39 (s, 3H, OCH3), 5.14-5.30 (br.m, 2H, H6), 5.31 (s, 2H, OCH2), 6.10 (s, 2H, OCH2O), 6.89 (s, 1H, H-4)a, 7.22 (s, 1H, H-14)a,
7.39 (s, 5H, ArH), 7.57 (d, J = 9.3 Hz, 1H, H-11), 7.68 (d, J = 9.3 Hz, 1H, H-12), 10.56
(s, 1H, H-8).

13

C NMR (75MHz, CDCl3): δ 28.6 (C5), 37.2 (CH2CO), 57.0 (OCH3),

57.4 (C6), 63.1 (OCH3), 68.0 (OCH2), 102.1 (OCH2O), 108.6 (C4)b, 109.1 (C14)b,
119.1 (C13b)c, 119.6 (C11), 121.6 (C8a), 125.4 (C12), 125.7 (C12a)d, 128.7 (5C,
ArCH), 133.2 (C13)d, 134.1 (C4a)c, 134.7 (ArC), 137.5 (C13a), 146.5 (C8), 147.2 (C9)e,
147.3 (C14a), 150.1 (C3a), 150.5 (C10)e, 170.3 (CO). HRMS (ES): m/z calcd for
C29H26NO6 [M]+: 484.1760; found: 484.1735. Anal.Calcd. for C29H26NO6Br.1.5H2O: C,
58.89 ; H, 4.94; N, 2.37%. Found: C, 58.70; H, 5.06; N, 2.26%.
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7.2.7 Preparation of 13-Carboxymethyl-9,10-dimethoxy-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium iodide (8)
To a solution of the ester 6a (90.0mg, 0.16mmol) in
O
N+

O
HOOCH2C

8

I-

MeOH (5mL), was added a 2% aqueous solution of LiOH
OCH3
OCH3

(6mL) and the mixture was then heated at reflux for 30min.
The cooled reaction mixture was then evaporated. The crude

product was added to ice water (100mL) and acidified to pH1 with 1M HCl. The
precipitate was filtered and washed with water.

The solid was dried and then

recrystallized from 3% EtOH in DCM to afford the quinolizinium iodide 8 (47.4mg,
53%) as a white solid, m.p. >250oC.

1

H-NMR (300MHz, CD3OD): δ 3.12 (t, J = 5.7

Hz, 2H, H-5), 4.09 (s, 3H, OCH3), 4.18 (s, 2H, CH2CO), 4.19 (s, 3H, OCH3), 4.80 (br.s,
2H, H-6), 4.89 (s, 2H, OCH2O), 7.00 (s, 1H, H-4)a, 7.70 (s, 1H, H-14)a, 8.07 (d, J = 9.9
Hz, 1H, H-11)b, 8.12 (d, J = 9.9 Hz, 1H, H-12)b, 9.78 (s, 1H, H-8).

13

C NMR (125MHz,

CD3OD): δ 29.1 (C5), 40.2 (CH2CO), 49.2 (OCH3), 57.5 (C6), 62.6 (OCH3), 103.6
(OCH2O), 109.1 (C4)c, 111.1 (C14)c, 122.0 (C8a), 122.4 (C11)d, 123.0 (C12a), 127.2
(C12)d, 132.1 (C4a), 134.8 (C13), 135.6 (C13a)e, 138.6 (C13b)e, 145.0 (C8), 146.1
(C9)f, 148.8 (C3a)g, 151.4 (C14a)g, 151.7 (C10)f, 177.1 (CO). HRMS (ES): m/z calcd
for C22H20NO6 [M]+: 394.1291; found: 394.1282.

7.3 8-Allyldihydroberberine route
7.3.1 Preparation of 8-Allyl-9,10-dimethoxy-5,8-dihydro-6H-benzo[g]1,3-benzodioxolo[5,6-a]quinolizine (9)143
To a suspension of dry berberine chloride (1) (1.30g, 3.50mmol) in dry DCM
(30mL) was added allyl tri-n-butyltin (3mL, 9.39mmol) in a sealed tube and the mixture
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then heated to 100oC for 8h. The resulting brown-yellow

O
N

O

solution was cooled to room temperature and then
OCH3

concentrated. The residue was crystallized from MeOH by
OCH3

9

placing the mixture in a freezer overnight. The crystals were

filtered, washed with cold MeOH and dried to give the allyl enamine 9 (1.12g) as a
yellow crystalline solid. The filtrate was concentrated and the residue recrystallized
from MeOH to yield further 9 (0.10g) for a total yield of pure 9 of 1.22g (92%); m.p.
109-110oC. 1H NMR (300MHz, CDCl3): δ 2.38-2.50 (m, 2H, CH2CH=CH2), 2.78-2.90
(m, 2H, H-5), 3.28-3.36 (m, 1H, H-6), 3.44-3.58 (m, 1H, H-6), 3.84 (s, 3H, OCH3), 3.89
(s, 3H, OCH3), 4.83-4.92 (m, 1H, H-8), 4.83-4.92 (m, 2H, CH2CH=CH2), 5.74-5.88 (m,
1H, CH2CH=CH2), 5.80 (s, 1H, H-13), 5.94 (d, J = 3.3 Hz, 2H, OCH2O), 6.58 (s, 1H,
H-4)a, 6.72 (d, J = 8.4 Hz, 1H, H-12), 6.76 (d, J = 8.4 Hz, 1H, H-11), 7.14 (s, 1H, H14)a.

13

C NMR (75MHz, CDCl3): δ 30.6 (C5), 36.5 (CH2CH=CH2), 47.3 (C6), 56.0

(OCH3), 58.3 (C8), 60.7 (OCH3), 94.6 (C13), 100.9 (OCH2O), 104.2 (C14)b, 107.7
(C4)b, 116.6 (CH2CH=CH2), 111.7 (C12), 118.2 (C11), 123.0 (C12a), 125.8 (C4a)c,
128.0 (C8a), 128.7 (C13b)c, 135.5 (CH2CH=CH2), 138.9 (C13a), 144.0 (C9)d, 146.4
(C14a), 149.7 (C10)d, 147.0 (C3a). HRMS (CI): m/z calcd for C23H24NO4 [MH]+:
378.1705; found: 378.1703. Anal.Calcd. for C23H23NO4: C, 73.19; H, 6.14; N, 3.71.
Found: C, 73.33; H, 6.17; N, 3.60.

7.3.2 Preparation of 13-Ethoxycarbonylmethyl-9,10-dimethoxy-5,6dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium bromide
(6b) from 8-Allyldihydroberberine (9)
143

Dry ethyl bromoacetate (2mL, 18.03mmol) was added
O
N

O
H3CH2CO2CH2C

6b

+ Br -

dropwise with stirring to 8-allyldihydroberberine (9)
OCH3

(50.5mg, 0.13mmol) at 0oC under a nitrogen atmosphere.

OCH3

The solution was then heated to 100oC for 2.5h to give a

suspension. Dry toluene (5mL) was added to the suspension, the mixture filtered and
the filtrate was then evaporated to give 6b (57.3mg) as an orange-yellow amorphous
solid. The solid was recrystallized from 1% MeOH in DCM, and diethyl diethyl ether
to give the quinolizinium bromide 6b (39.3mg, 59%) as yellow needles; m.p. 202204oC.

1

H NMR (300MHz, CDCl3): δ 1.37 (t, J = 7.2 Hz, 3H, OCH2CH3), 3.20-3.35

(br.t, 2H, H-5), 4.07 (s, 3H, OCH3), 4.27 (s, 2H, CH2CO), 4.36 (q, J = 7.2 Hz, 2H,
OCH2), 4.41 (s, 3H, OCH3), 5.30-5.70 (br.m, 2H, H-6), 6.10 (s, 2H, OCH2O), 6.90 (s,
1H, H-4), 7.24 (s, 1H, H-14), 7.71 (d, J = 9.3 Hz, 1H, H-11), 7.84 (d, J = 9.0 Hz, 1H, H12), 10.60 (s, 1H, H-8).

13

C NMR (75MHz, CDCl3): δ 14.3 (CH2CH3), 28.5 (C5), 37.2

(CH2CO), 57.0 (OCH3), 57.4 (C6), 62.3 (OCH2), 63.1 (OCH3), 102.1 (OCH2O), 108.6
(C4), 109.0 (C14), 119.3 (C13b)a, 119.6 (C11), 121.6 (C8a), 125.6 (C4a)a, 125.8 (C12),
133.2 (C13), 133.9 (C12a), 137.4 (C13a), 146.2 (C9)b, 146.9 (C14a), 147.3 (C8), 150.0
(C3a), 150.5 (C10)b, 170.4, (CO).

HRMS (ES): m/z calcd for C24H24NO6 [M]+:

422.1604; found: 422.1596. Anal.Calcd. for C24H24NO6Br.0.2CH2Cl2: C, 55.97 ; H,
4.74; N, 2.70%. Found: C, 55.83; H, 4.85; N, 2.54%.

7.3.3 Preparation of 13-Benzyloxycarbonylmethyl-9,10-dimethoxy-5,6dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium bromide
(7b) from 8-Allyldihydroberberine (9)
Dry benzyl bromoacetate (1.5mL, 9.47mmol) was added dropwise with stirring to
8- allyldihydroberberine (9) (36.4mg, 0.10mmol) at 0oC under a nitrogen atmosphere.
144

The solution was then heated to 100oC for 2.5h. The reaction mixture was cooled, then
adsorbed on celite and chromatographed on silica gel (4%MeOH in DCM) to give the
quinolizinium bromide 7b (31.2mg, 57%) as a yellow solid. All spectroscopic data for

7b was the same as that noted for this compound previously (Section 6.2.6).

7.3.4 Preparation of 9,10-Dimethoxy-13-(2-oxo-2-phenyl-ethyl)-5,6dihydrobenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium bromide
(10)
To a solution of 8-allyldihydroberberine (9) (46mg,

O
N

O

+ Br OCH3

PhOCH2C

10

OCH3

0.12mmol) in dry CH3CN (2mL) was added phenacyl
bromide (46mg, 0.23mmol) under a nitrogen atmosphere.
The mixture was refluxed for 4h, then concentrated and the

residue chromatographed on silica gel (4% MeOH in DCM) to give the quinolizinium
bromide 10 (35.6mg, 55%) as a yellow solid; m.p.181-183oC.

1

H NMR (300MHz,

CDCl3): δ 3.20-3.35 (br.m, 2H, H-5), 4.02 (s, 3H, OCH3), 4.33 (s, 3H, OCH3), 5.07 (s,
2H, CH2CO), 5.10-5.30 (br.m, 2H, H-6), 5.99 (s, 2H, OCH2O), 6.90 (s, 2H, H-14 and
H-4), 7.47 (d, J = 9.3 Hz, 1H, H-11), 7.62 (t, J = 7.8 Hz, 2H, ArH), 7.70-7.78 (m, 1H,
ArH), 7.77 (d, J = 9.3 Hz, 1H, H-12), 8.19 (br.d, J = 7.5Hz, 2H, ArH), 10.46 (s, 1H, H8).

13

C NMR (75MHz, CDCl3): δ 28.6 (C5), 42.03 (CH2CO), 57.0 (OCH3), 57.3 (C6),

63.0 (OCH3), 102.0 (OCH2O), 108.4 (C4)a, 108.6 (C14)a, 119.8 (C4a), 119.9 (C11),
121.7 (C8a), 125.7 (C12), 127.2 (C13b), 128.5 (2C, ArCH), 129.2 (2C, ArCH), 133.4
(C13)b, 133.9 (C12a)b, 134.5 (ArCH), 135.2 (ArC), 137.6 (C13a), 146.0 (C9)c, 146.5
(C8), 147.3 (C14a), 150.0 (C3a), 155.3 (C10)c, 196.7 (CO). HRMS (ES): m/z calcd for
C28H24NO5

[M]+:

454.1654;

found:

454.1649.

Anal.Calcd.

for

C28H24NO5Br.1.4CH3OH: C, 60.96; H, 5.15; N, 2.42. Found: C, 60.69; H, 5.17; N, 2.39.
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7.3.5 Preparation of 13-Benzyl-9,10-dimethoxy-5,6-dihydrobenzo[g]1,3-benzodioxolo[5,6-a]quinolizinium bromide (11)
Dry benzyl bromide (3.0mL, 25.26mmol) was added
O
O

N

dropwise

+ Br -

11

with

stirring

to

8-allyldihydroberberine

(9)

OCH3

(205.0mg, 0.54mmol) at 0oC under a nitrogen atmosphere.

OCH3

The mixture was then heated to 100oC for 11h. The resulting
suspension was cooled to room temperature and dry toluene

(ca 10mL) added. The slurry was suction filtered to give yellow solids (270.0mg). The
solids were recrystallized from 1% MeOH in DCM, and diethyl ether, to give the
quinolizinium bromide 11 (170.6mg, 62%) as yellow crystals; m.p. 223-225oC.

1

H

NMR (300MHz, CDCl3): δ 3.27 (t, J = 5.4 Hz, 2H, H-5), 4.02 (s, 3H, OCH3), 4.38 (s,
3H, OCH3), 4.68 (s, 2H, CH2Ph), 5.20-5.35 (m, 2H, H-6), 6.00 (s, 2H, OCH2O), 6.95 (s,
1H, H-14), 6.88 (s, 1H, H-4), 7.11 (br.d, J = 7.2 Hz, 2H, ArH), 7.26-7.42 (m, 3H, ArH),
7.62 (d, J = 9.6 Hz, 1H, H-12)a, 7.71 (d, J = 9.6 Hz, 1H, H-11)a, 10.61 (s, 1H, H8).

13

C

NMR (75MHz, CDCl3 + CD3OD): δ 28.3 (C5), 36.4 (CH2Ph), 56.7 (OCH3), 56.8 (C6),
62.6 (OCH3), 101.9 (OCH2O), 108.4 (C4)b, 108.6 (C14)b, 119.7 (C4a), 120.9 (C12)c,
121.5 (C8a), 125.6 (C11)c, 127.0 (ArCH), 127.6 (2C, ArCH), 129.2 (2C, ArCH), 130.3
(C13b), 133.3 (C13)d, 133.5 (C12a)d, 137.4 (C13a), 137.9 (ArC), 145.5 (C9)e, 145.6
(C8), 147.0 (C14a), 149.8 (C3a), 150.1 (C10)e. HRMS(ES): m/z calcd for C27H24NO4
[M]+: 426.1705; found: 426.1715. Anal.Calcd. for C27H24NO4Br: C, 64.04; H, 4.78; N,
2.77. Found: C, 63.65; H, 5.02; N, 2.55
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7.4 Synthesis of natural bacterial pump blocking agents
(Chapter 3)
7.4.1 Preparation of 5,7-Deoxyhydnocarpin-D (12)144
To a mixture of 3´,4´-dihydroflavone (160.6mg, 0.63mmol) and coniferyl alcohol
(98.5mg, 0.55mmol) were added dry benzene (12.5mL) and dry acetone (6.25mL) under
a nitrogen atmosphere. The mixture was warmed up to 60oC with stirring for 10min,
and then silver carbonate (70.0mg, 0.25mmol) was added to the reaction mixture and
further stirred vigorously for 10h. The mixture was then allowed to cool to room
temperature, filtered through celite, and washed with 5% MeOH in DCM. The filtrate
was evaporated to give an orange-yellow oil. The oil was then chromatographed on
silica gel (DCM with a gradient elution to MeOH) to give a major fraction (57.2mg,
eluent: 2% MeOH in DCM). Further purification of this major fraction was achieved by
multiple development PLC on silica gel (1% MeOH in DCM) to give 12 (29.0mg, 12%)
as an opaque white solid, 13 (2.0mg, 1%) as an opaque white solid, and 14 (3.2mg, 1%)
as an opaque white solid.
5´
8
7

1
9

6´

5

10

4

O

3

12: 1H NMR (300MHz, CDCl3): δ 3.58 (dd, J = 12.8,

11

OH

12
13

O
2´

6

O

2´´

O

6´´
5´´

OCH3

3.5 Hz, 1H, H-11), 3.85 (dd, J = 12.6, 2.4 Hz, 1H, H-

OH

11), 3.92 (s, 3H, OCH3), 4.08-4.14 (m, 1H, H-12), 5.00

12

(d, J = 8.4 Hz, 1H, H-13), 5.83 (br.s, 1H, OH), 6.72 (s, 1H, H-3), 6.95 (d, J = 7.8 Hz,
2H, H-5´´, H-6´´), 6.96 (s, 1H, H-2´´), 7.06 (d, J = 8.7 Hz, 1H, H-5´), 7.39 (ddd, J = 8.1,
7.2, 0.9 Hz, 1H, H-7), 7.46 (dd, J = 8.4, 2.1 Hz, 1H, H-8), 7.49 (d, J = 9.0 Hz, 1H, H6´), 7.58 (d, J = 2.1 Hz, 1H, H-2´), 7.66 (ddd, J = 8.4, 7.2, 1.5 Hz, 1H, H-6), 8.20 (dd, J
= 8.1, 1.2 Hz, 1H, H-5).

13

C NMR (75MHz, CDCl3): δ 55.9 (OCH3), 60.9 (C11), 76.3

(C13), 78.8 (C12), 105.9 (C3), 109.9 (C2´´), 114.9 (C2´), 115.3 (C5´´), 117.5 (C5´),
147

117.8 (C5), 120.0 (C6´), 120.5 (C6´´), 123.4 (C1´), 124.4 (C10), 125.2 (C8), 125.3 (C7),
127.1 (C1´´), 133.8 (C6), 144.0 (C3´), 146.5 (C4´´), 146.0 (C3´´), 147.2 (C4´), 155.9
(C9), 163.5 (C2), 178.8 (C4). HRMS (CI); m/z calcd for C25H21O7 [MH]+: 433.1287;
found: 433.1278.

O

O

O

12

O

13

13: 1H NMR (300MHz, CDCl3): δ 3.55-3.63 (m, 1H, H-

OCH3

11), 3.71-3.79 (m, 1H, H-11), 3.90 (s, 3H, OCH3), 4.574.63 (m, 1H, H-13 of 13a or H-12 of 13b), 5.27 (d, J =

OH

13a

O

OH

O

12

O

13

3.0 Hz, 1H, H-12 of 13a or H-13 of 13b), 5.67 (s, 1H,

OH
OCH3

13b

OH), 6.74 (s, 1H, H-3), 6.89 (d, J = 6.9 Hz, 1H, H-5´´),

OH

O

6.91 (s, 1H, H-2´´), 6.95 (d, J = 8.7 Hz, 1H, H-6´´), 7.12

(d, J = 8.4 Hz, 1H, H-5´), 7.40 (br.t, J = 8.1 Hz, 1H, H-7), 7.51 (dd, J = 8.4, 2.1 Hz, 1H,
H-8), 7.53 (dd, J = 7.8 Hz, 1H, H-6´), 7.59 (d, J = 2.1 Hz, 1H, H-2´), 7.68 (ddd, J = 8.4,
7.2, 1.8 Hz, 1H, H-6), 8.21 (dd, J = 8.1, 1.5 Hz, 1H, H-5). HRMS (CI); m/z calcd for
C25H21O7 [MH]+: 433.1287; found: 433.1281.

14: 1H NMR (300MHz, CDCl3): δ 3.52-3.62 (m, 1H, HOH
O
O

OCH3

O
OH

O

14

11), 3.85 (br.d, J = 13.2 Hz, 1H, H-11), 3.92 (s, 3H,
OCH3), 4.07-4.10 (m, 1H, H-13), 5.03 (d, J = 8.4 Hz,
1H, H-12), 5.72 (s, 1H, OH), 6.74 (s, 1H, H-3), 6.94 (d,

J = 12.3 Hz, 2H, H-5´´, H-6´´), 6.97 (s, 1H, H-2´´), 7.08 (d, J = 8.7 Hz, 1H, H-5´), 7.40
(br.t, J = 7.7 Hz, 1H, H-7), 7.49 (dd, J = 8.3, 2.6 Hz, 1H, H-8), 7.52 (d, J = 8.1 Hz, 1H,
H-6´), 7.58 (d, J = 2.1 Hz, 1H, H-2), 7.68 (td, J = 7.8, 1.8 Hz, 1H, H-6), 8.22 (br.d, J =
7.5 Hz, 1H, H-5). HRMS (CI); m/z calcd for C25H21O7 [MH]+: 433.1287; found:
433.1284.
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7.4.2 Acetylation of 5,7-Deoxyhydnocarpin-D144
To a solution of 5,7-deoxyhydnocarpin-D (12)
OCOCH3

(9.4mg, 0.02mmol) in dry pyridine (0.1mL) was

O
O

OCH3

O

15

O

added excess acetic anhydride (0.9mL) and the

OCOCH3

mixture stirred at room temperature for 12h. The

mixture was evaporated and then chromatographed on silica gel by PLC (DCM) to give
the diacetate product 15 (10.0mg, 89%) as an opaque white solid, m.p. 166-168oC
(Lit.144 172-174oC). 1H NMR (300MHz, CDCl3): δ 2.06 (s, 3H, COCH3), 2.31 (s, 3H,
COCH3), 3.85 (s, 3H, OCH3), 4.02 (dd, J = 12.3, 4.2 Hz, 1H, H-11), 4.26-4.36 (m, 1H,
H-12), 4.38 (dd, J = 12.2, 3.2 Hz, 1H, H-11), 4.98 (d, J = 7.8 Hz, 1H, H-13), 6.73 (s,
1H, H-3), 6.97 (dd, J = 7.8, 1.5 Hz, 1H, H-6´´), 6.99 (s, 1H, H-2´´), 7.09 (d, J = 8.4 Hz,
2H, H-8, H-5´´), 7.39 (br.t, J = 8.1 Hz, 1H, H-7), 7.48-7.54 (m, 2H, H-5´, H-6´), 7.58 (d,
J = 2.1 Hz, 1H, H-2´), 7.63-7.70 (m, 1H, H-6), 8.20 (dd, J = 7.8, 1.5 Hz, 1H, H-5).

13

C

NMR (75MHz, CDCl3): δ 20.7 (2C, COCH3), 55.0 (OCH3), 62.5 (C11), 75.9 (C12),
76.4 (C13), 106.6 (C3), 110.5 (C2´´), 115.4 (C2´), 117.7 (C5´´), 117.9 (C5´)a, 119.7
(C6´´), 120.3 (C6´)a, 123.3 (C1´), 123.8 (C8), 125.1 (C7), 125.3 (C1´´), 125.6 (C5),
133.6 (C6), 133.9 (C10), 140.6 (C3´)b, 143.6 (C4´´), 145.8 (C4´)b, 151.6 (C3´´), 156.0
(C9), 162.7 (C2), 168.5 (CO), 170.2 (CO), 178.2 (C4). HMRS (EI); m/z calcd for
C29H24O9 [M]+: 516.1420; found; 516.1419.

7.5 Synthesis of synthetic bacterial pump blocking agents
7.5.1 Attempted Fischer indole synthesis
O2N

3´

3
2

Method 1: A mixture of 4-acetylbenzonitrile

2´

CN
NH N

16

(145.0mg,

1.0mmol)

and

4-nitrophenylhydrazine

(153.0mg, 1.0mmol) in glacial acetic acid (1mL) and 1M HCl in diethyl ether (1mL)
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was refluxed at 115oC under a nitrogen atmosphere for 1 h. The solution was poured
into ice (50g), then adjusted to pH 8 with saturated aqueous Na2CO3, and extracted with
DCM (3 x 30mL).

The combined DCM extracts were dried, evaporated, and

chromatographed on silica gel (DCM) to give the hydrazone 16 (181.0mg, 65%) as an
orange solid. 1H NMR (300MHz, CDCl3): δ 3.35 (s, 3H, CH3), 7.40 (d, J = 9.3 Hz, 2H,
H-2), 7.86 (d, J = 8.4 Hz, 2H, H-3´), 8.00 (d, J = 8.7 Hz, 2H, H-2´), 8.15 (d, J = 9.0 Hz,
2H, H-3), 10.43 (s, 1H, NH). EIMS: m/z, [M]+: 280 (50%).
Method 2:

To a solution of 4-acetylbenzonitrile (145.0mg, 1.0mmol) in

isopropanol (10mL) and 1M HCl in diethyl ether (3mL), was added 4nitrophenylhydrazine (153.0mg, 1.0mmol) and refluxed at 80oC for 25min. The
suspension was cooled to room temperature. The precipitate was filtered, washed
thoroughly with water, then hexane, and dried to give the hydrazone 16 (180.1mg,
64%).
Method 3: The hydrazone 16 (100.0mg, 0.36mmol) and 98-100% formic acid
(1mL) were mixed in a microwave vessel which was irradiated at 110oC for 10min. The
mixture was allowed to cool down to room temperature, then poured into water (5mL)
and boiled for 2min to hydrolyze any N-formyl derivative, which might have formed.
The suspension was cooled to room temperature. The precipitate was filtered, washed
thoroughly with water, and dried to give only the hydrazone starting material 16.
Method 4: The hydrazone 16 (1.12g, 4.0mmol) and zinc chloride powder (1.61g,
16mmol) were mixed in a microwave vessel without solvent. The solid mixture was
irradiated at180oC for 1min using CH3CN for temperature probe vessel. The mixture
gave a black solid as carbonaceous residue.
Method 5:

A mixture of the hydrazone 16 (41.6mg, 0.15mmol) and p-

toluenesulfonic acid monohydrate (56.5mg, 0.30mmol) in xylene (3mL) was refluxed at
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140oC for 5h. The mixture was washed with water (5 x 3mL). The xylene layer was
dried and evaporated to give the hydrazone starting material 16.
Method 6: To a solution of polyphosphoric acid (72.4mg) in xylene (3mL) at
80oC, was added the hydrazone 16 (35mg, 0.13mmol) and heated at 110oC for 1 h. The
reaction was worked up in the same manner as in method 5 to give the hydrazone
starting material 16.
Method 7: A mixture of the hydrazone 16 (100.0mg, 0.36mmol), 85% phosphoric
acid (0.6mL) and toluene (2mL) was stirred vigorously at 100oC for 2h. The toluene
layer was decanted and fresh toluene (5mL) was added and further stirred for 4h. The
toluene was decanted again, then combined with the first toluene layer, dried, and
evaporated to give the hydrazone starting material 16.
Method 8: To a suspension of the hydrazone 16 (100.0mg, 0.36mmol) in glacial
acetic acid (3mL), was added a solution of BF3-diethyl etherate and the mixture heated
at reflux 110oC under a nitrogen atmosphere for 1h. The reaction was cooled to room
temperature and poured into iced water (100mL). The suspension was filtered and dried
to give a dark green solid. The solid was dissolved in DCM and filtered. The DCM
filtrate was evaporated to give the hydrazone 16 and two other unidentified components
in small amounts (these components on TLC analysis an silica gel did not give a brown
colouration with iodine vapour).
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7.5.2 N-Acylation reaction
Acid chloride route
7.5.2.1 Preparation of 1-Benzoyl-5-nitro-1H-indole (18)103
To a suspension of sodium hydride (1.55g of 50%

O2N
N

18 O

dispersion in mineral oil, 31.3mmol) in anhydrous DMF (24mL)
at 0oC, was added, with stirring, a solution of 5-nitroindole (17)

(2.90g, 17.9mmol) in DMF (50mL). The mixture was stirred for 30min at 0oC. The
mixture was then warmed to room temperature and stirring continued for 2h. Excess
DMF (180mL) was added and then the mixture was cooled to –60oC in a dry
ice/acetone bath. A solution of benzoyl chloride (3mL, 25.9mmol) in DMF (12mL) was
added dropwise to the cooled mixture, which was allowed to stir overnight with
warming to 70oC. The mixture was evaporated, added to ice water (700mL), and stirred
vigorously for 4h. The precipitate was filtered, washed with cold water, air dried, and
washed with EtOAc (to remove traces of the starting material), yielding 18 (4.22g, 89%)
as an opaque white solid, m.p. 158-159oC. 1H NMR (300MHz, CDCl3): δ 6.77 (dd, J =
3.8, 0.5 Hz, 1H, H-3), 7.50 (d, J = 3.9 Hz, 1H, H-2), 7.54-7.62 (m, 2H, H-3´), 7.63-7.70
(m, 1H, H-4´), 7.72-7.80 (m, 2H, H-2´), 8.26 (dd, J = 9.2, 2.3 Hz, 1H, H-6), 8.47 (dd, J
= 9.0, 0.6 Hz, 1H, H-7), 8.52 (d, J = 2.1 Hz, 1H, H-4). HRMS (EI); m/z calcd for
C15H10N2O3 [M]+: 266.0691; found: 266.0688.

7.5.2.2 Preparation of 1-(4-Methoxybenzoyl)-5-nitro-1H-indole (19)
To a solution of 17 (2.01g, 12.4mmol) in dry THF (250mL) at –60oC in a dry
ice/acetone bath was added dropwise of 2M n-BuLi solution in cyclohexane (6.20mL,
14.8mmol) and stirred for 30 min. 4-Methoxybenzoyl chloride (2.0mL, 14.8mmol) was
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added to the reaction mixture which was further stirred for 3h. The mixture was then
quenched with saturated N aH C 0 3 solution (2mL), dried and evaporated to dryness. The
residue was chromatographed on silica gel (40% DCM in PS) to afford 19 (1.62g,
44.2%) as a pale yellow solid, m.p,199-200°C. ‘H NMR
(300MHz, CDCI3): 5 3.92 (s, 3H, OCH3), 6.76 (d, J = 3.8
Hz, 1H, H-3), 7.05 (d, J =

8 .8

Hz, 2H, H-3'), 7.55 (d, J =

3.8 Hz, 1H, H-2), 7.77 (dd, .7=7.0, 1.8 Hz, 2H, H-2'), 8.25 (dd, J = 9.1, 2.1 Hz, 1H, H6 ),

8.41 (d, J = 9.1 Hz, 1H, H-7), 8.54 (d, J = 2.1 Hz, 1H, H-4). 13C NMR (75MHz,

CDCI3): 5 55.6 (OCH3), 108.3 (C3), 114.2 (2C, C3'), 116.2 (C7), 117.2 (C4), 119.9

(C 6 ), 125.1 (C l'), 130.4 (C3a), 130.6 (C2), 132.0 (2C, C2'), 129.1 (C7a), 114.1 (C5),
163.4 (C4'), 167.9 (CO). HRMS (El); m/z calcd for Q 6 H 12N 2O 4 [M]+: 296.0797; found:
296.0796.

7.5.2.3 Preparation of l-(4-B enzyloxybenzoyl)-5-nitro-l//-indole (22)
Preparation o f acid chloride: To a suspension of /?-hydroxybenzoic
9 CH2ph

acid (3.0g, 22.8mmol) and dry K2C 0 3 (7.0g, 50.0mmol) in dry DMF
(60mL), was added dropwise of benzyl bromide (5.4mL, 45.8mmol) under a

COOCH2Ph

20

nitrogen atmosphere. The reaction mixture was heated at reflux at 80 C for

6h. The mixture was evaporated, added to ice water (500mL), and acidified with 5M
HC1 to pH l. The suspension was filtered, washed several times with H 2O, then dried
and chromatographed on silica gel by VLC (60% DCM in PS) to give benzyl 4(benzyloxy) benzoate (20, 5.62g, 81%) as an off-white solid, m.p. 93-95°C. 'H NMR
(300MHz, CDCI3): 5 5.09 (s, 2H, OCH2), 5.33 (s, 2H, COOCH2), 6.97 (d, J = 8.7 Hz,
2H, H-3), 7.32-7.44 (m, 10H, ArH), 8.03 (d, J= 9.0 Hz, 2H, H-2).
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The suspension of 20 (5.0g, 15.7mmol) in MeOH (50mL) was added 30%
aqueous solution of KOH (10mL) and heated at reflux for 6h.

The solvent was

evaporated, added to ice water (300mL), and acidified to pH1. The white precipitate
was filtered and washed thoroughly with water and 20% DCM in PS (100mL) to
remove unreacted dibenzylated starting material. The precipitate was crystallized from
OCH2Ph

diethyl ether to give 4-benzyloxybenzoic acid (21,106 3.25g, 91%) as white
needles, m.p. 185-187oC (Lit.145 187-190oC).

COOH

21

1

H NMR (300MHz, CDCl3 +

CD3OD): δ 5.13 (s, 2H, OCH2), 7.00 (d, J = 9.0 Hz, 2H, H-3), 7.34-7.46 (m,

5H, ArH), 8.01 (d, J = 9.0 Hz, 2H, H-2).

13

C NMR (75MHz, CDCl3): δ 69.7 (OCH2),

114.1 (2C, ArCH), 122.6 (ArC), 127.1 (2C, ArCH), 127.8 (ArCH), 128.3 (2C, C-3),
131.5 (2C, C-2), 135.9 (C-1), 162.3 (C-4), 168.5 (CO).
The suspension of 21 (1.0g, 4.7mmol) in a 1:1 mixed solvent of THF/Benzene
(10mL) was added dropwise of oxalyl chloride (1.28mL, 6.9mmol) at room temperature
and stirred for 30h. The reaction mixture was monitored by alumina (2% MeOH in
DCM). The mixture was then concentrated to give crude of 4-(benzyloxy)benzoyl
chloride, which was used in the next step immediately without purification because it
was air sensitive.
Preparation of acylated product: To a solution of 5-

O2N

nitroindole (0.3g, 2.0mmol) in dry THF (40mL) at –60oC in

N
O

O

22

a dry ice/acetone bath was added dropwise 2M n-BuLi

solution in cyclohexane (1.0mL, 2.0mmol) and the mixture then stirred for 30min. The
crude 4-(benzyloxy)benzoyl chloride (0.5g, 2.2mmol) was added to the reaction mixture
and further stirred for 4.5h. The mixture was then quenched with saturated NaHCO3
solution (2mL), dried and evaporated to dryness. The residue was chromatographed on
silica gel by VLC (60% DCM in PS) to afford 22 (0.2g, 30%) as off-white needles, m.p.
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177-179oC. 1H NMR (300MHz, CDCl3): δ 5.19 (s, 2H, OCH2), 6.77 (dd, J = 3.8, 0.8
Hz, 1H, H-3), 7.12 (d, J = 9.0Hz, 2H, H-3´), 7.36-7.48 (m, 5H, ArH), 7.55 (d, J = 3.6
Hz, 1H, H-2), 7.77 (d, J = 8.7 Hz, 2H, H-2´), 8.25 (dd, J = 9.3, 2.1 Hz, 1H, H-6), 8.41
(d, J = 9.0 Hz, 1H, H-7), 8.54 (d, J = 2.1 Hz, 1H, H-4).

13

C NMR (75MHz, CDCl3): δ

70.3 (OCH2), 108.3 (C3), 115.0 (2C, C3´), 116.2 (C7), 117.2 (C4), 119.6 (C6), 125.4
(C1´), 127.5 (2C, C3´´), 128.4 (2C, C4´´), 128.8 (C2´´), 130.4 (C3a), 130.5 (C2), 132.1
(2C, C2´), 135.8 (C1´´), 139.1 (C7a), 144.2 (C5), 162.5 (C4´), 167.9 (CO). HMRS (EI);
m/z calcd for C22H16N2O4 [M]+: 372.1110; found; 372.1105.

7.5.2.4 Preparation of 5-Nitro-1-phenylethanoyl-1H-indole (23)
To a suspension of sodium hydride (63.0mg of a 50%
O2N

dispersion in mineral oil, 1.3mmol) in anhydrous DMF (1mL) at
N
O

0oC, was added, with stirring, a solution of 17 (93.0mg,
23

0.57mmol) in DMF (3mL). The mixture was stirred for 30min at 0oC. The mixture was
then warmed to room temperature and further stirred for 2h. Excess DMF (7mL) was
added and then the mixture was cooled to –60oC in a dry ice/acetone bath. A solution of
phenyl acetyl chloride (0.1mL, 0.75mmol) in DMF (0.4mL) was added dropwise to the
cooled mixture and then allowed to stir overnight with warming to 70oC. The mixture
was evaporated, then added to ice water (50mL), and stirred vigorously for 4h. The
precipitate was filtered, washed with cold water and air-dried. The crude product was
chromatographed on silica gel by VLC (4% EtOAc in PS) to give 23 (31.3mg, 19%) as
an off white solid, m.p. 96-98oC. 1H NMR (300MHz, CDCl3): δ 4.29 (s, 2H, CH2CO),
6.76 (dd, J = 3.8, 0.8 Hz, 1H, H-3), 7.29-7.42 (m, 5H, ArH), 7.68 (d, J = 3.9 Hz, 1H, H2), 8.24 (dd, J = 9.2, 2.3 Hz, 1H, H-6), 8.46 (d, J = 2.4 Hz, 1H, H-4), 8.60 (dt, J = 9.3,
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0.6 Hz, 1H, H-7).

13

C NMR (75MHz, CDCl3): δ 43.0 (CH2), 109.8 (C3), 116.9 (C7),

117.0 (C4), 120.5 (C6), 127.6 (C2), 127.8 (ArCH), 129.1 (4C, ArCH), 130.2 (C3a),
132.5 (ArC), 138.8 (C7a), 144.4 (C5), 169.4 (CO).

HMRS (EI); m/z calcd for

C16H12N2O3 [M]+: 280.0848; found: 280.0835.

Preparation of N-Acyl Indoles
7.5.2.5 Preparation of 1-Benzoyl-1H-indole (24)
To a solution of 1H-indole (23.4mg, 0.2mmol), DMAP
(24.4mg, 0.2mmol) and benzoic acid (48.8mg, 0.4mmol) in dry

N
O

DCM (2mL) at 0oC under a nitrogen atmosphere, was added a

24

solution of DCC (82.5mg, 0.4mmol) in DCM (1mL). The solution was then warmed to
room temperature and stirred for 15h. The resulting suspension was evaporated and
chromatographed on silica gel by PLC (5% EtOAc in PS) (multiple development) to
give 24 (14.0mg, 32%) as an off-white solid, m.p. 63-64°C (Lit.96 59-60°C and 6768oC94). 1H NMR (300MHz, CDCl3): δ 6.57 (dd, J = 3.9, 0.6 Hz, 1H, H-3), 7.25 (d, J =
3.9 Hz, 1H, H-2), 7.27-7.40 (m, 2H, H-5, H-6), 7.44-7.50 (m, 2H, H-3´), 7.52-7.60 (m,
2H, H-4´, H-4), 7.68-7.73 (m, 2H, H-2´), 8.40 (dd, J = 8.4, 0.9 Hz, 1H, H-7). HRMS
(EI): m/z calcd for C15H11NO [M]+: 221.0841; found: 221.0843.

7.5.2.6 Preparation of 1-(4-Methoxybenzoyl)-1H-indole (25)
To a solution of 1H-indole (23.4mg, 0.2mmol), DMAP
(24.4mg, 0.2mmol) and p-methoxybenzoic acid (60.9mg,

N
O

OCH3

25

0.4mmol) in dry DCM (2mL) at 0oC under a nitrogen

atmosphere, was added a solution of DCC (82.5mg, 0.4mmol) in DCM (1mL). The
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solution was then warmed to room temperature and stirred for 15 h. The resulting
suspension was evaporated and chromatographed on silica gel (5% EtOAc in PS) to
give the acylated product 25 (23.0mg, 46%) as an off-white solid, m.p. 138-139°C
(Lit.96 137-139°C).

1

H NMR (300MHz, CDCl3): δ 3.82 (s, 3H, OCH3), 6.53 (dd, J =

3.8, 0.8 Hz, 1H, H-3), 6.91-6.99 (m, 2H, H-3´), 7.18-7.32 (m, 3H, H-2, H-4, H-6), 7.517.54 (m, 1H, H-5), 7.64-7.69 (m, 2H, H-2´), 8.26 (dd, J = 8.3, 1.1 Hz, 1H, H-7). HRMS
(EI): m/z calcd for C16H13NO2 [M]+: 251.0946; found: 251.0947.

7.5.2.7 Preparation of 1-(2-Methoxybenzoyl)-1H-indole (26)
To a solution of 1H-indole (23.4mg, 0.2mmol), DMAP
N

(24.4mg, 0.2mmol) and o-methoxybenzoic acid (60.9mg, 0.4mmol)

O
H3CO

26

in dry DCM (2mL) at 0oC under a nitrogen atmosphere, was added a

solution of DCC (82.5mg, 0.4mmol) in DCM (1mL). The solution was then warmed to
room temperature and stirred for 72h. The resulting suspension was evaporated and
chromatographed on silica gel (5% EtOAc in PS) to give the acylated product 26
(17.1mg, 34%) as an off-white solid, m.p. 137-139°C. 1H NMR (300MHz, CDCl3): δ
3.79 (s, 3H, OCH3), 6.55 (dd, J = 3.8, 0.9 Hz, 1H, H-3), 7.03 (d, J = 8.5 Hz, 1H, H-3´),
7.07 (d, J = 3.3 Hz, 1H, H-2), 7.09 (td, J = 7.3, 0.9 Hz, 1H, H-5´), 7.33 (td, J = 7.6, 1.5
Hz, 1H, H-5), 7.37 (td, J = 7.3, 1.5 Hz, 1H, H-6), 7.45 (dd, J = 7.6, 1.8 Hz, 1H, H-6´),
7.51 (ddd, J = 8.5, 7.3, 1.8 Hz, 1H, H-4´), 7.57 (ddd, J = 7.6, 1.5, 0.6 Hz, 1H, H-4), 8.44
(bd, J = 8.2 Hz, 1H, H-7).

13

C NMR (75MHz, CDCl3): δ 55.7 (OCH3), 108.6 (C3),

111.4 (C3´), 116.5 (C7), 120.7 (C5´)a, 120.8 (C4)a, 123.9 (C5), 124.8 (C1´), 124.9 (C6),
127.4 (C2), 129.0 (C6´), 131.0 (C3a), 132.1 (C4´), 135.6 (C7a), 156.3 (C2´), 167.2
(CO). HRMS (EI): m/z calcd for C16H13NO2 [M]+: 251.0946; found: 251.0955.
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7.5.2.8 Preparation of 1-Benzoyl-5-methoxy-1H-indole (27)
To

H3CO

a

solution

of

5-methoxy-1H-indole

(29.4mg,

0.2mmol), DMAP (24.4mg, 0.2mmol) and benzoic acid

N

(48.8mg, 0.4mmol) in dry DCM (2mL) at 0oC under a nitrogen

O

27

atmosphere, was added a solution of DCC (82.5mg, 0.4mmol) in DCM (1mL). The
solution was then warmed to room temperature and stirred for 15h. The resulting
suspension was evaporated and chromatographed on silica gel (5% EtOAc in PS) to
give the acylated product 27 (14.0mg, 32%) as an off-white solid, m.p. 106-107°C
(Lit.96 109-111°C).

1

H NMR (300MHz, CDCl3): δ 3.88 (s, 3H, OCH3), 6.54 (dd, J =

3.8, 0.8 Hz, 1H, H-3), 7.00 (dd, J = 9.2, 2.6 Hz, 1H, H-6), 7.06 (d, J = 2.4 Hz, 1H, H-4),
7.26 (d, J = 2.1 Hz, 1H, H-2), 7.48-7.62 (m, 3H, H-3´, H-4´), 7.70-7.75 (m, 2H, H-2´),
8.31 (d, J = 8.7 Hz, 1H, H-7). HRMS (EI): m/z calcd for C16H13NO2 [M]+: 251.0946;
found: 251.0950.

7.5.2.9 Preparation of 5-Methoxy-1-(4-methoxybenzoyl)-1H-indole (28)
To a solution of 5-methoxy-1H-indole (29.4mg,

H3CO

0.2mmol),

N
O

28

OCH3

DMAP

(24.4mg,

0.2mmol)

and

p-

methoxybenzoic acid (60.9mg, 0.4mmol) in dry DCM

(2mL) at 0oC under a nitrogen atmosphere, was added a solution of DCC (82.5mg,
0.4mmol) in DCM (1mL). The solution was then warmed to room temperature and
stirred for 15h. The resulting suspension was evaporated and chromatographed on silica
gel (5% EtOAc in PS) to give 28 (7.7mg, 15%) as an off-white solid, m.p. 105-106°C.
1

H NMR (300MHz, CDCl3): δ 3.81 (s, 3H, OCH3), 3.83 (s, 3H, OCH3), 6.47 (dd, J =

3.8, 0.6 Hz, 1H, H-3), 6.89 – 7.00 (m, 4H, H-4, H-6, H-3´), 7.26 (d, J = 3.8, 1H, H-2),
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7.66 (tt, J = 9.7, 2.7 Hz, 2H, H-2´), 8.18 (d, J = 9.1 Hz, 1H, H-7). 13C-NMR (75MHz,
CDCl3): δ 55.5 (OCH3), 55.7 (OCH3), 103.4 (C6), 108.0 (C3), 113.3 (C4), 113.8 (2C,
C3´), 117.0 (C7), 126.6 (C1´), 128.4 (C2), 130.8 (C3a), 131.6 (2C, C2´), 131.6 (C7a),
156.5 (C5), 162.6 (C4´), 167.9 (CO). HRMS (EI): m/z calcd for C17H15NO3 [M]+:
281.1052; found: 281.1053.

7.5.2.10 Preparation of 1-Benzoyl-5-fluoro-1H-indole (29)
To a solution of 5-fluoro-1H-indole (27.0mg, 0.2mmol),
F

DMAP (24.4mg, 0.2mmol) and benzoic acid (48.8mg, 0.4mmol) in
N
O

29

dry DCM (2mL) at 0oC under a nitrogen atmosphere, was added a
solution of DCC (82.5mg, 0.4mmol) in DCM (1mL). The solution

was then warmed to room temperature and stirred for 24h. The resulting suspension
was evaporated and chromatographed on silica gel (5% EtOAc in PS) to give 29
(42.7mg, 89%) as an opaque white solid, m.p. 65-66°C. 1H NMR (300MHz, CDCl3): δ
6.50 (d, J = 3.8 Hz, 1H, H-3), 7.03 (td, J = 9.1, 2.3 Hz, 1H, H-6), 7.18 (dd, J = 8.8, 2.6
Hz, 1H, H-4), 7.25 (d, J = 3.8 Hz, 1H, H-2), 7.46 (tt, J = 8.5, 1.5 Hz, 2H, H-3´), 7.54 (tt,
1H, J = 6.2, 1.2 Hz, 1H, H-4´), 7.65 (dd, J = 8.8, 1.8 Hz, 2H, H-2´), 8.31 (dd, J = 9.1,
5.3 Hz, 1H, H-7). 13C NMR (75MHz, CDCl3): δ 106.4 (d, J = 23.9 Hz, C4), 108.2 (d, J
= 4.0 Hz, C3), 112.7 (d, J = 24.8 Hz, C6), 117.4 (d, J = 9.2 Hz, C7), 128.6 (2C, C3´),
129.1 (C2), 129.1 (2C, C2´), 131.7 (d, J = 10.1 Hz, C3a), 132.0 (C4´), 132.4 (C1´),
134.2 (C7a), 159.8 (d, J = 240.4 Hz, C5), 168.5 (CO). HRMS (EI): m/z calcd for
C15H10NOF [M]+: 239.0746; found: 239.0738.
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7.5.2.11 Preparation of 5-Fluoro-1-(4-methoxybenzoyl)- 1H-indole (30)
To
F

a

0.2mmol),

solution
DMAP

of

5-fluoro-1H-indole

(24.4mg,

0.2mmol)

(27.0mg,
and

p-

N
O

OCH3

30

methoxybenzoic acid (60.9mg, 0.4mmol) in dry DCM (2mL)
at 0oC under a nitrogen atmosphere, was added a solution of

DCC (82.5mg, 0.4mmol) in DCM (1mL). The solution was then warmed to room
temperature and stirred for 24h.

The resulting suspension was evaporated and

chromatographed on silica gel (5% EtOAc in PS) to give 30 (47.0mg, 87%) as an
opaque white solid, m.p. 133-135°C.

1

H NMR (300MHz, CDCl3): δ 3.91 (s, 3H,

OCH3), 6.57 (d, J = 3.8, 0.9 Hz, 1H, H-3), 7.02 (dt, J = 9.4, 2.6 Hz, 2H, H-3´), 7.09 (td,
J = 9.1, 2.6 Hz, 1H, H-6), 7.25 (dd, J = 8.5, 2.3 Hz, 1H, H-4), 7.40 (d, J = 3.8 Hz, 1H,
H-2), 7.74 (dt, J = 9.7, 2.9 Hz, 2H, H-2´), 8.32 (ddd, J = 9.3, 4.8, 0.6 Hz, 1H, H-7).

13

C

NMR (75MHz, CDCl3): δ 55.5 (OCH3), 106.3 (d, J = 23.9 Hz, C4), 107.7 (d, J = 3.7
Hz, C3), 112.5 (d, J = 25.0 Hz, C6), 113.9 (2C, C3´), 117.2 (d, J = 9.2 Hz, C7), 126.2
(C1´), 129.2 (C2), 131.5 (C3a), 131.7 (2C, C2´), 132.5 (C7a), 159.7 (d, J = 239.9 Hz,
C5), 162.8 (C4´), 168.0 (CO). HRMS (EI): m/z calcd for C16H12NO2F [M]+: 269.0852;
found: 269.0854

7.5.2.12 Preparation of 5-Fluoro-1-(2-methoxybenzoyl)- 1H-indole (31)
To a solution of 5-fluoro-1H-indole (27.0mg, 0.2mmol),
F

DMAP (24.4mg, 0.2mmol) and p-methoxybenzoic acid (60.9mg,
N

0.4mmol) in dry DCM (2mL) at 0oC under a nitrogen atmosphere,

O
H3CO

31

was added a solution of DCC (82.5mg, 0.4mmol) in DCM (1mL).

The solution was then warmed to room temperature and stirred for 3h. The resulting
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suspension was evaporated and chromatographed on silica gel (5% EtOAc in PS) to
give 31 (45.7mg, 85%) as a pale yellow solid, m.p. 100-101°C.

1

H NMR (300MHz,

CDCl3): δ 3.79 (s, 3H, OCH3), 6.50 (d, J = 3.8 Hz, 1H, H-3), 7.01 – 7.12 (m, 4H, H-3´,
H-5´, H-2, H-6), 7.22 (dd, J = 8.2, 2.1 Hz, 1H, H-4) 7.44 (dd, J = 7.3, 2.3 Hz, 1H, H-6´),
7.51 (td, J = 8.5, 1.8 Hz, 1H, H-4´), 8.44 (bdd, J = 8.8, 4.7 Hz, 1H, H-7). 13C NMR
(75MHz, CDCl3): δ 55.6 (OCH3), 106.3 (d, J = 23.9 Hz, C4), 108.2 (d, J = 4.0 Hz, C3),
111.4 (C3´), 112.4 (d, J = 24.8 Hz, C6), 117.5 (d, J = 9.2 Hz, C7), 120.8 (C5´), 124.4
(C1´), 128.9 (C6´)a, 129.1 (C2)a, 131.9 (C3a)b, 132.0 (C7a)b, 132.3 (C4´), 156.3 (C2´),
159.8 (d, J = 240.1 Hz, C5), 167.0 (CO). HRMS (EI): m/z calcd for C16H12NO2F [M]+:
269.0852; found: 269.0854.

7.5.2.13 Preparation of 1-Benzoyl-5-nitro-1H-indole (18)
To a solution of 5-nitro-1H-indole (17) (32.4mg, 0.2mmol), DMAP (24.4mg,
0.2mmol) and benzoic acid (48.8mg, 0.4mmol) in dry DCM (2mL) at 0oC under a
nitrogen atmosphere, was added a solution of DCC (82.5mg, 0.4mmol) in DCM (1mL).
The solution was then warmed to room temperature and stirred for 6h. The resulting
suspension was dried and to the crude residue was added MeOH (20mL).

The

suspension was filtered and the precipitate then washed with cold MeOH and dried to
give 18 (40.4mg) as an opaque white solid.

The filtrate was concentrated and

recrystallized from MeOH to yield further 18 (8.0mg) for a total yield of pure product of
48.4 mg (92%). All spectroscopic data for 18 was the same as that noted for this
compound previously (Section 6.5.2.1).
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7.5.2.14 Preparation of 1-(4-Methoxybenzoyl)-5-nitro-1H-indole (19)
To a solution of 17 (32.4mg, 0.2mmol), DMAP (24.4mg, 0.2mmol) and pmethoxy benzoic acid (60.9mg, 0.4mmol) in dry DCM (2mL) at 0oC under a nitrogen
atmosphere, was added a solution of DCC (82.5mg, 0.4mmol) in DCM (1mL). The
solution was then warmed to room temperature and stirred for 4h.

The resulting

suspension was dried and to the crude residue was added MeOH (20mL). The
suspension was filtered and the precipitate then washed with cold MeOH and dried to
give 19 (45.7mg) as a pale yellow solid.

The filtrate was concentrated and

recrystallized from MeOH to yield further 19 (10.4mg) for a total yield of pure product
of 56.1mg (95%), m.p. 199-200oC. All spectroscopic data for 19 was the same as that
noted for this compound previously (Section 6.5.2.2).

7.5.2.15 Preparation of 1-(2-Methoxybenzoyl)-5-nitro-1H-indole (32)
To a solution of 17 (32.4mg, 0.2mmol), DMAP (24.4mg,

O2N
N
O

32

H3CO

0.2mmol) and o-methoxybenzoic acid (60.9mg, 0.4mmol) in dry
DCM (2mL) at 0oC under a nitrogen atmosphere, which was

added a solution of DCC (82.5mg, 0.4mmol) in DCM (1mL). The solution was then
warmed to room temperature and stirred for 3h. The resulting suspension was dried in
vacuo and to the crude residue was added MeOH (20mL). The suspension was filtered
and the precipitate then washed with MeOH and dried to give 32 (38.1mg) as a slight
yellow solid. The filtrate was concentrated and recrystallized from MeOH to yield
further 32 (9.2mg) for a total yield of pure product of 47.3mg (80%), m.p. 144-145oC.
1

H NMR (300MHz, CDCl3): δ 3.71 (s, 3H, OCH3), 6.61 (d, J = 3.5 Hz, 1H, H-3), 6.98

(d, J = 8.5 Hz, 1H, H-3´), 7.05 (t, J = 7.5 Hz, 1H, H-5´), 7.17 (d, J = 3.5 Hz, 1H, H-2),
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7.41 (d, J = 7.3 Hz, 1H, H-6´), 7.49 (t, J = 7.6 Hz, 1H, H-4´), 8.17 (t, J = 9.1 Hz, 1H, H6), 8.41-8.46 (m, 2H, H-4, H-7).

13

C NMR (75MHz, CDCl3): δ 55.7 (OCH3), 108.7

(C3), 111.5 (C3´), 116.5 (C7), 116.9 (C4), 120.1 (C6), 121.0 (C5´), 123.5 (C1´), 129.4
(C6´), 130.3 (C2), 130.9 (C3a), 133.0 (C4´), 138.5 (C7a), 144.3 (C5), 156.4 (C2´),
167.2 (CO). HRMS (EI): m/z calcd for C16H12N2O4 [M]+: 296.0797; found: 296.0804.

7.5.2.16 Preparation of 5-nitro-1-phenylethanoyl-1H-indole (23)
A mixture of 17 (320.6mg, 1.98mmol), phenyl acetic acid (299.0mg, 2.20mmol),
and boric acid (37.3mg, 0.60mmol) in mesitylene (30mL) was heated at reflux for 2
days using a Dean-Stark water separator.

The reaction mixture was evaporated,

triturated with PS, filtered, and washed thoroughly with PS to remove the mesitylene.
The crude solid was chromatographed on silica gel by VLC (10% EtOAc in PS) to give
the starting indole (200.0mg, 1.23mmol), and 23 (9.0mg, 4%).

7.5.2.17 Preparation of 1-(4-benzyloxybenzoyl)-5-nitro-1H-indole (22)
To a solution of 17 (2.35g, 14.5mmol), DMAP (0.23g, 1.89mmol) and pbenzyloxybenzoic acid (21, 4.00g, 18.6mmol) in dry DCM (150mL) at 0oC under a
nitrogen atmosphere, was added a solution of DCC (3.89g, 18.6mmol) in DCM (50mL).
The solution was then refluxed at 40oC for 2 days. The resulting suspension was
filtered and washed with DCM. The filtrate was evaporated and then chromatographed
on silica gel by VLC (40% DCM in hexane) to give the starting indole (510.0mg,
3.15mmol) and 22 (2.80g, 52%).
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7.5.3 Palladium Cyclization reactions
7.5.3.1 Preparation of 2-Nitro-isoindolo[2,1-a]indol-6-one (33)

1

O2N

Method 1: A solution of 18 (200mg, 0.75mmol) and

11
10

3

9

5N 6

4

33

O

palladium (II) acetate (167.8mg, 0.75mmol) in glacial acetic

8
7

acid (20mL) was heated at 110oC under a nitrogen atmosphere

for 11h. The black suspension was filtered through celite and washed with acetone.
The filtrate was then evaporated and added to ice water (200mL). The precipitate was
filtered, dried and chromatographed on silica gel by VLC (40-60% DCM in PS) to give

33 (100.1mg, 50%) as yellow needles, m.p. 268.8oC (decomp.).

1

H NMR (300MHz,

CDCl3): δ 6.79 (d, J = 0.6 Hz, 1H, H-11), 7.43-7.49 (ddd, J = 8.4, 5.9, 2.6 Hz, 1H, H-9)
7.62-7.65 (m, 2H, H-10, H-8), 7.84 (dt, J = 7.5, 0.9 Hz, 1H, H-7), 7.98 (d, J = 8.7 Hz,
1H, H-4), 8.23 (dd, J = 8.7, 2.1 Hz, 1H, H-3), 8.41 (d, J = 2.1 Hz, 1H, H-1). 13C NMR
(125MHz, DMSO-d6): δ 104.2 (C11), 112.6 (C4), 118.8 (C1), 121.8 (C3), 122.8 (C7),
125.6 (C10), 130.2 (C9)a, 132.5 (C10a), 133.8 (C11a), 134.6 (C6a), 135.1 (C8)a, 136.1
(C4a), 141.1 (C10b), 143.9 (C2), 162.0 (C6). HRMS (EI); m/z calcd for C15H8N2O3
[M]+: 264.0535; found: 264.0533.
Method 2: A solution of 18 (103.7mg, 0.38mmol), palladium (II) acetate (8.5mg,
0.038mmol) and copper (II) acetate monohydrate (180mg, 0.99mmol) in glacial acetic
acid (6mL) was heated at 95oC for 5 days. The reaction was worked up as in method 1
to give 33 (30.2mg, 29%). All spectroscopic data were the same as those reported
above.
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7.5.3.2 Preparation of 9-Methoxy-2-nitro-isoindolo[2,1-a]indol-6-one (34)
O2N
OCH3
N

34

O

A solution of 19 (379mg, 1.28mmol) and palladium
(II) acetate (287.3mg, 1.28mmol) in glacial acetic acid
(80mL) was heated at 110oC under a nitrogen atmosphere

for 16h. The black suspension was filtered through celite and washed with acetone.
The filtrate was then evaporated and added to ice water (200mL). The precipitate was
filtered, dried and chromatographed on silica gel by VLC (40–60% DCM in PS) to give

34 (279.4mg, 74%) as yellow needles, m.p. 238-240oC.

1

H NMR (300MHz, CDCl3 +

CD3OD): δ 3.95 (s, 3H, OCH3), 6.77 (s, 1H, H-11), 6.91 (dd, J = 8.7, 2.1 Hz, 1H, H-8),
7.11 (d, J = 2.7 Hz, 1H, H-10), 7.74 (d, J = 8.4 Hz, 1H, H-7), 7.95 (d, J = 8.7 Hz, 1H,
H-4), 8.20 (dd, J = 8.7, 2.1 Hz, 1H, H-3), 8.40 (d, J = 2.1 Hz, 1H, H-1).

13

C NMR

(75MHz, CDCl3+CD3OD): δ 55.8 (OCH3), 103.0 (C11), 107.7 (C10), 112.6 (C4), 115.1
(C8), 118.3 (C1), 121.7 (C3), 125.0 (C10a), 127.5 (C7), 134.1 (C11a), 136.3 (C4a),
136.5 (C6a), 140.8 (C10b), 144.0 (C2), 162.3 (CO), 165.1 (C9). HRMS (EI); m/z calcd
for C16H10N2O4 [M]+: 294.0641; found: 294.0648.

7.5.3.3 Preparation of 9-Benzyloxy-2-nitro-isoindolo[2,1-a]indol-6-one (35)
A solution of 22 (189.7mg, 0.51mmol) and palladium (II) acetate (120.7mg,
0.54mmol) in glacial acetic acid (34mL) was heated at 110oC under a nitrogen
atmosphere for 20h. The black suspension was filtered through celite and then washed
with acetone. The filtrate was then evaporated and added to ice water (100mL). The
precipitate was filtered, dried and then chromatographed on silica gel by VLC (PS with
gradient elution to DCM and then MeOH) to give 35 (35.0mg, 20%, eluent: 40-60%
DCM in PS) as pale yellow needles, and the more polar fraction (eluent: 2% MeOH in
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DCM) which gave two colors (gray and brown) in the same spot on TLC after exposure
to iodine vapor. This fraction was added to 2% MeOH in DCM and then filtered to
afford 9-hydroxy-2-nitro-isoindolo[2,1-a]indol-6-one (36) (32.3mg, 22%) as a pale
yellow solid, and the filtrate was evaporated to give 1-(4-hydroxybenzoyl)-5-nitro-1Hindole (37) (50.1mg, 35%) as a pale yellow solid.

35: m.p. >250oC,

O2N
O
N
O

1

H NMR (300MHz, CDCl3 +

CD3OD): δ 5.21 (s, 2H, OCH2), 6.79 (s, 1H, H-11),
7.01 (dd, J = 8.7, 2.1 Hz, 1H, H-8), 7.22 (d, J = 2.1

35

Hz, 1H, H-10), 7.43-7.50 (m, 5H, ArH), 7.76 (d, J = 8.7 Hz, 1H, H-7), 7.97 (d, J = 8.7
Hz, 1H, H-6), 8.22 (dd, J = 8.7, 2.4 Hz, 1H, H-3), 8.42 (d, J = 2.1 Hz, 1H, H-1).

13

C

NMR (75MHz, CDCl3 + CD3OD or DMSO-d6) spectrum showed only methine and
methylene carbon signals without quaternary carbon signals due to precipitating whilst
the experiment was underway. HRMS (EI); m/z calcd for C22H14N2O4 [M]+: 370.0954;
found: 370.0944.

36: m.p. 199-201oC, 1H NMR (300MHz, DMSO-d6): δ 6.82
O2N
OH

(dd, J = 8.6, 2.3 Hz, 1H, H-8), 7.07 (s, 1H, H-11), 7.16 (d, J

N

= 2.1 Hz, 1H, H-10), 7.60 (d, J = 8.7 Hz, 1H, H-7), 7.81 (d, J

O

36

= 9.0 Hz, 1H, H-4), 8.13 (dd, J = 8.7, 2.4 Hz, 1H, H-3), 8.45 (d, J = 1.8 Hz, 1H, H-1).
13

C NMR (75MHz, DMSO-d6): δ 103.6 (C11), 109.6 (C10), 112.1 (C4), 116.7 (C8),

118.6 (C1), 121.5 (C3), 122.7 (C10), 127.6 (C7), 134.1 (C11a), 135.9 (C4a), 136.2
(C6a)a, 140.6 (C10b)a, 143.4 (C2), 161.6 (CO), 163.9 (C9). HRMS (EI); m/z calcd for
C15H8N2O4 [M]+: 280.0484; found: 280.0480.
O2N

37: m.p. 201-203oC, 1H NMR (300MHz, DMSO-d6): δ 6.92

N
O

OH

(d, J = 3.3 Hz, 1H, H-3), 6.91-6.93 (m, 2H, aromatic), 7.64-

37

7.67 (m, 2H, ArH), 7.73 (d, J = 3.3 Hz, 1H, H-2), 8.17 (dd, J
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= 9.3, 2.4 Hz, 1H, H-6), 8.27 (d, J = 9.0 Hz, 1H, H-7), 8.60 (d, J = 1.8 Hz, 1H, H-4),
10.53 (br s, 1H, OH).

13

C NMR (75 MHz, DMSO-d6): δ 108.1 (C3), 115.6 (2C,

ArCH), 115.8 (C7), 117.3 (C1´), 119.3 (C6), 123.0 (C4), 130.3 (C2), 131.7 (C3a), 132.5
(2C, ArCH), 138.6 (C7a), 143.4 (C5), 162.0 (C4´), 167.6 (CO). HRMS (EI); m/z calcd
for C15H10N2O4 [M]+: 282.0641; found: 282.0638.

7.5.3.4 Conversion of 36 to 35:
To a suspension of 36 (200.0mg, 0.71mmol) and cesium carbonate (230.0mg,
0.70mmol) in dry DMF (20mL), was added dropwise with stirring of benzyl bromide
(0.1mL, 0.84mmol). The reaction was heated at 80oC under a nitrogen atmosphere for
7h. The reaction was allowed to cool to room temperature and then filtered. The
precipitate was washed thoroughly with water and dried to give 35 as a pale yellow
solid (196.1mg, 74%).

7.5.4 Ring opening reactions
7.5.4.1 Preparation of 2-(5-Nitro-1H-indol-2-yl)benzoic acid (38)
4

O2 N
6

7

COOH

3

N
H

2'

2

1'

5'

3'

38

A solution of t-BuOH (192mL) and H2O (19.2mL)

6'

containing t-BuOK (4.25 g, 37.9mmol) was added to 33 (1g,

4'

3.79mmol) and heated at 82oC for 12h.

The mixture was

evaporated and added to ice water (400mL). The solution was acidified to pH1 with 5M
HCl. The solution was stirred vigorously with solid NaCl for 2h, and then extracted
with diethyl ether (3 x 400mL). The combined diethyl ether extracts were dried and
evaporated to give 38 (1.016g, 95%) as a pale yellow solid, m.p. 250-252oC. 1H NMR
(300MHz, DMSO-d6): δ 6.98 (s, 1H, H-3), 7.33-7.45 (m, 2H, H-4´, H-5´), 7.52 (d, J =
167

9.0 Hz, 1H, H-7), 7.67 (br.d, J = 7.2 Hz, 1H, H-3´), 7.75 (br.d, J = 7.5 Hz, 1H, H-6´),
7.94 (dd, J = 9.03, 2.4 Hz, 1H, H-6), 8.52 (d, J = 2.4, 1H, H-4).

13

C NMR (75MHz,

DMSO-d6): δ 102.2 (C3), 117.8 (C7), 116.3 (C6), 116.8 (C4), 127.5 (C3a), 127.8 (C5´),
128.5 (C2), 128.7 (C4´), 128.9 (C6´), 129.9 (C3´), 138.5 (C2´), 139.3 (C7a), 140.5 (C5),
142.2 (C1´), 171.7 (CO). HRMS (EI); m/z calcd for C15H10N2O4 [M]+: 282.0641;
found: 282.0643.

7.5.4.2 Preparation of 4-Methoxy-2-(5-nitro-1H-indol-2-yl)benzoic acid (39)
COOH

O 2N

containing t-BuOK (1.98g, 17.7mmol) was added to 34

N
H

39

A solution of t-BuOH (88.5mL) and H2O (8.9mL)

OCH3

(520.0mg, 1.77mmol) and heated at 82oC for 12h. The reaction

mixture was evaporated and added to ice water (200mL). The solution was acidified to
pH1 with 5M HCl. The solution was stirred vigorously with solid NaCl for 2h, and then
extracted with diethyl ether (3 x 200mL). The combined diethyl ether extracts were
dried and evaporated to give 39 (520.0g, 94%) as a pale yellow solid, m.p. 206-208oC.
1

H NMR (300MHz, DMSO-d6): δ 3.86 (s, 3H, OCH3), 6.78 (dd, J = 2.1, 0.6 Hz, 1H, H-

3), 7.08 (dd, J = 7.8, 2.7 Hz, 1H, H-5´), 7.11 (s, 1H, H-3´), 7.50 (d, J = 8.7 Hz, 1H, H7), 7.89 (d, J = 7.8 Hz, 1H, H-6´), 8.00 (dd, J = 9.0, 2.4 Hz, 1H, H-6), 8.55 (d, J = 2.4
Hz, 1H, H-4), 12.07 (s, 1H, NH).

13

C NMR (75MHz, DMSO-d6): δ 55.7 (OCH3), 103.3

(C3), 111.5 (C7), 114.0 (C5´), 116.4 (C3´), 116.7 (C6), 117.1 (C4), 123.8 (C2), 127.4
(C3a), 132.3 (C6´), 134.1 (C1´)a, 139.6 (C7a), 140.7 (C5), 141.5 (C2´)a, 161.3 (C4´),
167.9 (CO). HRMS (EI); m/z calcd for C16H12N2O5 [M]+: 312.0746; found: 312.0749.
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7.5.4.3 Preparation of 4-Benzyloxy-2-(5-nitro-1H-indol-2-yl)-benzoic acid
(40)
A solution of t-BuOH (22.5mL) and H2O (2.3mL)

COOH

O2 N

containing t-BuOK (503.5mg, 4.49mmol) was added to 35

N
H

40

O

(166.0mg, 0.45mmol) and heated at 82oC for 12h. The

reaction mixture was evaporated and added to ice water (70mL). The solution was
acidified to pH1 with 5M HCl. The solution was stirred vigorously with solid NaCl for
2h, and then extracted with diethyl ether (3 x 50mL). The combined diethyl ether
extracts were dried and evaporated to give 40 (167.0mg, 96%) as a pale yellow solid,
m.p. 233-235oC. 1H NMR (300MHz, DMSO-d6): δ 5.24 (s, 2H, OCH2), 6.78 (s, 1H, H3), 7.16 (dd, J = 8.6, 2.6 Hz, 1H, H-5´), 7.24 (d, J = 2.7 Hz, 1H, H-3´), 7.30-7.50 (m,
5H, ArH), 7.52 (d, J = 9.0 Hz, 1H, H-7), 7.85 (d, J = 8.7, 1H, H-6´), 8.00 (dd, J = 8.9,
2.3 Hz, 1H, H-6), 8.55 (d, J = 2.4 Hz, 1H, H-4), 12.20 (s, 1H, NH), 12.57 (s, 1H,
COOH).

13

C NMR (75MHz, DMSO-d6): δ 69.6 (OCH2), 103.2 (C3), 111.5 (C7), 114.6

(C5´), 116.6 (C6), 117.0 (C3´), 117.1 (C4), 124.1 (C2), 127.3 (C3a), 127.7 (2C, ArCH),
128.0 (ArCH), 128.4 (2C, ArCH), 132.1 (C6´), 133.8 (C2´), 136.4 (ArC), 139.6 (C7a),
140.6 (C5), 141.1 (C1´), 160.2 (C5´), 167.9 (CO).

HRMS (EI); m/z calcd for

C22H16N2O5 [M]+: 388.1059; found: 388.1069.

7.5.5 Reduction reactions
7.5.5.1 Preparation of [2-(5-Nitro-1H-indol-2-yl)-phenyl]-methanol (41)
CH2OH

O2N

To a solution of 38 (997.0mg, 3.54mmol) in dry THF
(90mL) was slowly added 1M BH3-THF complex solution

N
H

41

(7.1mL, 7.1mmol) at 0oC under a nitrogen atmosphere. After
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vigorous stirring at room temperature for 2h, the excess hydride was carefully destroyed
by adding a solution of 50% THF in H2O (20mL) until the gas bubbling ceased. The
aqueous layer was saturated with anhydrous K2CO3. The THF layer was separated and
the aquoeus layer was extracted with diethyl ether. The combined THF and diethyl
ether extracts were dried, then evaporated, and chromatographed on silica gel by VLC
(2% MeOH in DCM) to give 41 (940.5mg, 99%) as bright yellow needles, m.p.132134oC. 1H NMR (300MHz, CDCl3): δ 4.77 (s, 2H, CH2O), 6.91 (d, J = 1.2 Hz, 1H, H3), 7.36-7.47 (m, 4H, H-7, ArH), 7.79 (br.d, J = 7.8 Hz, 1H, ArH), 8.12 (dd, J = 8.9, 2.4
Hz, 1H, H-6), 8.61 (d, J = 2.4 Hz, 1H, H-4 ), 10.92 (s, 1H, NH).

13

C NMR (75MHz,

CDCl3): δ 65.1 (CH2), 103.5 (C3), 111.2 (C7), 117.5 (C6), 117.6 (C4), 127.8 (C3a),
128.8 (ArCH), 129.4 (ArCH), 130.3 (ArCH), 131.1 (ArCH), 132.8 (C2), 135.8 (C2´),
139.6 (C7a), 141.4 (C1´), 141.8 (C5). HRMS (EI); m/z calcd for C15H12N2O3 [M]+:
268.0848; found: 268.0838.

7.5.5.2 Preparation of [4-Methoxy-2-(5-nitro-1H-indol-2-yl)-phenyl]methanol (42)
To a solution of 39 (520.0mg, 1.67mmol) in dry THF
CH2OH

O2N
N
H

42

(50mL) was slowly added 1M BH3-THF complex solution
(3.3mL, 3.3mmol) at 0oC under a nitrogen atmosphere. After

OCH3

vigorous stirring at room temperature for 2h, the excess hydride

was carefully destroyed by adding a solution of 50% THF in H2O (10mL) until the gas
bubbling ceased. The aqueous layer was saturated with anhydrous K2CO3. The THF
layer was separated and the aquoeus layer was extracted with diethyl ether.

The

combined THF and diethyl ether extracts were dried, then evaporated, and
170

chromatographed on silica gel by VLC (2% MeOH in DCM) to give 42 (470.7mg,
95%) as bright yellow needles, m.p. 206-208oC. 1H NMR (300MHz, CDCl3): δ 3.89 (s,
3H, OCH3), 4.70 (s, 2H, CH2), 6.91 (d, J = 1.8 Hz, 1H, H-3), 6.92 (dd, J = 8.4, 2.7 Hz,
1H, H-5´), 7.30 (d, J = 2.7 Hz, 1H, H-3´), 7.34 (d, J = 8.7 Hz, 1H, H-6´), 7.46 (d, J = 8.7
Hz, 1H, H-7), 8.10 (dd, J = 8.7, 2.1 Hz, 1H, H-6), 8.62 (d, J = 2.1 Hz, 1H, H-4), 11.02
(s, 1H, NH).

13

C NMR (75MHz, CDCl3): δ 55.5 (OCH3), 64.6 (CH2O), 103.5 (C3),

111.3 (C7), 113.9 (C5´), 115.7 (C3´), 117.6 (C6), 117.7 (C4), 127.7 (C3a), 128.3 (C2),
132.6 (C6´), 134.2 (C1´)a, 139.6 (C2´)a, 141.4 (C7a), 141.8 (C5), 160.1 (C4´). HRMS
(EI); m/z calcd for C16H14N2O4 [M]+: 298.0954; found: 298.0941.

7.5.5.3 Preparation of [4-Benzyloxy-2-(5-nitro-1H-2-yl)-phenyl]-methanol
(43)
CH2OH

O2 N
N
H

43

To a solution of 40 (200.0mg, 0.52mmol) in dry
THF (15mL) was slowly added 1M BH3-THF complex

O

solution (1.0mL, 1.0mmol) at 0oC under a nitrogen

atmosphere. After vigorous stirring at room temperature for 2h, the excess hydride was
carefully destroyed by adding a solution of 50% THF in H2O (2mL) until the gas
bubbling ceased. The aqueous layer was saturated with anhydrous K2CO3. The THF
layer was separated and the aquoeus layer was extracted with diethyl ether.

The

combined THF and diethyl ether extracts were dried, then evaporated, and
chromatographed on silica gel by VLC (2% MeOH in DCM) to give 43 (163.5mg,
85%) as bright yellow needles, m.p. 70-72oC.

1

H NMR (300MHz, CDCl3): δ 4.63 (s,

2H, CH2OH), 5.08 (s, 2H, OCH2), 6.80 (dd, J = 2.0, 0.8 Hz, 1H, H-3), 6.90 (dd, J = 8.4,
2.7 Hz, 1H, H-5´), 7.23-7.42 (m, 8H, H-7, H-3´, H-6´, ArH), 8.03 (dd, J = 9.0, 2.1 Hz,
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1H, H-6), 8.54 (d, J = 2.4 Hz, 1H, H-4), 10.92 (s, 1H, NH).

13

C NMR (75MHz,

CDCl3): δ 64.6 (CH2OH), 70.2 (OCH2), 103.5 (C3), 111.3 (C7), 114.7 (C5´), 116.7
(C6´), 117.6 (C6), 117.7 (C4), 112.4 (2C, ArCH), 127.7 (C2), 128.2 (ArCH), 128.5
(C3a), 128.7 (2C, ArCH), 132.6 (C3´), 134.2 (ArC), 136.4 (C2´), 139.6 (C7a), 141.3
(C5), 141.9 (C1´), 159.3 (C4´). HRMS (EI); m/z calcd for C22H18N2O4 [M]+: 374.1267;
found: 374.1256.

7.5.6 Amination reactions
7.5.6.1 Preparation of 2-(2-Azidomethyl-phenyl)-5-nitro-1H-indole (44)
CH2N3

O2N
N
H

44

A mixture of 41 (285.0mg, 1.06mmol), sodium azide
(75.5mg, 1.16mmol) and

triphenyl phosphine (546.0mg,

2.08mmol) in a solution of 25% CCl4 in DMF (10mL) was

heated at 90oC under a nitrogen atmosphere for 5h. The reaction mixture was then
cooled to room temperature, quenched by adding H2O (10mL), and stirred for 10min.
The mixture was diluted with diethyl ether (40mL) and washed thoroughly with H2O.
The organic layer was dried, then concentrated, and chromatographed on silica gel by
VLC (30% DCM in PS) to give 44 (231.0mg, 74%) as bright yellow needles, m.p. 146148oC.

1

H NMR (300MHz, CDCl3): δ 4.40 (s, 2H, CH2N3), 6,86 (dd, J = 2.1 Hz, 0.6

Hz, 1H, H-3), 7.44-7.54 (m, 4H, H-7, ArH), 7.69 (dd, J = 6.2, 1.7 Hz, 1H, ArH), 8.13
(dd, J = 9, 2.1 Hz, 1H, H-6), 8.61 (d, J = 2.1 Hz, 1H, H-4), 9.53 (s, 1H, NH).

13

C NMR

(75MHz, CDCl3,): δ 54.0 (CH2N3), 104.7 (C3), 111.1 (C7), 117.8 (C6), 117.9 (C4),
127.8 (C3a), 129.2 (ArCH), 129.5 (ArCH), 130.7 (ArCH), 131.2 (ArCH), 132.1 (C2),
132.3 (C1´), 139.4 (C7a), 140.0 (C2´), 142.1 (C5).

HRMS (CI); m/z calcd for

C15H12N5O2 [MH]+: 294.0991; found: 294.0987.
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7.5.6.2 Preparation of 2-(5-Nitro-1H-indol-2-yl)-benzylamine (45)
Method 1: To a mixture of 44 (260.0mg, 0.89mmol) and sodium borohydride
(25.0mg, 0.66mmol) in dry THF (10mL) heated at reflux, was slowly added MeOH
(1.0mL) and the mixture stirred for 2h.

Further sodium borohydride (25.0mg,

0.66mmol) was then added and stirring continued for 3 days. The mixture was cooled
to room temperature and then 1M HCl (3mL) was added until the gas bubbling ceased.
The mixture was basified to pH11 with a saturated NaOH solution and then extracted
with DCM (3 x 20mL). The combined DCM extracts were dried, concentrated and then
chromatographed on silica gel by VLC (PS by gradient elution to DCM, then MeOH
and TEA) to give starting material 44 (70.2mg, 0.24mmol; eluent: 30% DCM in PS), 2nitro-6H-isoindolo[2,1-a]indole 46 (30.1mg, 14%; eluent: 40% DCM in PS) as a
yellow solid, and the benzylamine 45 (70.6 mg, 30%; eluent: 30:1:2 DCM/MeOH/TEA)
as a brown solid.
CH2NH2

O 2N
2'

45: m.p. 127-129oC, 1H NMR (300MHz, CDCl3): δ 3.99 (s,

1'

2H, CH2), 6.87 (br.s, 1H, H-3), 7.26-7.46 (m, 4H, H-7, ArH),

N
H

45

7.78 (d, J = 7.5 Hz, 1H, ArH), 8.08 (dd, J = 8.7, 2.4 Hz, 1H, H-

6), 8.61 (d, J = 2.1 Hz, 1H, H-4), 13.63 (s, 1H, NH).

13

C NMR (75MHz, CDCl3): δ 46.0

(CH2), 102.5 (C3), 111.2 (C7), 117.1 (C6), 117.6 (C4), 127.9 (C3a), 128.5 (ArCH),
128.7 (ArCH), 130.3 (ArCH), 131.4 (ArCH), 133.1 (C2), 136.4 (C2´), 139.6 (C7a),
141.4 (C5), 142.7 (C1´). HRMS (EI); m/z calcd for C15H13N3O2 [M]+: 267.1008; found:
267.0995.
1

O2N

46: m.p. 234-236oC, 1H NMR (300MHz, CDCl3): δ 5.12 (s, 2H,

11
10

3

9

N
4

8

46

6

H-6), 6.75 (s, 1H, H-11), 7.33 (d, J = 9.0 Hz, 1H, H-4), 7.38-

7

7.51 (m, 3H, ArH), 7.74 (d, J = 7.2 Hz, 1H, ArH), 8.09 (dd, J =

9.0, 2.1 Hz, 1H, H-3), 8.58 (d, J = 2.1 Hz, 1H, H-1).

13

C NMR (75MHz, CDCl3): δ 48.8
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(C6), 93.6 (C11), 108.8 (C4), 117.3 (C3), 118.7 (C1), 121.6 (ArCH) 123.7 (ArCH),
128.3 (ArCH), 128.6 (ArCH), 132.0 (C10b), 136.6 (C11a), 141.3 (2C, C6a, C10a),
141.6 (C2), 147.1 (C4a). HRMS (EI); m/z calcd for C15H10N2O2 [M]+: 250.0742; found:
250.0732.
Method 2: To a solution of 44 (99.6mg, 0.34mmol), TEA (0.09mL, 0.68mmol),
and 2 drops of 1,3-propanedithiol (ca. 0.1mL, 1.0mmol) in 35% MeOH in i-PrOH
(12mL), was added sodium borohydride (128.6mg, 3.4mmol) at 0oC. After 2h, more
sodium borohydride (64mg, 1.7mmol) was added and the mixture stirred for a further
10min to complete the reaction. The reaction mixture was evaporated, then added to
H2O (50mL) and extracted with 40% Et2O in PS (2 x 40mL). The aqueous layer was
basified to pH11 with a saturated NaOH solution and extracted with DCM (3 x 50mL).
The combined DCM extract was dried, concentrated and then chromatographed on
silica gel by VLC (4% MeOH in DCM) to give the amine 45 (81.6mg, 90%) as a brown
yellow solid after washing with 40% diethyl ether in PS to remove traces of 1,3propanedithiol.

7.5.6.3 Preparation

of

2-(2-Azidomethyl-5-methoxyphenyl)-5-nitro-1H-

indole (47)
CH2N3

O 2N
1'

2'

N
H

A mixture of 42 (298.0mg, 1.0mmol), sodium azide
(65.0mg,

1.0mmol)

and

triphenylphosphine

(524.6mg,

5'

47

OCH3

2.0mmol) in a solution of 25% CCl4 in DMF (9mL) was heated

to 90oC under a nitrogen atmosphere for 5h. The reaction mixture was cooled to room
temperature, quenched by adding H2O (10mL), and stirred for 10min. The mixture was
diluted with diethyl ether (40mL) and washed thoroughly with H2O. The organic layer
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was dried, concentrated, and chromatographed on silica gel by VLC (40% DCM in PS)
to give 47 (198.0mg, 61%) as bright yellow needles, m.p. 138-140oC.

1

H NMR

(300MHz, CDCl3): δ 3.79 (s, 3H, OCH3), 4.26 (s, 2H, CH2), 6.78 (dd, J = 2.1, 0.9 Hz,
1H, H-3), 6.89 (dd, J = 8.7, 2.7 Hz, 1H, H-4´), 7.12 (d, J = 2.7 Hz, 1H, H-6´), 7.29 (d, J
= 8.7 Hz, 1H, H-3´), 7.37 (d, J = 8.4 Hz, 1H, H-7), 8.03 (dd J = 9.0, 2.1 Hz, 1H, H-6),
8.52 (d, J = 2.1 Hz, 1H, H-4), 9.77 (s, 1H, NH).

13

C NMR (75MHz, CDCl3): δ 53.6

(CH2), 55.5 (OCH3), 104.6 (C3), 111.2 (C7), 114.2 (C5´), 116.1 (C6´), 117.7 (C4),
117.9 (C6), 124.6 (C2), 127.7 (C3a), 132.6 (C3´), 133.5 (C1´)a, 139.5 (C7a), 140.0
(C2´)a, 142.3 (C5), 160.1 (C5´). HRMS (EI); m/z calcd for C16H13N5O3 [M]+: 323.1018;
found: 323.1024.

7.5.6.4 Preparation of 4-Methoxy-2-(5-nitro-1H-indol-2-yl)-benzylamine
(48)
To a solution of 47 (109.0mg, 0.34mmol), TEA (0.09mL,
CH2NH2

O2N
2'

1'

N
H

48

0.68mmol), and 2 drops of 1,3-propanedithiol (ca. 0.1mL,
1.0mmol) in i-PrOH (9mL) and MeOH (3mL), was added

4'

OCH3

sodium borohydride (128.6mg, 3.4mmol) at 0oC. After 2h,

more sodium borohydride (64mg, 1.7mmol) was added and stirring continued for
10min. The reaction mixture was evaporated, then added to H2O (50mL) and extracted
with 40% diethyl ether in PS (2 x 40mL). The aqueous layer was basified to pH11 with
a saturated NaOH solution and extracted with DCM (3 x 50mL). The combined DCM
extracts were dried, concentrated and then chromatographed on silica gel by VLC (4%
MeOH in DCM) to give 48 (91.0mg, 91%) as a yellow solid after washing with 40%
diethyl ether in PS to remove traces of 1,3-propanedithiol, m.p. 170-178oC.

1

H NMR
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(300MHz, CDCl3): δ 3.86 (s, 3H, OCH3), 3.91 (s, 2H, CH2), 6.84 (br.s, 1H, H-3), 6.86
(dd, J = 7.9, 2.6 Hz, 1H, H-5´), 7.23 (d, J = 8.1 Hz, 1H, H-6´), 7.28 (s, 1H, H-6´), 7.40
(d, J = 9.3 Hz, 1H, H-7), 8.06 (dd, J = 9.3, 2.4 Hz, 1H, H-6), 8.59 (d, J = 2.1 Hz, 1H, H4), 13.66 (s, 1H, NH).

13

C NMR (75MHz, DMSO-d6): δ 42.5 (CH2), 55.3 (OCH3),

103.4 (C3), 111.9 (C7), 114.1 (C5´), 114.6 (C3´), 116.7 (C6), 117.0 (C4), 127.6 (C3a),
129.0 (C2), 131.8 (C6´), 132.9 (C1´)a, 139.6 (C2´)a, 140.7 (C5), 141.4 (C7a), 158.6
(C4´). HRMS (EI); m/z calcd for C16H15N3O3 [M]+: 297.1113; found: 297.1101.

7.5.7 N-Alkylation reactions

7.5.7.1 Preparation of 2-Bromo-N-[2-(5-nitro-1H-indol-2-yl)benzyl]acetamide (49)
CH2NHCOCH2Br

O2N
N
H

49

To a solution of 45 (70.6mg, 0.26mmol) and TEA
(0.17mL, 1.2mmol) in dry DCM (4mL), was added
bromoacetyl chloride (0.1mL, 1.2mmol) at 0oC under a

nitrogen atmosphere, and stirred for 15min. The reaction mixture was then added to
H2O (20mL) and extracted with DCM (3 x 20mL). The combined DCM extracts were
dried, concentrated and then chromatographed on silica gel (60% DCM in PS) to give

49 (63.8mg, 62%) as a yellow solid, m.p.181-183oC.

1

H NMR (300MHz, CDCl3): δ

3.85 (s, 2H, CH2Br), 4.45 (d, J = 6.6 Hz, 2H, CH2N), 6.65 (d, J = 1.5 Hz, 1H, H-3),
7.28-7.50 (m, 6H, H-7, NHCO, ArH), 8.02 (dd, J = 8.9, 2.3 Hz, 1H, H-6), 8.51 (d, J =
2.4 Hz, 1H, H-4), 11.36 (s, 1H, NH-indole).

13

C NMR (75MHz, CDCl3): δ 28.7

(CH2Br), 42.3 (CH2N), 104.4 (C3), 111.3 (C7), 117.5 (2C, C-4, C-6), 127.9 (C3a),
128.3 (ArCH), 129.3 (ArCH), 129.5 (ArCH), 131.1 (ArCH), 131.6 (C2), 134.7 (C2´),
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139.7 (C7a), 140.9 (C1´), 141.7 (C5), 167.2 (CO).

HRMS (EI); m/z calcd for

C17H14N3O3Br [M]+: 389.0198; found: 389.0197.

7.5.7.2 Preparation

of

2-Bromo-N-[4-methoxy-2-(5-nitro-1H-indol-2-yl)-

benzyl)-acetamide (50)
To a solution of 48 (80mg, 0.27mmol) and TEA
CH2NHCOCH2Br

O2 N

(0.1mL, 0.27mmol) in dry DCM (8mL), was added
N
H

50

OCH3

bromoacetyl chloride (0.05mL, 0.60mmol) at 0oC under a

nitrogen atmosphere for 15min. The reaction mixture was then added to H2O (10mL)
and extracted with DCM (3 x 10mL). The DCM extracts were dried, concentrated and
then chromatographed on silica gel (50% DCM in PS) to give 50 (72.0mg 64%) as a
yellow solid, m.p.176-179oC. 1H NMR (300MHz, CDCl3): δ 3.84 (s, 3H, OCH3), 3.91
(s, 2H, CH2Br), 4.44 (d, J = 6 Hz, 2H, CH2), 6.72 (dd, J = 2.1, 0.8 Hz, 1H, H-3), 6.96
(dd, J = 8.4, 3.0 Hz, 1H, C-4´), 7.04 (d, J = 2.7 Hz, 1H, C-6´), 7.30 (d, J = 8.4 Hz, 1H,
H-3´), 7.33 (br s, 1H, NHCO), 7.47 (d, J = 9.0 Hz, 1H, H-7), 8.09 (dd, J = 9.0, 2.4 Hz,
1H, H-6), 8.58 (d, J = 2.4 Hz, H-4), 11.52 (s, 1H, NH-indole).

13

C NMR (75MHz,

CDCl3): δ 28.8 (CH2Br), 41.9 (CH2N), 55.5 (OCH3), 104.4 (C3), 111.3 (C7), 115.5
(C6´), 115.6 (C4´), 117.6 (2C, C4, C6), 126.8 (C2), 127.8 (C3a), 131.0 (C3´), 132.9
(C1´)a, 139.7 (C7a), 141.0 (C2´)a, 141.9 (C5), 159.2 (C5´), 167.1 (CO). HMRS (EI);
m/z calcd for C18H16N3O4Br [M+]: 417.0324; found; 417.0332.
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7.5.8 O-Alkylation reactions
7.5.8.1 Preparation of Bromoacetic acid 2-(5-nitro-1H-indol-2-yl)-benzyl
ester (51)
CH2OCOCH2Br

O 2N
N
H

To a solution of 41 (200mg, 0.75mmol), anhydrous
TEA (0.21mL, 1.5mmol) and dry THF (25mL), was

51

slowly added a solution of bromoacetyl chloride (0.13mL, 1.5mmol) in THF (5mL) at
0oC under a nitrogen atmosphere and the mixture then heated at 50oC for 5h. The
reaction mixture was then filtered and concentrated. The resulting residue was added to
water (50mL), extracted with EtOAc (3 x 30mL) and washed with H2O. The combined
EtOAc extracts were dried and chromatographed on silica gel by VLC (20% EtOAc in
PS) to give 51 (160.0mg, 70%) as yellow needles, m.p. 139-141oC. 1H NMR (300MHz,
CDCl3): δ 3.97 (s, 2H, CH2Br), 5.31 (s, 2H, CH2O), 6.83 (d, J = 1.8 Hz, 1H, H-3), 7.447.64 (m, 5H, H-7, ArH), 8.13 (dd, J = 9.0, 1.8 Hz, 1H, H-6), 8.62 (d, J = 1.8 Hz, 1H, H4), 9.63 (s, 1H, NH).

13

C NMR (75MHz, CDCl3): δ 40.9 (CH2Br), 66.4 (CH2O), 104.9

(C3), 111.1 (C7), 117.7 (C6), 117.8 (C4), 127.8 (C3a), 129.1 (ArCH), 129.5 (ArCH),
130.3 (ArCH), 131.2 (ArCH), 132.2 (C2), 132.5 (C2´), 139.6 (C7a), 139.7 (C1´), 142.0
(C5), 167.0 (CO). HRMS (EI); m/z calcd for C17H13N2O4Br [M]+: 338.0059; found:
338.0056.

7.5.8.2 Preparation of Bromoacetic acid 4-methoxy-2-(5-nitro-1H-indol-2yl)phenyl)-benzyl ester (52)
CH2OCOCH2Br

O 2N
N
H

52

To a solution of 42 (220mg, 0.74mmol), anhydrous
TEA (0.1mL, 0.74mmol) and dry DCM (20mL), was

OCH3
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slowly added a solution of bromoacetyl chloride (0.13mL, 1.5mmol) at 0oC under a
nitrogen atmosphere, and the mixture then stirred for 15min. The reaction mixture was
added to water (30mL), then extracted with DCM (3 x 30mL) and washed with H2O.
The combined DCM extracts were dried and chromatographed on silica gel by VLC (PS
by gradient elution to DCM and then MeOH) to give the starting material 42 (31.1mg,
0.1mmol; eluent: 2% MeOH in DCM) and 52 (120.0mg, 39%; eluent: 60% DCM in PS)
as an amorphous solid. 1H NMR (300MHz, CDCl3): δ 3.81 (s, 3H, OCH3), 3.88 (s, 2H,
CH2CO), 5.17(s, 2H, CH2O), 6.76 (dd, J = 2.1, 0.9 Hz, 1H, H-3), 6.91 (dd, J = 8.4, 2.7
Hz, 1H, H-5´), 7.06 (d, J = 2.7 Hz, 1H, H-3´), 7.40 (d, J = 9.3 Hz, 1H, H-7), 7.44 (d, J =
8.4 Hz, 1H, H-6´), 8.06 (dd, J = 9.0, 2.4 Hz, 1H, H-6), 8.54 (d, J = 2.4 Hz, 1H, H-4),
9.59 (s, 1H, NH).

13

C NMR (75MHz, CDCl3): δ 25.9 (CH2Br), 55.5 (OCH3), 66.6

(CH2O), 104.9 (C3), 111.1 (C7), 114.6 (C5´), 115.8 (C6´), 117.8 (C4), 118.0 (C6),
124.2 (C2), 127.8 (C3a), 133.5 (C6´), 134.2 (C1´)a, 139.5 (C7a), 140.0 (C2´)a, 142.2
(C5), 160.3 (C4´), 166.8 (CO).

HRMS (EI); m/z calcd for C18H15N2O5Br [M]+:

420.0144; found: 420.0151.

7.5.9 Bromination reactions
7.5.9.1 Preparation of 2-(2-Bromomethylphenyl)-5-nitro-1H-indole (53)
CH2Br

O 2N

A yellow suspension of 41 (200mg, 0.75mmol),

2'

N
H

53

1'

triphenylphosphine (390mg, 1.5mmol) and carbon tetrabromide
(490mg, 1.5mmol) in dry diethyl ether (60mL) was stirred with

warming at 40oC under a nitrogen atmosphere for 2 days. The reaction mixture was
then filtered and the filtrate concentrated. The residual yellow oil was chromatographed
on silica gel by VLC (20% EtOAc in PS) to give 53 (102.3mg, 41%) as a yellow solid,
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m.p. 164-166oC. 1H NMR (300MHz, CDCl3,): δ 4.64 (s, 2H, CH2Br), 6.93 (d, J = 1.2
Hz, 1H, H-3), 7.43-7.58 (m, 5H, H-7, ArH), 8.16 (dd, J = 9.0, 2.1 Hz, 1H, H-6), 8.64 (d,
J = 2.1 Hz, 1H, H-4), 9.14 (s, 1H, NH).

13

C NMR (75MHz, CDCl3): δ 33.0 (CH2Br),

105.1 (C3), 111.1 (C7), 117.8 (C4), 118.6 (C6), 127.9 (C3a), 129.4 (ArCH), 129.6
(ArCH), 130.5 (ArCH), 131.7 (ArCH), 131.8 (C2), 135.6 (C1´), 139.3 (C7a), 139.6
(C2´), 142.3 (C5). HRMS (EI); m/z calcd for C15H11N2O2Br [M]+: 330.0003; found:
329.9982.

7.5.9.2 Attempted bromination of the benzyl alcohol 42
Method 1: A yellow suspension of 42 (510mg,

BrPPh3

O2 N

1.7mmol), triphenylphosphine (472mg, 1.8mmol) and carbon
N
H

54

tetrabromide (597.0mg, 1.8mmol) in dry diethyl ether (80mL)
OCH3

was stirred at room temperature under a nitrogen atmosphere
for 3 days. The reaction mixture was filtered and then concentrated. The residue was
chromatographed on silica gel by VLC (1% MeOH in DCM) to give [4-methoxy-2-(5nitro-1H-indol-2-yl)-triphenyl-phosphonium bromide (54) (500.0mg, 47%) as an orange
solid. 1H NMR (300MHz, CDCl3,): δ 3.71 (s, 3H, OCH3), 5.17 (d, J = 11.7 Hz, 2H,
CH2), 5.95 (s, 1H, H-3), 6.57 (d, J = 7.8 Hz, 1H, H-5´), 6.78 (d, J = 6.9 Hz, 1H, H-6´),
6.91 (br.s, 1H, H-3´), 7.18-7.97 (m, 15H, ArH), 7.80 (br.d, J = 9.3 Hz, 1H, H-7), 7.93
(br.d, J = 9.0 Hz, 1H, H-6), 8.30 (d, J = 1.5 Hz, 1H, H-4), 12.03 (s, 1H, NH).

13

C NMR

(75MHz, CDCl3,): δ 29.2 (CH2, very weak signal), 55.4 (OCH3), 103.6 (C3), 112.5
(C7), 114.8 (C4´), 116.2 (d, J = 35.4 Hz, 3C, ArC), 116.4 (C2)a, 116.8 (C6´), 116.9
(C4), 117.2 (C6), 117.5 (C1´)a, 127.1 (C3a), 130.0 (d, J = 49.2 Hz, 6C, ArCH), 133.2
(C3´), 133.5 (d, J = 38.7 Hz, 6C, ArCH), 134.9 (3C, ArCH), 139.3 (C2´)a, 140.0 (C7a),
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141.4 (C5), 159.7 (C5´). HRMS (ES): m/z calcd for C34H28N2O3P [M]+: 543.1838;
found: 543.1838.

7.5.9.3 Preparation of 2-(5-Methoxy-2-vinylphenyl)-5-nitro-1H-indole (55)
To a solution of 54 (355.0mg, 0.57mmol) in DCM (20mL)

O2 N
1'

2'

was added 40mg/mL aqueous solution of formaldehyde (2mL,

N
H
5'

55

OCH3

2.66mmol). The reaction mixture was stirred vigorously, 0.1%

aqueous NaOH (23mL, 0.57mmol) was added slowly over 10min at room temperature.
Stirring of the reaction mixture was continued for 40min. The mixture was then washed
sequentially with water (30mL), 1M HCl (30mL), water (30mL), and brine (30mL).
The DCM layer was dried, evaporated and then chromatographed on silica gel (50%
DCM in hexane) to give 55 (5.0mg, 3%) as a yellow solid and 2-(5-methoxy-2-methylphenyl)-5-nitro-1H-indole (56) (82.7mg, 49%) as bright yellow needles.

55: m.p. 151-153oC, 1H NMR (300MHz, CDCl3,): δ 3.87 (s, 3H, OCH3), 5.29 (dd, J =
11.0, 1.4 Hz, 1H, C=CH2), 5.68 (dd, J = 17.3, 1.4 Hz, 1H, C=CH2), 6.69 (dd, J = 2.1,
0.9 Hz, 1H, H-3), 6.88 (dd, J = 17.6, 11.0 Hz, 1H, CH=CH2), 6.98 (dd, J = 8.4, 2.7 Hz,
1H, H-4´), 7.03 (d, J = 2.4 Hz, 1H, H-6´), 7.44 (d, J = 8.7 Hz, 1H, H-7), 7.58 (d, J = 8.4
Hz, 1H, H-3´), 8.13 (dd, J = 9.2, 2.3 Hz, 1H, H-6), 8.61 (d, J = 1.8 Hz, 2H, H-4, NH).
13

C NMR (75MHz, CDCl3,): δ 55.5 (OCH3), 105.2 (C3), 110.8 (C7), 114.2 (C6´), 115.0

(C4´), 115.3 (CH=CH2), 117.7 (C4), 117.9 (C6), 127.9 (C3a), 128.4 (C3´), 129.4 (C2´)a,
131.2 (C2), 134.8 (CH=CH2), 139.1 (C7a), 140.1 (C1´)a, 142.1
CH3

O2 N
N
H

56

(C5), 159.3 (C5´). HRMS (EI); m/z calcd for C17H14N2O3 [M]+:
294.1004; found: 294.0988.

OCH3

56: m.p. 194-196oC, 1H NMR (300MHz, CDCl3 + CD3OD): δ
181

2.43 (s, 3H, CH3), 3.90 (s, 3H, OCH3), 6.75 (d, J = 0.9 Hz, 1H, H-3), 6.89 (dd, J = 8.5,
2.6 Hz, 1H, H-4´), 7.05 (d, J = 2.7 Hz, 1H, H-6´), 7.25 (d, J = 8.4 Hz, 1H, H-3´), 7.44
(d, J = 8.1 Hz, 1H, H-7), 8.10 (dd, J = 9.2, 2.3 Hz, 1H, H-6), 8.59 (d, J = 2.4 Hz, 1H, H13

4).

C NMR (75MHz, CDCl3 + CH3OD): δ 20.0 (CH3), 55.4 (OCH3), 104.3 (C3),

110.7 (C7), 113.8 (C4´), 114.4 (C6´), 117.4 (C6), 117.5 (C4), 127.9 (C3a), 128.3 (C2),
132.1 (C3´), 132.3 (C2´)a, 139.2 (C1´)a, 140.7 (C7a), 141.6 (C5), 157.6 (C5´). HRMS
(CI); m/z calcd for C16H15N2O3 [MH]+: 283.1083; found: 283.1092.

7.5.9.4 Attempted N-protection of the benzyl alcohol 42
Method 1: A mixture of 42 (20.0mg, 0.067mmol), (Boc)2O (14.65mg,
0.067mmol) and DMAP (8.2mg, 0.067mmol) in dry DMF (2mL), was stirred under a
nitrogen atmosphere at room temperature for 24h. The mixture was evaporated and
then diethyl ether (10mL) was added. The ethereal solution was washed with 10% citric
acid, dried and then evaporated. The residue was chromatographed on silica gel by PLC
OCH3
1

O 2N

12

13

10
5

3

7%) as an opaque white solid and the O-Boc product 58

9

N
4

(70% DCM in PS) to give the cyclized product 57 (1.5mg,

6

O

O

57

(11.5mg, 43%) as a yellow solid.

8

7

57: 1H NMR (300MHz, CDCl3): δ 3.83 (s, 3H, OCH3), 4.91

(br.d, J = 9.6 Hz, 2H, OCH2), 6.67 (s, 1H, H-13), 6.86 (d, J = 2.7 Hz, 1H, H-12), 6.97
(dd, J = 8.6, 2.6 Hz, 1H, H-10), 7.43 (d, J = 9.0 Hz, 1H, H-9), 8.23 (dd, J = 9.5, 2.3 Hz,
1H, H-3), 8.40 (d, J = 9.3 Hz, 1H, H-4), 4.48 (d, J = 2.4 Hz, 1H, H-1). MS (CI): m/z
OCOC(CH3)3

O 2N

58: 1H NMR (300MHz, CDCl3): δ 1.52 (s, 9H, CH3),

N
H

58

325 (M+1, 100 %).

OCH3

3.87 (s, 3H, OCH3), 5.11 (s, 2H, OCH2), 6.81 (d, J = 1.5
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Hz, 1H, H-3), 6.97 (dd, J = 8.4, 2.7 Hz, 1H, H-5´), 7.11 (d, J = 2.7 Hz, 1H, H-3´), 7.45
(d, J = 9.0 Hz, 1H, H-7), 7.53 (d, J = 8.7 Hz, 1H, H-6´), 8.13 (dd, J = 8.9, 2.3 Hz, 1H,
H-6), 8.61 (d, J = 2.4 Hz, 1H, H-4), 9.99 (s, 1H, NH).

13

C NMR (75MHz, CDCl3): δ

27.8 (3C, CH3), 55.5 (OCH3), 66.9 (OCH2), 83.2 (OCMe3), 104.6 (C3), 111.1 (C7),
114.6 (C5´), 115.5 (C3´), 117.7 (2C, C4, C6), 124.9 (C1´)a, 127.8 (C3a), 133.3 (C6´),
133.7 (C2), 139.4 (C7a), 140.4 (C2´)a, 142.0 (C5), 153.5 (CO), 160.0 (C4´). MS (CI):
m/z 399 (M+1, 50 %), 299 (50 %), 281 (100 %).
Method 2: To a solution of 42 (30.0mg, 0.1mmol) in dry THF (1mL) at –60oC in a
dry ice/acetone bath under a nitrogen atmosphere, was added dropwise 2M n-BuLi
solution in cyclohexane (0.05mL, 0.1mmol). The cooling bath was removed and the
reaction mixture stirred for 45min while warming to 0oC. The reaction mixture was
then re-cooled to –60oC, and a solution of benzenesulfonyl chloride (20.8mg,
0.15mmol) in dry THF was added (1mL). The mixture was allowed to warm slowly to
room temperature and stirring continued overnight. A 5% NaHCO3 solution (1mL) was
added to the mixture which was then extracted with DCM (3 x 5mL). The combined
OSO2Ph

DCM extracts were washed with 5% NaHCO3, water and

O2N

then brine. The solution was dried, evaporated, and then

N

SO2Ph

59

OCH3

chromatrographed on silica gel by PLC (50% DCM in

hexane) to give the dibenzenesulfonyl indole 59 (4.5mg, 8%) as an opaque white solid.
1

H NMR (300MHz, CDCl3): δ 3.89 (s, 3H, OCH3), 5.33 (s, 2H, OCH2), 6.76 (d, J = 0.6

Hz, 1H, H-3), 6.91 (dd, J = 8.4, 2.1 Hz, 1H, H-6), 6.94-7.01 (m, 1H, ArH), 7.00 (d, J =
8.4 Hz, 1H, H-4´), 7.11 (d, J = 1.8 Hz, 1H, H-6´), 7.12-7.22 (m, 2H, ArH), 7.32-7.42
(m, 3H, H-3´, ArH), 7.52-7.59 (m, 2H, ArH), 7.76 (d, J = 8.7 Hz, 1H, H-7), 7.98 (d, J =
8.7 Hz, 1H, ArH), 8.17-8.25 (m, 2H, ArH), 8.42 (d, J = 1.8 Hz, 1H, H-4). MS (CI): m/z
579 (M+H, 1%), 295 (100%).
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7.6 Alkylation reactions (Chapter 4)
7.6.1 Preparation of 9,10-Dimethoxy-13-[2-(5-nitro-1H-indol-2-yl)benzyloxycarbonyl-methyl]-5,6-dihydrobenzo[g]-1,3benzodioxolo[5,6-a]quinolizinium bromide (60)

4

O

A solution of the dihydroberberine 9 (100.0mg,

5
6

2

N+

O

14

Br OMe

13
6''
5''
4''
3''

1''

12

O

2''

2'

O

60

11

4'

NO2
7'

6'

OMe

dry CH3CN (8mL), was heated at reflux for 48h under a
nitrogen atmosphere.

3'

HN

0.26mmol) and the bromoester 51 (108.8mg, 0.32mmol) in

8

The reaction mixture was then

concentrated by evaporation of the CH3CN. The residue

was chromatographed on silica gel (4% MeOH in DCM), followed by PLC (multiple
development, silica gel, 4% MeOH in DCM) of the main fraction from the column.
Subsequently, the polar fraction was crystallized from 1% MeOH in DCM to give 60
(66.6mg, 35%) as a yellow solid; m.p. 212-214oC.

1

H NMR (300MHz, DMSO-d6): δ

3.03 (br.t, J = 5.1 Hz, 2H, H-5), 4.04 (s, 3H, OCH3), 4.07 (s, 3H, OCH3), 4.48 (s, 2H,
CH2CO), 4.78 (br.s, 2H, H-6), 5.39 (s, 2H, CH2O), 6.14 (s, 2H, OCH2O), 6.74 (s, 1H,
H-3´), 7.07 (s, 1H, H-4)a, 7.13 (s, 1H, H-14)a, 7.42-7.62 (m, 5H, H-7´, ArH), 7.87 (d, J
= 9.3 Hz, 1H, H-11)b, 8.00 (d, J = 8.1 Hz, 1H, H-6´), 8.03 (d, J = 9.3 Hz, 1H, H-12)b,
8.48 (s, 1H, H-4´), 9.91 (s, 1H, H-8), 12.19 (s, 1H, NH).

13

C NMR (75MHz, DMSO-

d6): δ 27.4 (C5), 36.5 (CH2CO), 56.9 (C6), 57.1 (OCH3), 61.2 (OCH3), 65.5 (CH2O),
102.3 (OCH2O), 104.3 (C3´), 108.7 (C4)c, 108.8 (C14)c, 111.9 (C7´), 117.2 (2C, C4´,
C6´), 119.8 (C4a), 121.0 (C8a)d, 121.1 (C11)e, 126.0 (C12a)d, 126.2 (C12)e, 127.6
(C3a´), 129.0 (2C, C4´´, C5´´), 129.8 (C3´´)f, 130.2 (C6´´)f, 131.6 (C2´), 132.8 (C13),
133.2 (C2´´), 134.3 (C13b), 137.2 (C13a), 139.6 (C1´´), 139.9 (C7a´), 141.0 (C5´),
184

144.4 (C9)g, 145.8 (C8), 146.9 (C3a)h, 149.6 (C14a)h, 150.4 (C10)g, 170.3 (CO).
HRMS (ES): m/z calcd for C37H30N3O8 [M]+: 644.2033; found: 644.2034.

7.6.2 Preparation of 9,10-Dimethoxy-13-[4-methoxy-2-(5-nitro-1Hindol-2-yl)-benzyloxycarbonylmethyl]-5,6-dihydrobenzo[g]-1,3benzodioxolo[5,6-a] quinolizinium bromide (61)
O
N+

O

A solution of the dihydroberberine 9 (91.0mg,

Br OMe

O

OMe

O

H3CO
HN

61

CH3CN.

NO2

0.24mmol)

and

the

bromoester

52

(100.0mg,

0.24mmol) in dry CH3CN (14mL) was heated at reflux
for 48h under a nitrogen atmosphere.

The reaction

mixture was then concentrated by evaporation of the

The residue was chromatographed on silica gel (4% MeOH in DCM),

followed by PLC (multiple development, silica gel, 4% MeOH in DCM) of the main
fraction from the column. Subsequently, the polar fraction was crystallized from 1%
MeOH in DCM to give 61 (40.7mg, 22%) as a yellow solid; m.p. 230oC (decomp.). 1H
NMR (500MHz, DMSO-d6): δ 3.03 (t, J = 5.5 Hz, 2H, H-5), 3.84 (s, 3H, OCH3), 4.04
(s, 3H, OCH3), 4.06 (s, 3H, OCH3), 4.47 (s, 2H, CH2CO), 4.78 (s, 2H, H-6), 5.31 (s, 2H,
CH2O), 6.14 (s, 2H, OCH2O), 6.72 (s, 1H, H-3´), 7.05 (dd, J = 5.1, 1.5 Hz, 1H, H-5´´),
7.08 (s, 1H, H-4)a, 7.13 (s, 1H, H-14)a, 7.16 (d, J = 1.5 Hz, 1H, H-3´´), 7.51 (d, J = 9.3
Hz, 1H, H-6´´), 7.54 (d, J = 9.6 Hz, 1H, H-7´), 7.85 (d, J = 5.7 Hz, 1H, H-11)b, 8.01 (dd,
J = 9.3, 1.2 Hz, 1H, H-6´), 8.03 (d, J = 5.7 Hz, 1H, H-12)b, 8.46 (d, J = 1.2 Hz, 1H, H4´), 9.90 (s,1H, H-8), 12.24 (s, 1H, NH).

13

C NMR (125MHz, DMSO-d6): δ 27.3 (C5),

36.5 (CH2CO), 55.6 (OCH3), 56.9 (C6), 57.0 (OCH3), 62.1 (OCH3), 65.4 (CH2O), 102.3
(OCH2O), 104.2 (C3´), 108 6 (C4)c, 108.7 (C14)c, 111.9 (C7´), 114.4 (C5´´), 114.6
(C3´´), 117.1 (2C, C4´, C6´), 119.8 (C4a), 120.9 (2C, C12, C8a)d, 125.0 (C2´), 126.1
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(2C, C11, C12a)d, 127.4 (C3a´), 132.7 (2C, C13, C6´´), 133.2 (C1´´)e, 134.2 (C13b),
137.2 (C13a), 139.4 (C2´´)e, 139.8 (C7a´), 140.9 (C5´), 144.3 (C9)f, 145.7 (C8), 146.8
(C3a)g, 149.5 (C14a)g, 150.3 (C10)f, 159.5 (C4´´), 170.3 (CO). HRMS (ES): m/z calcd
for C38H32N3O9 [M]+: 674.2139; found: 674.2134.

7.6.3 Preparation of 9,10-Dimethoxy-13-{[2-(5-nitro-1H-indol-2-yl)benzylcarbamoyl]-methyl}-5,6-dihydrobenzo[g]-1,3benzodioxolo[5,6-a]quinolizinium bromide (62)
A solution of the dihydroberberine 9 (22.5mg,
O
N+

O

0.06mmol) and the bromoamide 49 (25.0mg, 0.07mmol) in

Br OMe

N
H
HN

62

OMe

O

NO2

dry CH3CN (3mL) was heated at reflux for 48h under a
nitrogen atmosphere.

The reaction mixture was then

concentrated by evaporation of the CH3CN. The residue
was chromatographed on silica gel (4% MeOH in DCM),

followed by PLC (multiple development, silica gel, 4% MeOH in DCM) of the polar
fraction from the column. Subsequently, the polar fraction was crystallized from 1%
MeOH in DCM to give 62 (5.0mg, 12%) as a yellow solid; m.p. 209-211oC. 1H NMR
(500MHz, CD3OD): δ 3.11 (br.t, J = 4.8 Hz, 2H, H-5), 4.03 (s, 3H, OCH3), 4.19 (s, 3H,
OCH3), 4.33 (s, 2H, CH2CO), 4.69 (s, 2H, CH2N), 4.88 (br.s, 2H, H-6), 6.12 (s, 2H,
OCH2O), 6.83 (s, 1H, H-3´), 7.02 (s, 1H, H-4)a, 7.40 (s, 1H, H-14)a, 7.46-7.63 (m, 5H,
H-7´, ArH), 7.82 (d, J = 9.6 Hz, 1H, H-11)b, 7.98 (d, J = 9.6 Hz, 1H, H-12)b, 8.06 (dd, J
= 9, 2.1 Hz, 1H, H-6´), 8.52 (d, J = 2.1 Hz, 1H, H-4´), 9.84 (s, 1H, H-8).

13

C NMR

(125MHz, CD3OD): δ 27.8 (C5), 37.3 (CH2CO), 42.0 (CH2N), 56.2 (OCH3), 57.3 (C6),
61.2 (OCH3), 102.5 (C2), 104.1 (C3´), 108.3 (C4)c, 109.3 (C14)c, 111.0 (C7´), 116.9
(C7´), 117.1 (C4´), 120.0 (C4a), 120.4 (C11)d, 121.7 (C8a)e, 126.2 (C12)d, 127.8
186

(C12a)e, 127.9 (ArCH), 128.1 (C3a´), 128.8 (ArCH), 129.4 (ArCH), 129.8 (ArCH),
131.8 (C2´), 134.1 (2C, C13b, C13), 136.0 (C1´´)f, 138.2 (C13a), 139.2 (C2´´)f, 140.7
(C5´), 141.3 (7a´), 144.9 (C8), 145.1 (C9)g, 147.9 (C3a)h, 150.2 (C14a)h, 150.7 (C10)g,
170.8 (CO). HRMS (ES): m/z calcd for C37H31N4O7 [M]+: 643.2193; found: 643.2184.

7.6.4 Preparation of 9,10-Dimethoxy-13-{[4-methoxy-2-(5-nitro-1Hindol-2-yl)-benzylcarbamoyl]-methyl}-5,6-dihydrobenzo[g]-1,3benzodioxolo[5,6-a]quinolizinium bromide (63)
A solution of the dihydroberberine 9 (58.0mg,
O
N+

O

Br -

0.15mmol) and the bromoamide 50 (70.0mg,
OMe

N
H

O

reflux for 48h under a nitrogen atmosphere. The

H3CO
HN

0.16mmol) in dry CH3CN (3mL) was heated at

OMe

NO2

mixture was then concentrated and the residue

63

triturated with diethyl ether.

The precipitate was

filtered and washed with diethyl ether. The solid was chromatographed on silica gel
(4% MeOH in DCM), and the product was crystallized from 1% MeOH in DCM to give

63 (25.4mg, 22%) as a yellow solid; m.p. >250oC. 1H NMR (300MHz, CD3OD): δ 3.12
(br t, J = 5.7 Hz, 2H, H-5), 3.87 (s, 3H, OCH3), 4.06 (s, 3H, OCH3), 4.19 (s, 3H, OCH3),
4.30 (s, 2H, CH2CO), 4.62 (s, 2H, CH2N), 4.79 (br.t, J = 5.7 Hz, 2H, H-6), 6.12 (s, 2H,
OCH2O), 6.83 (d, J = 0.9 Hz, 1H, H-3´), 7.02 (s, 1H, H-4)a, 7.06 (dd, J = 8.6, 2.9 Hz,
1H, H-5´´), 7.14 (d, J = 2.4 Hz, 1H, H-3´´), 7.4 (s, 1H, H-14)a, 7.48 (d, J = 9.0 Hz, 1H,
H-7´), 7.52 (d, J = 8.4 Hz, 1H, H-6´´), 7.80 (d, J = 9.3 Hz, 1H, H-12)b, 7.94 (d, J = 9.3
Hz, 1H, H-11)b, 8.04 (dd, J = 9.2, 2.3 Hz, 1H, H-6´), 8.49 (d, J = 2.1 Hz, 1H, H-4´),
9.82 (s, 1H, H-8).

13

C NMR (75MHz, CD3OD): δ 29.1 (C5), 38.5 (CH2CO), 42.9

(CH2N), 56.0 (OCH3), 57.5 (OCH3), 58.7 (C6), 62.7 (OCH3), 103.8 (C2), 105.2 (C3´),
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109.4 (C4)c, 110.5 (C14)c, 112.3 (C7´), 115.7 (C5´´), 116.0 (C3´´), 118.2 (C4´), 118.3
(C6´), 121.4 (C12)d, 121.5 (C11)d, 122.8 (C8a)e, 127.4 (C4a), 128.9 (C12a)e, 129.0
(C2´), 129.3 (C3a´), 132.6 (C6´´), 134.2 (C1´´)f, 135.1 (C13), 135.2 (C13b), 139.4
(C13a), 141.2 (C2´´)f, 141.5 (C7a´), 142.9 (C5´), 146.3 (C9)g, 146.4 (C8), 148.9 (C3a)h,
151.7 (C14a)h, 151.8 (C10)g, 160.7 (C4´´), 171.9 (CO). HRMS (ES): m/z calcd for
C38H33N4O8 [M]+: 673.2298; found: 673.2305.

7.6.5 Preparation of 9,10-Dimethoxy-13-[2-(5-nitro-1H-indol-2yl)benzyl]-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6a]quinolizinium bromide (64)
O
O2N

A solution of the dihydroberberine 9 (91.0mg,

Br N+

O

OMe
OMe

N
H

0.24mmol) and the benzyl bromide 53 (102.3mg,
0.30mmol) in dry CH3CN (7mL) was heated at reflux for
24h under a nitrogen atmosphere. The mixture was then

64

concentrated and the residue triturated with diethyl ether. The precipitate was filtered
and washed with diethyl ether. The solid was chromatographed on silica gel (6%
MeOH in DCM) to give 64 (55.0mg, 35%) as a yellow solid; m.p. 206oC (decomp.). 1H
NMR (300MHz, CD3OD): δ 3.03 (t, J = 5.5 Hz, 2H, H-5), 4.01 (s, 3H, OCH3), 4.17 (s,
3H, OCH3), 4.80 (br.s, 2H, H-6), 4.84 (s, 2H, CH2Ph), 5.96 (s, 2H, OCH2O), 6.72 (s,
1H, H3´), 6.86 (s, 1H, H-4)a, 6.90 (s, 1H, H-14)a, 6.96 (d, J = 7.8 Hz, 1H, H-6´´), 7.27
(td, J = 7.7, 1.5 Hz, 1H, H-5´´), 7.37 (br.t, J = 7.5 Hz, 1H, H-4´´), 7.42 (d, J = 9.0 Hz,
1H, H-7´), 7.58 (dd, J = 7.7, 1.1 Hz, 1H, H-3´´), 7.78 (d, J = 9.3 Hz, 1H, H-11)b, 7.88
(dd, J = 9.0, 2.4 Hz, 1H, H-6´), 7.94 (d, J = 9.3 Hz, 1H, H-12)b, 8.34 (d, J = 2.1 Hz, 1H,
H-4´), 9.8 (s, 1H, H-8).

13

C NMR (75MHz, CD3OD): δ 29.1 (C5), 36.4 (CH2Ar), 57.5

(OCH3), 58.8 (C6), 62.7 (OCH3), 103.6 (OCH2O), 105.6 (C3´), 109.3 (C4)c, 109.8
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(C14)c, 112.3 (C7´), 118.2 (C6´), 118.3 (C4´), 121.4 (C4a), 122.5 (C11)d, 122.9 (C8a)e,
127.3 (C12)d, 128.6 (C4´´), 129.2 (C3a´), 130.4 (2C, C6´´, C5´´), 131.8 (C3´´), 132.8
(C12a)e, 133.4 (C2´), 135.0 (C13b), 135.1 (C13), 138.6 (C1´´)f, 139.0 (C13a), 141.2
(C7a´), 141.5 (C2´´)f, 142.9 (C5´), 146.1 (C8), 146.2 (C9)g, 148.6 (C3a)h, 151.4
(C14a)h, 151.7 (C10)g. HRMS (ES): m/z calcd for C35H28N3O6 [M]+: 586.1978; found:
586.1984.

7.6.6 Preparation of 9,10-Dimethoxy-13-[4-methoxy-2-(5-nitro-1Hindol-2-yl)benzyl]-5,6-dihydrobenzo[g]-1,3-benzodioxolo[5,6a]quinolizinium chloride (65)
Method 1: A suspension of 42 (30.0mg, 0.10mmol),

O
O2N

N

O

N
H
OCH3

65

+ Cl -

9

OMe

dihydroberberine

(37.9mg,

0.1mmol),

OMe

triphenylphosphine (52.5mg, 0.20mmol), and carbon
tetrabromide (331.6mg, 1.0mmol) in DMF (1mL) was
heated at 90oC for 20h under a nitrogen atmosphere. The

mixture was then evaporated and the residue chromatographed on silica gel (6% MeOH
in DCM) to give a yellow solid (9.4mg). The solid was crystallized from 2% MeOH in
CHCl3 to give berberine bromide (5.1mg, 12.2%) as a yellow solid.
Method 2: A solution of 42 (20.0mg, 0.07mmol), dihydroberberine 9 (25.0mg,
0.07mmol), and triphenylphosphine (35.1mg, 0.13mmol) in 25% CCl4 in DMF (1mL)
was heated at 90oC for 12h under a nitrogen atmosphere.

The mixture was then

evaporated and the residue chromatographed on silica gel (4% MeOH in DCM),
followed by multiple development PLC on silica gel (4% MeOH in DCM). An almost
pure fraction was crystallized from hot MeOH to give 65 (1.8mg, 4%) as a yellow solid;
m.p. 230oC (decomp.). 1H NMR (500MHz, CD3OD): δ 3.04 (t, 5.9 Hz, 2H, H-5), 3.83
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(s, 3H, OCH3), 4.06 (s, 3H, OCH3), 4.19 (s, 3H, OCH3), 4.78 (s, 2H, H-6 ), 4.80 (s, 2H,
CH 2Ph), 6.00 (s, 2H, 0C H 20 ), 6.78 (s, IH, H-3'), 6.84-6.91 (m, 2H, H-6 " , H-5"), 6.92
(s, IH, H-4)a, 7.00 (s, IH, H-14)a, 7.22 (d, J = 2.4 Hz, IH, H -3"), 7.48 (d, J = 8.7 Hz,
IH, H-7'), 7.81 (d, J = 9.6 Hz, IH, H-12)b, 8.00 (d, J = 9.5 Hz, IH, H-1 l)b, 8.02 (dd, J=
8.9, 2.2 Hz, IH, H-6 '), 8.47 (d, J = 2.1 Hz, IH, H-4'), 9.81 (s, IH, H- 8 ). 13C NMR
(125MHz, CD 3OD): 5 29.0 (C5), 35.7 (CH 2Ph), 56.0 (OCH3), 57.5 (OCH3), 58.8
(OCH 3), 62.7 (C 6 ), 103.6 (0C H 20 ), 105.7 (C3'), 109.3 (C4)c, 109.8 (C14)c, 112.3
(C7'), 115.5 (C 5"), 117.3 (C3"), 118.3 (2C, C4', C 6 '), 121.4 (C4a), 122.6 (C12)d,
122.9 (C 8 a)e, 127.3 (C 11 )d, 129.2 (C3a'), 130.3 (C2'), 131.6 (C 3"), 133.1 (Cl3b),
134.3 ( C l" ) f, 135.0 (C12a)e, 135.2 (C13), 138.9 (C13a), 141.1 (2C, C 7a',C 2"f), 142.9
(C5'), 146.0 (C9)g, 146.2 (C 8 ), 148.6 (C3a)h, 151.4 (C14a)h, 151.7 (C10)g, 160.2 (C4").
HRMS (ES): m/z calcd for C 36H30N 3O 7 [M]+: 616.2084; found: 616.2090.

7.7 Attempted synthesis to increase the bond length between
berberine and pump blocker (Chapter 4)
7.7.1 P reparation o f 13-A llyl-9,10 -d im eth o x y -5 ,6 -d ih y d ro b en zo [g ]-l,3
b en zod ioxolo[5,6-a]q u in olizin iu m brom ide (6 6 )133
A

suspension

o f the

dihydroberberine

9 (380.0mg,

l.Olmmol) and allyl bromide (2mL) was refluxed at 100°C under
a nitrogen atmosphere for 2h. Diethyl ether (lOmL) was added
66

to the reaction until no further precipitate formed.

The

precipitate was filtered and then chromatographed on silica gel (3% MeOH in DCM) to
give

66

(241.Omg, 52%) as a yellow solid. 'H NMR (300MHz, CDCI3 + CD 3OD):

8

3.23 (t, J = 5.9 Hz, 2H, H-5), 3.90-4.01 (m, 2H, CH 2 CH=CH2), 4.06 (s, 3H, OCH3),
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4.36 (s, 3H, OCH3), 4.91 (br.d, J = 17.4 Hz, 1H, CH2CH=CH2), 5.24 (br.s, 2H, H-6),
5.43 (br.d, J = 10.5 Hz, 1H, CH2CH=CH2), 6.07 (s, 2H, OCH2O), 6.31-6.42 (m, 1H,
CH2CH=CH2), 6.87 (s, 1H, H-4)a, 7.34 (s, 1H, H-14)a, 7.82 (s, 2H, H-11, H-12), 10.53
(s, 1H, H-8).

13

C NMR (75MHz, CDCl3 + CD3OD): δ 28.5 (C5), 34.7 (CH2CH=CH2),

57.0 (OCH3), 57.6 (C6), 63.2 (OCH3), 102.0 (OCH2O), 108.4 (C4)b, 108.8 (C14)b,
119.3 (C12)c, 120.0 (C13b)d, 120.8 (CH2CH=CH2), 121.7 (C8a)e, 125.4 (C11)c, 129.7
(C4a)d, 133.3 (C13), 133.5 (C12a)e, 135.1 (CH2CH=CH2), 136.9 (C13a), 145.9 (C9)f,
146.4 (C14a)g, 147.0 (C8), 149.7 (C3a)g, 150.3 (C10)f. HRMS (ES): m/z calcd for
C23H22NO4 [M]+: 376.1549; found: 376.1548.

7.7.2 Attempted cross metathesis reaction of 66
A mixture of 66 (5.1mg, 0.01mmol), indole 55 (4.0mg, 0.01mmol) and polymer
bound benzylidine-bis(triscyclohexylphosphine)-dichlororuthenium 0.1mmol/g (1.4mg,
0.001mmol), in dry DCM (5mL) was stirred and heated at refluxed for 2 days under a
nitrogen atmosphere. The catalyst was then removed by filtration of the mixture. The
filtrate was then evaporated. The residue was chromatographed on silica gel (3%
MeOH in DCM) to give a two component mixture of product (5.2mg), which could not
be identified. MS (CI) of the mixture: m/z, [MH]+ showed 208 (100%) and 313 (100%).

7.7.3 Attempted O-alkylation of 42
Method 1: To a solution of the benzyl alcohol 42 (13.0mg, 0.05mmol) in 10%
TEA in THF (2mL) was added 10% allyl bromide in THF (0.1mL, 0.01mmol) at 0oC
under a nitrogen atmosphere. The solution was then heated at 50oC for 30h. The
reaction mixture was then evaporated and the residue chromatographed on silica gel by
VLC (1% MeOH in DCM) to give only starting material 42 (10.0mg).
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Method 2: To a suspension of sodium hydride (5.0mg of
CH2OH

O2N
N

67

a 50% dispersion in mineral oil, 0.1mmol) in anhydrous DMF
(1mL) at 0oC, was added a solution of 42 (30.0mg, 0.1mmol) in

OCH3

DMF (2mL) and the mixture then stirred for 30min.

The

mixture was warmed to room temperature and stirred for a further 2h. Excess DMF
(2mL) was added and then the mixture was cooled to –60oC in a dry ice/acetone bath.
A solution of 10% allyl bromide in DMF (0.1mL, 0.13mmol) was added dropwise to the
cooled mixture and then allowed to stir overnight at 80oC. The mixture was evaporated
and the residue added to ice water (20mL), and the mixture stirred vigorously for 4h.
The precipitate was filtered, washed with cold water, and dried. The residue was
chromatographed on silica gel by PLC (50% DCM in hexane) to give 67 (7.0mg, 21%)
as an amorphous solid. 1H NMR (300MHz, CDCl3): δ 3.83 (s, 3H, OCH3), 4.48 (s, 2H,
CH2), 4.61 (d, J = 3.6 Hz, 2H, CH2CH=CH2), 4.85 (d, J = 17.1 Hz, 1H, CH2CH=CH2),
5.16 (d, J = 10.5 Hz, 1H, CH2CH=CH2), 5.78-5.91 (m, 1H, CH2CH=CH2), 6.71 (s, 1H,
H-3), 6.87 (d, J = 2.4 Hz, 1H, H-6´), 7.04 (dd, J = 8.7, 2.4 Hz, 1H, H-4´), 7.35 (d, J =
9.3 Hz, 1H, H-7), 7.52 (d, J = 8.4 Hz, 1H, H-3´), 8.13 (dd, J = 8.9, 2.0 Hz, 1H, H-6),
8.59 (d, J = 1.8 Hz, 1H, H-4).

13

C NMR (75MHz, CDCl3): δ 46.7 (CH2CH=CH2), 55.4

(OCH3), 62.4 (CH2OH), 104.9 (C3), 110.2 (C7), 115.3 (C4´), 116.2 (C6´), 117.2
(CH2CH=CH2), 117.4 (C6), 117.7 (C4), 127.1 (C3a), 130.4 (C3´), 131.3 (C2), 132.6
(C1´)a, 132.7 (CH2CH=CH2), 139.6 (C7a), 141.6 (C2´)a, 141.9 (C5), 158.7 (C5´).
HRMS (CI): m/z calcd for C19H19N2O4 [MH]+: 339.1345; found: 339.1349.
Method 3: To a suspension of sodium hydride (50% dispersion in mineral oil,
1.6g, 36.0mmol, after being washed with dry diethyl ether) in dry THF (30mL) was
added ethylene glycol (2mL, 36.0mmol) at room temperature and the mixture stirred for
1h. After this time, tert-butyldimethylsilyl chloride (5.4g, 36.0mmol) was slowly added
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to the mixture and vigorous stirring was continued for 45min. The mixture was poured
into diethyl ether (200mL), and then washed with 10% aqueous K2CO3 solution (60mL)
and brine (60mL).

The diethyl ether layer was dried, concentrated and then

chromatographed on silica gel by VLC (20% EtOAc in hexane) to give 2-(tertbutyldimethylsilanyloxy)ethanol (1.13g, 33%) as a pale yellow oil.

1

H NMR134

(300MHz, CDCl3): δ 0.01 (s, 6H, Si(CH3)2), 0.82 (s, 9H, C(CH3)3), 2.71 (br s, 1H, OH),
3.51-3.64 (m, 4H, CH2). CIMS: m/z 177 ([MH]+, 100%).
To a suspension of sodium hydride (11.0mg of a 50% dispersion in mineral oil,
0.23mmol) in anhydrous DMF (1mL) at 0oC, was added a solution of 2-(tertbutyldimethylsilanyloxy)ethanol (49.0mg, 0.28mmol) in DMF (1mL) and the mixture
stirred for 30min. The mixture was then warmed to room temperature and stirred for a
further 2h. Excess DMF (3mL) was added and then the mixture was cooled to –60oC in
a dry ice/acetone bath. A solution of benzyl bromide 53 (75.9mg, 0.23mmol) in DMF
(4mL) was added dropwise to the cooled mixture and then the mixture was allowed to
stir for 2 days at 80oC. The mixture was evaporated, then added to ice water (30mL),
and stirred vigorously for 4h. The precipitate was filtered, then washed with cold water,
and dried. The residue was chromatographed on silica gel by PLC (30% DCM in
hexane) to give the cyclised product 46 (39.6mg, 69%). All spectroscopic data for 46
was the same as that noted for this compound previously (Section 6.5.6.2).
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7.8 Enzymatic hydrolysis of 9,10-Dimethoxy-13-[2-(5-nitro-1Hindol-2-yl)-benzyloxycarbonyl-methyl]-5,6-dihydrobenzo[g]1,3-benzodioxolo[5,6-a]quinolizinium bromide (60)
To a solution of 60 (4.7mg, 0.006mmol) in DMSO (30µL), was added a
suspension of porcine liver carboxyl esterase (EC 3.1.1.1, 1mg, 46units: one unit
represents 1µmol product produced per min) in Tris-HCl buffer solution at pH7.2
(1mL).

The buffer solution was prepared as follows: 0.2M trishydroxymethyl-

aminomethane (25mL) was mixed with 0.1M HCl (45mL), then adjusted to pH7.2, and
the volume made up to 100mL with water. The reaction mixture was warmed to 37oC,
and stirred at this temperature for 24 h. The suspension was then extracted with DCM
(3 x 3mL) and the DCM extract washed with water (10mL). The DCM extract was
dried and evaporated to give a residue in which the benzyl alcohol 41 was identified by
TLC analysis (silica gel, DCM) and comparison with the authentic alcohol.
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APPENDIX I
Antibacterial activity testing using Fluorescein Diacetate (FDA)
and Antimicrobial (cell lysis/ cell stasis) assays137

Materials and Methods
Maintenance and preparation of microbial cultures
Stock cultures of S. aureus ACM844 and E. coliACM845 were obtained from the
Culture Collection at the University of Queensland and maintained at –78oC in 15%
glycerol. The cultures were prepared by streaking onto Nutrient Agar (NA) (Oxoid
CM3; pH 7.4). After an overnight incubation, single colonies were used to inoculate
sterile liquid media. The broth consisted of yeast extract (5g; ICN 103303-17), peptone
(10g; Oxoid L37), and NaCl (5g, ICN 102892) in distilled water (1L). Inoculated
broths were placed on an orbital shaker (150rpm) and incubated overnight at 37oC.

FDA assay
The overnight cultures of the microorganisms were diluted to an absorbance of
0.12 (600nm) and grown to 0.18 (ca 30min; 37oC; 150rpm). The wells of a 96 well
tissue culture plate (3072 Microtest III, Becton Dickinson) were filled with 175µL of
the culture. To each well 20µL of the test compound or appropriate control was added.
Three replicates were made at each test concentration.

The microtiter plate was

incubated for 30min at 37oC before 5µL FDA (0.2% solution in acetone) was added.
Incubation was continued for a further 2h or until the production of fluorescein was
easily visible under an ultraviolet lamp (λ 254nm). The results were simply recorded as
positive or negative according to the detection of fluorescence.
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Test compounds used in the assay were dissolved in acetone (100%, AR Grade) and
tested at a maximum concentration of 10mg/mL. Two procedural controls, consisting
of 20µL of acetone and 20µL of Milli Q water with FDA, were added to each test plate
(three replicates) to determine any effects of the acetone on the viability of the cells.
Additional procedural controls included 20µL of test substance in 175µL of broth with
FDA, to ascertain whether the test compound hydrolysed FDA, and 195µL of broth with
FDA to check for contamination in the broth.

Antimicrobial (cell lysis/ cell stasis) assay
After the FDA assay was completed, 20µL of culture (four replicates) from all the
wells that did not show fluorescence, were spread on to agar to determine if the cells
could recover. The plates were incubated overnight at 37oC. Counts of visibly growing
colonies were performed and compared to a dilution series of a control culture from the
FDA plate containing acetone.
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APPENDIX II
Antibacterial activity and MDR inhibitory activity testing using
turbidometric assay56 (performed by Lewis, K. and Ball, A.,
Northeastern University, USA)

Materials and Methods
Microbial strains used for antimicrobial activity testing were Gram-positive
bacteria: S. aureus 8325-4 (wild-type strain which expresses NorA MDR pump), S.
aureus K1758 (NorA mutant strain lacking the NorA MDR pump), S. aureus K2361
(resistance strain which overexpresses the NorA MDR pump), E. faecalis V583, and E.
faecium DO; Gram-negative bacteria: E. coli K12, S. enterica Serovar Typhimurium
SL1344R2, and P. auerginosa PA1; and Yeast: S. cerevisiae BY4742, C. albicans F5,
and C. albicans F5 M432.

Cell Culturing and Susceptibility Testing
Growth of microbe and susceptibility measurements were performed according to
the National Center for Clinical Laboratory Standards Recommendations. All strains
were cultured in Mueller-Hinton (MH) broth overnight with aeration at 37oC. Cells
were then inoculated into fresh MH medium at a 1:10 dilution and were allowed to
grow for 1h. This suspension was dilute 1:2000 into MH broth and 0.05 mL was
dispensed per well of microtiter plates.

For measurements of direct antimicrobial

activity, test compounds were dissolved in DMSO at 10mg/mL and then serially diluted
with water. The final volume of a well was 0.2 mL, and the cell concentration was 105
cells/mL. All tests were done in triplicate. Minimum inhibitory concentrations (MICs)
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were determined by serial 2-fold dilution of test compounds. Two procedural controls
were used. One contained cells and MH broth to observe the normal growth rate of
microorganisms within the wells. Another one contained only MH broth to observe any
contamination. MIC was defined as a concentration (µg/mL) of an antimicrobial that
completely prevented cell growth during an 18h incubation at 37oC. Growth was
assayed with a microtiter plate reader (Bio-Rad) by absorption at 600nm.
Test for MDR inhibitory activity were done in similarly, but with antibiotic
(Berberine chloride or Ciprofloxacin) present at a sub-inhibitory concentration
throughout. The test substance was then serially diluted 2-fold, and MIC for test
substances was then defined as their minimal concentration that completely inhibited
cell growth in the presence of sub-inhibitory concentration of antibiotic.

Effect of NorA inhibitors on antibacterial accumulation in
bacterial cells using uptake assay (performed by Lewis, K. and
Ball, A., Northeastern University, USA)

Materials and Methods
Microbial strains used for antimicrobial activity testing were Gram-positive
bacteria: S. aureus 8325-4 (wild-type strain which expresses NorA MDR pump), S.
aureus K1758 (NorA mutant strain lacking the NorA MDR pump), S. aureus K2361
(resistance strain which overexpresses the NorA MDR pump).
Cells were grown to an OD of 1.5 (600nm) in 1 milliliter of MH broth. Cells were
centrifuged at 12,000 Rpm for two minutes and washed in 20mM HEPES/KOH buffer
pH 7 twice. Cells were resuspended to an OD of 0.6 in 20mM HEPES/KOH buffer
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containing 10mM sucrose and incubated for 1h. Cells were centrifuged and washed with
20mM HEPES buffer and resuspended to an OD 0.3. Cells were then added to 96 well
microtiter plates at an OD of 0.15. Uptake of berberine can be measured due to its
ability to intercalate with DNA. Accumulation of berberine 30µg/mL was measured by
fluorescence (λ 355nm excitation, λ 517nm emission) in the presence or absence of
inhibitor 10µg/mL.
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APPENDIX III
Antibacterial activity testing146 (performed by Avexa Ltd.,
Australia)

Materials and Methods
The bacterial strains were used S. aureus ATCC 6538P, and 4 strains of E.
faecium VRE243, VRE449, VRE820 and VRE987. It should be noted that, VRE243
and 987 were sensitive to vancomycin and VRE449 and VRE820 were resistant to
vancomycin.

Antimicrobial assay
The Mueller-Hinton Broth (MHB) Medium culture media was prepared with final
concentrations of 1 µg/mL MgCl2 and 2 µg/mL CaCl2 and was pre-warmed for 2-3 h at
37oC before use. Mueller-Hinton Agar (MHA) Medium culture media was prepared
with final concentrations of 1.5% Agar (Merck Agar 1.01614). S. aureus was streaked
onto MHA and the plate was incubated overnight at 37oC. From this plate, 10 cryovial
were prepared by looping several colonies into 0.5 mL of 20% glycerol solution and
were immediately stored at −140oC. A cryovial was removed from −140oC storage and
thawed at room temperature. The MHA plate was streaked with a loopful of bacterial
suspension and incubated overnight at 37oC to create a parent plate (P1). The parent
plate was stored at 4oC. A daughter plate (D1) was incubated overnight at 37oC and its
loop of colony was used to inoculate a 125 mL flask containing 20 mL of MHB
containing 25 µg/mL CaCl2.2H2O) and 12.5 µg/mL MgCl2.6H2O. The flask was shaken
at 260 rpm for 18 h at 37oC on an orbital incubator shaker. The parent plates 1 and 2
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were each used twice to generate two daughter plates (D1 and D2) before being
discarded.
The standardised inocula for assays was prepared as 1/10 dilution of seed cultures
by adding 250 µL of the cultures to 2,250 µL of MHB in a disposable cuvette and the
required dilution factor was calculated by dividing the observed OD650. Sufficient
volumes of the final inoculum cultures were prepared in pre-warmed MHB (37oC) by
diluting the standardised cultures to the required final concentration (108 dilution).

Assay Procedure for 96-well Microtitre Plates
To each well of the 96-well microtitre plate was added 50 µL of liquid medium
and 50 µL of test compound solution which was prepared by dissolving in 2.5 % DMSO
was added in triplicate to the top of the microtitre plate. A vancomycin control set
(triplicate) and a compound negative control set (triplicate) were also set up on each
plate. The inoculated culture medium was incubated at 37oC for 30 min shaking it at
130 rpm and using the multichannel pipette and multistepper pipette the adding,
transferring and mixing of the inoculum were performed on the wells of the plates. The
plates were incubated at 37oC for 18 h shaking at 100 rpm in an environment with 90%
relative humidity and the results were recorded as the highest dilution of test compound
that prevented bacterial growth (MIC). The MIC was also determined for DMSO (2.5%)
as a control measure.
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APPENDIX IV
Antimalarial

activity

testing147

(performed

by

Kamchonwongpaisan, S., BIOTEC, Thailand)

Materials and Methods
Samples were made up in DMSO solution. Using the Microdilution Radioisotope
Technique, the in vitro antimalarial activity of the alkaloids was tested against P.
falciparum, TM4 and K1 strains. The first strain is an anti-folate sensitive one while the
second is an antifolate resistant strain.

Antimalarial assay
The sample (25 µl, in the culture medium) was placed in triplicate in a 96-well
plate. Red blood cells (200 µl) infected with P. falciparum with a cell suspension
(1.5%) of parasitemia (0.5-1%) were added to the wells. The range of the final
concentrations of the samples varied from 1 x 10-5 to 1 x 10-8 g/ml with 0.1% of the
organic solvent. The plates were cultured under standard conditions for 24 hours and the
3

H-hyphoxanthine (25 µl, 0.5 mCi) was added. The culture was incubated for 18-20

hours. The parasites’ DNA was then harvested from the culture onto glass fibre filters.
A radiation counter determined the amount of

3

H-hypoxanthine. The inhibitory

concentration of the sample was determined from its dose-response curves or by
calculation.
The Trager and Jensen method148 was used to culture the P. falciparum K1 strain.
The parasites were maintained in human red blood cells in a culture medium. RPMI
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1640 was supplemented with 25 mM HEPES, 0.2% sodium bicarbonate, and 8% human
serum, at 37oC in a CO2 incubator.
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APPENDIX V
Cytotoxicity testing (performed by Vine, K., University of
Wollongong)

Materials and Methods
Test compounds 40, 60 and 64 were made up in 10% MeOH in DCM solution. Using
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl-2-(4-sulfophenyl)-2H
tetrazolium, inner salt (MTS) assay, the in vitro cytotoxicity of these compounds was
tested against human hystiocytic lymphoma cells (cell line U937).
The U937 cancer cells were supplied by the Garvan Institute of Medical Research,
Sydney, Australia.

Cells were routinely maintained in vitro (37oC, 5% CO2 in

humidified atmosphere) in a culture medium of RPMI-1640 media supplemented with
2mM L-glutamine, 5.6% (2g/L) sodium bicarbonate (Univar Analytical Reagents, Ajax
Chemicals) and 5% Foetal Calf Serum (FCS) (MultiSerTM Thermo Trace).

Cytotoxicity testing
Test compounds were tested for cytotoxicity against human hystiocytic lymphoma cells
(cell line U937). Test compound dissolved in 10% MeOH in DCM solution was added
to the wells of a sterile, 96 well microtitre plate from 100µg/mL to 1µg/mL. The 10%
MeOH/DCM in the test solution was removed by either N2 or Ar gas until the
compound was completely dry. Cells (2x104 cells/well) in RPMI/5% FBS were added
to the test compounds to give a final volume of 100µL. Positive control cultures were
incubated with RPMI/5% FCS only, or in the case of solvent controls, 100µL EtOH
dried with N2 or Ar gas. Negative control cultures were incubated with RPMI/5% FCS
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and 50% EtOH, all in triplicate. The cells were incubated for 24h at 37oC (5% CO2
atmosphere), and then MTS (20 L) was added in the dark. The cells were incubated
for a further 3h to allow colour development. Plates were read in the SpectroMax® 250
plate reader using Softmax Pro software V. 4.0 (Molecular devices, USA) at 490 nm.
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